Õx ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ Õx ... · 2019....

ÕX ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ ÕX UKRAINIAN NATIONAL CONGRESS OF CARDIOLOGY ÕX ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ ÕX UKRAINIAN NATIONAL CONGRESS OF CARDIOLOGY ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ

MINISTRY OF HELTH OF UKRAINENATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE

SI «NATIONAL SCIENTEFICCENTER «ACADEMIC M.D. STRAZHESKO INSTITUTE

OF CARDIOLOGY» NAMS OF UKRAINE»UKRAINIAN ASSOCIATION OF CARDILOGY

ASSOCIATION OF RESEACHERS OF UKRAINEUKRAINIAN ASSOCIATION OF PREVENTIVE

CARDIOLOGY AND REHABILITATIONALL-UKRAINIAN ASSOCIATION OF ARRHYTHMOLOGISTS

OF UKRAINEACUTE CARDIAC CARE ASSOTIATION

OF UKRAINEUKRAINIAN ANTIHYPERTENSIVE SOCIETY

UKRAINIAN HEART FAILURE ASSOCIATION

UKRAINIAN ATHEROSCLEROSIS SOCIETY

Ì²Í²ÑÒÅÐÑÒÂÎ ÎÕÎÐÎÍÈ ÇÄÎÐÎÂ’ß ÓÊÐÀ¯ÍÈÍÀÖ²ÎÍÀËÜÍÀ ÀÊÀÄÅÌ²ß ÌÅÄÈ×ÍÈÕ ÍÀÓÊ ÓÊÐÀ¯ÍÈ

ÄÓ «ÍÀÖ²ÎÍÀËÜÍÈÉ ÍÀÓÊÎÂÈÉ ÖÅÍÒÐ «²ÍÑÒÈÒÓÒ ÊÀÐÄ²ÎËÎÃ²¯ ²ÌÅÍ² ÀÊÀÄÅÌ²ÊÀ

Ì.Ä. ÑÒÐÀÆÅÑÊÀ» ÍÀÌÍ ÓÊÐÀ¯ÍÈ»ÂÑÅÓÊÐÀ¯ÍÑÜÊÀ ÀÑÎÖ²ÀÖ²ß ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ

ÀÑÎÖ²ÀÖ²ß ÄÎÑË²ÄÍÈÊ²Â ÓÊÐÀ¯ÍÈÂÑÅÓÊÐÀ¯ÍÑÜÊÀ ÀÑÎÖ²ÀÖ²ß ÏÐÅÂÅÍÒÈÂÍÎ¯

ÊÀÐÄ²ÎËÎÃ²¯ ÒÀ ÐÅÀÁ²Ë²ÒÀÖ²¯ÂÑÅÓÊÐÀ¯ÍÑÜÊÀ ÀÑÎÖ²ÀÖ²ß ÀÐÈÒÌÎËÎÃ²Â

ÓÊÐÀ¯ÍÈÂÑÅÓÊÐÀ¯ÍÑÜÊÀ ÀÑÎÖ²ÀÖ²ß Ç ÍÅÂ²ÄÊËÀÄÍÎ¯

ÊÀÐÄ²ÎËÎÃ²¯ÂÑÅÓÊÐÀ¯ÍÑÜÊÀ ÀÍÒÈÃ²ÏÅÐÒÅÍÇÈÂÍÀ ÀÑÎÖ²ÀÖ²ßÂÑÅÓÊÐÀ¯ÍÑÜÊÀ ÀÑÎÖ²ÀÖ²ß ÔÀÕ²ÂÖ²Â Ç ÑÅÐÖÅÂÎ¯

ÍÅÄÎÑÒÀÒÍÎÑÒ²ÓÊÐÀ¯ÍÑÜÊÅ ÒÎÂÀÐÈÑÒÂÎ Ç ÀÒÅÐÎÑÊËÅÐÎÇÓ

ÕX ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈÕX UKRAINIAN NATIONAL CONGRESS OF CARDIOLOGY

ÏÐÎÃÐÀÌÀSCIENTIFIC PROGRAM

25–27 âåðåñíÿ 2019 ð.ÊÈ¯Â

25th–27th OF SEPTEMBER, 2019KYIV

ÕX ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ ÕX UKRAINIAN NATIONAL CONGRESS OF CARDIOLOGY ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ

2

SCIENTIFIC AND ORGANIZING COMMITTEE OF THE XX NATIONAL CARDIOLOGY CONGRESS OF UKRAINE

Presidium of the scientific and organizing committee:V.M. Kovalenko (co-chairman), V.I. Tzymbalyuk (co-chairman), K.M. Amosova, O.M. Bilovol, Yu.V. Voronenko, V.V. Lasorishinets, M.I. Lutay, O.M. Parkhomenko, Yu.M. Sirenko, O.S. Sychov, Yu.M. Sokolov, E.G. Nesukay

Members of the scientific and organizing committee:V.V. Bratus, L.L. Vavilova, O.P. Volosovets, L.G. Voronkov, T.I. Gavrilenko, M.M. Dolzhenko, I.M. Emets, V.M. Zhdan, O.A. Koval, S.M. Koval, S.M. Kozhukhov, O.V. Korkushko, V.M. Kornatskyi, O.I. Mitchenko, V.A. Mikhnyov, V.Z. Netiazhenko, O.S. Nikonenko, L.A. Mishchenko, M.V. Rishko, A.V. Rudenko, K.V. Rudenko, N.M. Seredyuk, M.Yu. Sokolov, T.V. Talaeva, V.K. Tashchuk, B.M. Todurov, M.D. Tronko, M.K. Furkalo, V.Yo. Tseluyko, V.O. Shumakov

Secretariat:L.L. Vavilova (chairman), V.M. Korzhenko, V.E. Piletskiy, O.M. Romanova, T.V. Getman, O.V. Sribna, R.G. Ivanets, M.A. Gulya-nytska, T.M. Movchanovska, M.P. Mostovyak

ÍÀÓÊÎÂÎ-ÎÐÃÀÍ²ÇÀÖ²ÉÍÈÉ ÊÎÌ²ÒÅÒ ÕX ÍÀÖ²ÎÍÀËÜÍÎÃÎ ÊÎÍÃÐÅÑÓ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ

Ïðåçèä³ÿ íàóêîâî-îðãàí³çàö³éíîãî êîì³òåòó:Â.Ì. Êîâàëåíêî (ñï³âãîëîâà), Â.². Öèìáàëþê (ñï³âãîëîâà), Ê.Ì. Àìîñîâà, Î.Ì. Á³ëîâîë,Þ.Â. Âîðîíåíêî, Â.Â. Ëàçîðè-øèíåöü, Ì.². Ëóòàé, Î.Ì. Ïàðõîìåíêî, Þ.Ì. Ñ³ðåíêî, Î.Ñ. Ñè÷îâ, Þ.Ì. Ñîêîëîâ, Î.Ã. Íåñóêàé

×ëåíè íàóêîâî-îðãàí³çàö³éíîãî îðãêîì³òåòó:Ë.Ë. Âàâ³ëîâà, Î.Ï. Âîëîñîâåöü, Ë.Ã. Âîðîíêîâ, Ò.². Ãàâðèëåíêî, Ì.Ì. Äîëæåíêî, ².Ì. ªìåöü, Â.Ì. Æäàí, Î.À. Êîâàëü, Ñ.Ì. Êîâàëü, Ñ.Ì.Êîæóõîâ, Î.Â. Êîðêóøêî, Â.Ì. Êîðíàöüêèé, Î.². Ì³ò÷åíêî, Â.À. Ì³õíüîâ, Â.Ç. Íåòÿæåíêî, Ë.À. Ì³-ùåíêî, Ì.Â. Ð³øêî, À.Â. Ðóäåíêî, Ê.Â. Ðóäåíêî, Í.Ì. Ñåðåäþê, Ì.Þ. Ñîêîëîâ, Ò.Â. Òàëàåâà, Â.Ê. Òàùóê, Á.Ì. Òîäóðîâ, Ì.Ä. Òðîíüêî, Ì.Ê. Ôóðêàëî, Î.Î.Õàíþêîâ, Â.É. Öåëóéêî, Â.Î.Øóìàêîâ

Ñåêðåòàð³àò: Ë.Ë. Âàâ³ëîâà (ãîëîâà), Ð.Ã. ²âàíåöü, Â.Ì. Êîðæåíêî, Â.Å. Ï³ëåöüêèé, Î.Ì.Ðîìàíîâà, Ò.Â. Ãåòüìàí, Î.Â. Ñð³áíà, Ì.À. Ãóëÿ-íèöüêà, Ò.Ì. Ìîâ÷àíîâñüêà, Ì.Ï. Ìîñòîâ’ÿê


3

Âåëüìèøàíîâíèé(-à) êîëåãî!Ì³í³ñòåðñòâî îõîðîíè çäîðîâ’ÿ Óêðà¿íè, Íàö³îíàëüíà àêàäåì³ÿ ìåäè÷íèõ íàóê Óêðà¿íè, Àñîö³àö³ÿ

êàðä³îëîã³â Óêðà¿íè, Ãðîìàäñüêà îðãàí³çàö³ÿ «Âñåóêðà¿íñüêà Àñîö³àö³ÿ àðèòìîëîã³â Óêðà¿íè», Àñîö³à-ö³ÿ äîñë³äíèê³â Óêðà¿íè, Âñåóêðà¿íñüêà àñîö³àö³ÿ ïðåâåíòèâíî¿ êàðä³îëîã³¿ òà ðåàá³ë³òàö³¿, ÄÓ «Íà-ö³îíàëüíèé íàóêîâèé öåíòð «²íñòèòóò êàðä³îëîã³¿ ³ìåí³ àêàäåì³êà Ì.Ä. Ñòðàæåñêà» ÍÀÌÍ Óêðà¿íè», Âñåóêðà¿íñüêà àñîö³àö³ÿ êàðä³îëîã³â Óêðà¿íè çàïðîøóþòü Âàñ âçÿòè ó÷àñòü ó ðîáîò³ XX Íàö³îíàëüíîãî êîíãðåñó êàðä³îëîã³â, ùî â³äáóäåòüñÿ â Êèºâ³ 25–27 âåðåñíÿ 2019 ð.

Îñíîâíå ïîñëàííÿ Êîíãðåñó — êîìîðá³äí³ñòü â êàðä³îëîã³¿. Ïðîáëåìà áóäå ðîçãëÿíóòà ç ïîçèö³é ìóëüòèäèñöèïë³íàðíîãî ï³äõîäó äî âèçíà÷åííÿ òà ä³àãíîñòèêè êîìîðá³äíèõ ñòàí³â òà ìîæëèâèõ íà-ïðÿìê³â ë³êóâàííÿ.

Ó ðàìêàõ Êîíãðåñó áóäóòü ïðîâåäåí³ ñï³ëüíå çàñ³äàííÿ àðèòìîëîã³â êðà¿í Ñõ³äíî¿ òà Öåíòðàëü-íî¿ ªâðîïè, ñï³ëüíå çàñ³äàííÿ ªâðîïåéñüêîãî òîâàðèñòâà ç àòåðîñêëåðîçó, Óêðà¿íñüêîãî òîâàðèñòâà

ç àòåðîñêëåðîçó òà Ïîëüñüêî¿ ë³ï³äíî¿ àñîö³àö³¿.Âè çìîæåòå îçíàéîìèòèñÿ ç îñòàíí³ìè äîñÿãíåííÿìè íàóêè â ëåêö³ÿõ ïðîâ³äíèõ â÷åíèõ-êàðä³îëîã³â ç Ïîëüù³

(M. Banach — ïðåçèäåíò Ïîëüñêî¿ ë³ï³äíî¿ àñîö³àö³¿, M. Chudzik PhD — çàñòóïíèê äèðåêòîðà êîì³ñ³¿ ç îñâ³òè ªâðîïåé-ñüêî¿ àñîö³àö³¿ àðèòìîëîã³â), Ëèòâè (ïðîô. V. Sapoka — ãîëîâà êë³í³êè âíóòð³øí³õ õâîðîá, ñ³ìåéíî¿ ìåäèöèíè òà îíêîëîã³¿ ïðè ìåäè÷íîìó ôàêóëüòåò³ Â³ëüíþñüêîãî óí³âåðñèòåòó, ïðîô. Z. Petrulioniene–ïðåçèäåíò Òîâàðèñòâà àòåðîñêëåðîçó Ëèò-âè), Â³ðìåí³¿ (ïðîô. Ñ.Â. Ãðèãîðÿí — ïðåçèäåíò Â³ðìåíñüêî¿ àñîö³àö³¿ ðèòìó ñåðöÿ), ÑØÀ (â ðåæèì³ on-line Dr. Mikhail N. Kosiborod, MD — äèðåêòîð ãðóïè êàðä³îìåòàáîë³÷íèõ äîñë³äæåíü ²íñòèòóòó Ñâÿòîãî Ëóêè, Êàíçàñ-Ñ³ò³).

Ñêëàäí³ êë³í³÷í³ âèïàäêè áóäóòü ïðåäñòàâëåí³ â ñåêö³¿ «Øêîëà ïðàêòèêóþ÷îãî ë³êàðÿ» òà «Êë³í³÷í³ àñïåêòè íåâ³äêëàä-íèõ ñòàí³â â êàðä³îëîã³¿».

Òàêîæ ï³ä ÷àñ Êîíãðåñó äëÿ ë³êàð³â ³ç ñïåö³àëüíîñò³ «Çàãàëüíà ïðàêòèêà — ñ³ìåéíà ìåäèöèíà» áóäå ïðî÷èòàíî êóðñ ëåêö³é «Êàðä³îëîã³ÿ äëÿ ñ³ìåéíèõ ë³êàð³â» òà êóðñ «Áàçèñí³ îñíîâè àðèòìîëîã³¿».

Âæå ñòàëî òðàäèö³ºþ ïðîâåäåííÿ êîíêóðñó íàóêîâèõ ðîá³ò ìîëîäèõ â÷åíèõ òà îáãîâîðåííÿ ñòåíäîâèõ äîïîâ³äåé. Çàâåðøèòüñÿ Êîíãðåñ Ãåíåðàëüíîþ àñàìáëåºþ Âñåóêðà¿íñüêî¿ àñîö³àö³¿ êàðä³îëîã³â Óêðà¿íè. Ìè âïåâíåí³, ùî Êîíãðåñ äàñòü ìîæëèâ³ñòü ò³ñíîãî íàóêîâîãî ñï³ëêóâàííÿ, ïðîôåñ³éíîãî çðîñòàííÿ òà ñîö³àëüíî¿

âçàº ìîä³¿ âñ³õ ó÷àñíèê³â. Ïðîòÿãîì öèõ äí³â ñï³ëêóâàííÿ äåëåãàò³â òà ãîñòåé Êîíãðåñó îá³öÿº áóòè ³íôîðìàòèâíèì òà êî-ðèñíèì.

Dear Colleague!National Academy of Medical Sciences of Ukraine, Ministry of Health of Ukraine, Ukrainian Association of Cardiology, SI «NSC

«Academic M.D. Strazhesko Institute of Cardiology» of National Academy of Medical Sciences of Ukraine» invite you to take part in the XX National Congress of Cardiologists which will be held in Kyiv on 25–27-th of September 2019.

The main message of the Congress is comorbidity in cardiology. The problem will be addressed from the standpoint of a mul-tidisciplinary approach to the definition and diagnosis of comorbidities and possible treatment trends.

In the frames of the Congress will be held the Joint Scientific Session of the European Society of Cardiology and Ukrainian Association of Cardiology, the Joint Meeting of arrhythmologists from the central and eastern Europe countries, Joint Meeting of European atherosclerosis Society and Polish Lipid Association, Joint session of the Ukraine Association of Cardioliogy.

You will have the possibility to get acquai n ted with the latest scientific achievements in lectures of the prominent sci-entists — cardiologists from Poland (M. Banach — President of Polish Lipid Association (PoLA), M. Chudzik PhD), Lithuania (prof. V. Sapoka — Head of Vilnius University Clinics of Internal Medicine, prof. Z. Petrulioniene), Armenia (prof. S.V. Grigo-ryan — President of Armenian Arrhythmological Association), USA (on-line Dr. Mikhail N. Kosiborod MD, — Director of the Cardio-metabolic Research Group at the St. Luke Institute, Kansas City).

The complex clinical events will be presented in the section : in assistance to the practicing doctor and clinical aspects of emer-gency situations in cardiology.

Also at the Congress for doctors on the specialty «General Practice — Family Medicine» will be read the course of lectures «Cardiology for Family Doctors» and the course «Basic Fundamentals of Arrhythmology».

It has already become the tradition to carry out the competition of the youg scientists’ work and the discussion of the poster reports.

The Congress will be ended by the General Assembly of the Ukraine Association of Cardiology.We are sure that the Congress wi ll give the possibility of tight commu ni cati ons, professional growth and social coopera-

tion of all participants. We hope that during these days the communication of the delegates and guests of the Congress would be very informative and useful.


4

ÇÀÃÀËÜÍÀ ²ÍÔÎÐÌÀÖ²ß

Ì³ñöå ïðîâåäåííÿ Ðîáîòà Êîíãðåñó ïðîâîäèòèìåòüñÿ â ÍÑÊ «Îë³ìï³éñüêèé» — 25–27 âåðåñíÿ 2019 ð.(âóë. Âåëèêà Âàñèëüê³âñüêà, 55)Ãîòåëü «Ðóñü» — 26 âåðåñíÿ 2019 ð.(âóë. Ãîñï³òàëüíà, 4)

Ðåºñòðàö³ÿ Ðåºñòðàö³ÿ äåëåãàò³â òà ó÷àñíèê³â:ÍÑÊ «Îë³ìï³éñüêèé» (2-é ïîâåðõ)25 âåðåñíÿ — ç 8:00 äî 18:0026 âåðåñíÿ — ç 8:00 äî 17:0027 âåðåñíÿ — ç 8:00 äî 15:00Ãîòåëü «Ðóñü» (1-é ïîâåðõ)26 âåðåñíÿ — ç 8:00 äî 18:00Çàðåºñòðîâàíèì ó÷àñíèêàì Êîíãðåñó áóäóòü íàäàí³ ïîðòôåëü äåëåãàòà, ÿêèé ì³ñòèòü çá³ðíèê òåç, ïðîãðàìó, ïîñ³áíèêè, ìåòîäè÷í³ ðåêîìåíäàö³¿, ñåðòèô³êàò ³ çàïðîøåííÿ äëÿ îòðèìàííÿ ëàí÷-áîêñó

Óðî÷èñòåâ³äêðèòòÿ

Óðî÷èñòå â³äêðèòòÿ XX Íàö³îíàëüíîãî êîíãðåñó êàðä³îëîã³â Óêðà¿íè â³äáóäåòüñÿ 25 âå-ðåñíÿ î 17:15 â ÍÑÊ «Îë³ìï³éñüêèé» (âóë. Âåëèêà Âàñèëüê³âñüêà, 55) ç ïðèâ³òàííÿ Íàö³-îíàëüíîãî àêàäåì³÷íîãî îðêåñòðó íàðîäíèõ ³íñòðóìåíò³â Óêðà¿íè

Ãåíåðàëüíà àñàìáëåÿ

Ãåíåðàëüíà Àñàìáëåÿ XX Íàö³îíàëüíîãî êîíãðåñó êàðä³îëîã³â Óêðà¿íè â³äáóäåòüñÿ 27 âåðåñíÿ î 13.15 â ÍÑÊ «Îë³ìï³éñüêèé», çàëà «Õîë ×åìï³îí³â»

Ïðî¿çä Ïðî¿çä äî ÍÑÊ «Îë³ìï³éñüêèé» òà Ãîòåëþ «Ðóñü» — ñòàíö³ÿ ìåòðî «Îë³ìï³éñüêà»

²íôîðìàö³ÿäëÿ äîïîâ³äà÷³â

Óñ³ çàëè îñíàùåí³ ìóëüòèìåä³éíèìè ïðîåêòîðàìè ³ íîóòáóêàìè. Íà êîìï’þòåðàõ âñòàíîâëåí³ îïåðàö³éíà ñèñòåìà Windows 7, MS Power Point 2010: Äîïîâ³äà÷àì íåîáõ³äíî íå ï³çí³øå í³æ çà 30 õâ äî ïî÷àòêó çàñ³äàííÿ íàäàòè ñâî¿ íîñ³¿ ³íôîðìàö³¿ (ôëåø-êàðòè, CD, DVD-äèñêè) â³ä-ïîâ³äàëüíîìó ç òåõí³÷íîãî ñóïðîâîäó â çàë³

Îðãêîì³òåò 03151, Êè¿â-151, âóë. Íàðîäíîãî îïîë÷åííÿ, 5, ÄÓ «ÍÍÖ «²íñòèòóò êàðä³îëîã³¿ ³ìåí³ àêàäåì³êà Ì.Ä.Ñòðàæåñêà» ÍÀÌÍ Óêðà¿íè»Òåëåôîíè äëÿ äîâ³äîê: (044) 249-70-03, 275-66-22Ôàêñ: (044) 249-70-03, 275-42-09E-mail: [email protected]


5

ÃÅÍÅÐÀËÜÍ² ÏÀÐÒÍÅÐÈ ÊÎÍÃÐÅÑÓ

SERVIER(Ôðàíö³ÿ)

BAYER(Í³ìå÷÷èíà)

ÊÐÊÀ, ä. ä., Íîâî ìåñòî (Ñëîâåí³ÿ)

NOVARTIS(Øâåéöàð³ÿ)

ÄÀÐÍÈÖß (Óêðà¿íà)

PFIZER (ÑØÀ)

ARTERIUM(Óêðà¿íà)

BOEHRINGER INGELHEIM(Í³ìå÷÷èíà)

ÃÎËÎÂÍ² ÏÀÐÒÍÅÐÈ ÊÎÍÃÐÅÑÓ

ÊÈ¯ÂÑÜÊÈÉ Â²ÒÀÌ²ÍÍÈÉ ÇÀÂÎÄ(Óêðà¿íà)

ÊÓÑÓÌ ÔÀÐÌ(Óêðà¿íà)

Astra Zeneca(Âåëèêà Áðèòàí³ÿ)

TAKEDA(ßïîí³ÿ)

ÒÎÂ «Ñàíîô³-Àâåíò³ñ Óêðà¿íà»

ÏÀÐÒÍÅÐÈ ÊÎÍÃÐÅÑÓ

ACINO (Øâåéöàð³ÿ), ASPEN PHARMA (²ðëàíä³ÿ), BERLIN-CHEMIE (Í³ìå÷÷èíà), D-r REDDY’S (²íä³ÿ), EGIS Pharmaceuticals (Óãîðùèíà), GEDEON RICHTER (Óãîðùèíà), GRINDEKS (Ëàòâ³ÿ), MEDOCHEMIE LTD (Ê³ïð), OLFA (Ëàòâ³ÿ), PRO.MED.CS Praha a.s. (×åõ³ÿ), ROSTGROUP (Óêðà¿íà), WOERWAG PHARMA (Í³ìå÷÷èíà), Áîðùàã³âñüêèé ÕÔÇ (Óêðà¿íà), ÇÄÐÀÂÎ (Óêðà¿íà), Ì²ÊÐÎÕ²Ì (Óêðà¿íà), ÑÀÍÄÎÇ (Í³ìå÷÷èíà/Øâåéöàð³ÿ), ÒÎÂ «Íîâî Íîðä³ñê Óêðà¿íà» (Äàí³ÿ), ÒÎÂ «Ôîðñ-Ôàðìà Äèñòðèáþøí» (Óêðà¿íà), ÒÎÂ «Øàéºð Óêðà¿íà» (÷àñòèíà êîìïàí³¿ TAKEDA), ÞÐ²ß-ÔÀÐÌ (Óêðà¿íà)

Ï³ä ÷àñ ïðîâåäåííÿ Êîíãðåñó ïðàöþâàòèìóòü âèñòàâêè ë³êàðñüêèõ ïðåïàðàò³â ³ ìåäè÷íèõ âèðîá³â òà ïðèëàä³â ïðîâ³äíèõ êîìïàí³é Óêðà¿íè ³ ñâ³òó:

SERVIER (Ôðàíö³ÿ), BAYER (Í³ìå÷÷èíà), ÊÐÊÀ, ä. ä., Íîâî ìåñòî, (Ñëîâåí³ÿ), NOVARTIS (Øâåéöàð³ÿ), ÄÀÐÍÈÖß (Óêðà¿ íà), PFIZER (ÑØÀ), ARTERIUM (Óêðà¿íà), Êè¿âñüêèé â³òàì³ííèé çàâîä (Óêðà¿íà), ÊÓÑÓÌ ÔÀÐÌ (Óêðà¿íà), Astra Zeneca (Âåëèêà Áðèòàí³ÿ), BOEHRINGER INGELHEIM (Í³ìå÷÷èíà), TAKEDA (ßïîí³ÿ), ÒÎÂ «Ñàíîô³-Àâåíò³ñ Óêðà¿íà», MEDOCHEMIE LTD (Ê³ïð), Ì²ÊÐÎÕ²Ì (Óêðà¿íà), ACINO (Øâåéöàð³ÿ), ÞÐ²ß-ÔÀÐÌ (Óêðà¿íà), BERLIN-CHEMIE (Í³ìå÷-÷èíà), ROSTGROUP (Óêðà¿íà), GEDEON RICHTER (Óãîðùèíà), GRINDEKS (Ëàòâ³ÿ), ÒÎÂ «Íîâî Íîðä³ñê Óêðà¿íà» (Äà-í³ÿ), OLFA (Ëàòâ³ÿ), ÑÀÍÄÎÇ (Í³ìå÷÷èíà/Øâåéöàð³ÿ), PRO.MED.CS Praha a.s. (×åõ³ÿ), ÇÄÐÀÂÎ (Óêðà¿íà), D-r REDDY’S (²íä³ÿ), ÞÒÀÑ (Óêðà¿íà), Áîðùàã³âñüêèé ÕÔÇ (Óêðà¿íà), ASPEN PHARMA (²ðëàíä³ÿ), ALVOGEN (Óêðà¿íà), WOERWAG PHARMA (Í³ìå÷÷èíà), ÒÎÂ «Ôîðñ-Ôàðìà Äèñòðèáþøí» (Óêðà¿íà), EGIS Pharmaceuticals (Óãîðùèíà), ÑÎÍÀ-ÔÀÐÌÅÊ-Ñ²Ì (Óêðà¿íà), ÒÎÂ «ÇÌ» (Óêðà¿íà), IMESÑ (Óêðà¿íà), ÓêðÒåëåÌåä (Óêðà¿íà), HOFFMANN-La ROCHE Ltd (Øâåéöàðñüêà Êîíôåäåðàö³ÿ), ÌÅÄ ÅÊÑ²Ì (Óêðà¿íà), ÔÀÐÊÎÑ (Óêðà¿íà), Ñàí Ôàðìà (Óêðà¿íà), ÊÀÐÄ²ÎË²ÒÀ (Ëèòâà), MUCOSPHARMA (Í³ìå÷÷èíà), ÒÎÂ «Øàéºð Óêðà¿íà» (÷àñòèíà êîìïàí³¿ TAKEDA), SCHILLER AG (Óêðà¿íà), ÂÑÌ Óêðà¿íà.

²ÍÔÎÐÌÀÖ²ÉÍÅ ÇÀÁÅÇÏÅ×ÅÍÍß

«Óêðà¿íñüêèé êàðä³îëîã³÷íèé æóðíàë», Âèäàâíè÷èé ä³ì «ÌÎÐ²ÎÍ»: «Óêðà¿íñüêèé ìåäè÷íèé ÷àñîïèñ», Âèäàâíè÷èé ä³ì «ÇÀÑËÀÂÑÜÊÈÉ»: ãàçåòà «Íîâîñòè ìåäèöèíû è ôàðìàöèè», Âèäàâíèöòâî MEDIX: «Ìèñòåöòâî ë³êóâàííÿ», «Ë³êè Óêðà¿íè», «Ìåäè÷íà ãàçåòà «Çäîðîâ’ÿ Óêðà¿íè ÕÕ² ñòîð³÷÷ÿ», Âèäàâíè÷èé ä³ì «Çäîðîâ’ÿ Óêðà¿íè, Ìåäè÷í³ æóðíàëè»: «Ïðàêòè÷íà àíã³îëîã³ÿ», «Ðàö³îíàëüíà ôàðìàêîòåðàï³ÿ», Âèäàâíèöòâî «Ìåäêíèãà»: «Ïðàêòèêóþ÷èé ë³êàð», Æóðíàë íåâðîëîã³¿ ³ì. Á.Ì. Ìàíüêîâñüêîãî, Èçäàòåëüñòâî «Ïðîôåññèîíàëüíûå èçäàíèÿ Âîñòî÷íàÿ Åâðîïà»: «Êàðäèîëîãèÿ: îò íàóêè ê ïðàêòèêå», «Óêðà¿íñüêèé ìåäè÷íèé â³ñíèê»: æóðíàë «Ôàðìàöåâò ïðàêòèê», ÒÎÂ «Â²Ò-À-ÏÎË» (Ñåðöå ³ ñó-äèíè), ªâðîïåéñüêà ôóíäàö³ÿ ðîçâèòêó ìåäèöèíè é îñâ³òè «ªâðîìåä», Îñâ³òíüî-³íôîðìàö³éíà îíëàéí-ïëàòôîðìà (accemedin.com), Åëåêòðîííèé íàóêîâî-ïðàêòè÷íèé æóðíàë ïðî êàðä³îëîã³þ www.webcardio.org; Óêðà¿íñüêèé êàðä³î-ëîã³÷íèé æóðíàë, ïîðòàë www.ukrcardio.org, www.strazhesko.org.ua, www.facebook.com/strazhesko/

ÐÎÇÊ

ËÀ

Ä Ç

ÀÑ

²ÄÀ

ÍÜ

ÕX

ÍÀ

Ö²Î

ÍÀ

ËÜÍ

ÎÃÎ

ÊÎ

ÍÃÐ

ÅÑÓ

ÊÀ

ÐÄ²Î

ËÎ

Ã²Â

ÓÊ

ÐÀ¯Í

È

Ñåðåäà 25 âåðåñíÿÍ

ÑÊ «

ÎË

²ÌÏ

²ÉÑÜ

ÊÈ

É»

ÕÎË

×ÅÌ

Ï²Î

Í²Â

Êîíô

åðåí

ö-ç

àëà

«ÑÏ

ÀÐÒ

À»

Êîíô

åðåí

ö-ç

àëà

«ÎÄ

²ÑÑÅ

É»

Êîíô

åðåí

ö-ç

àëà

«ÀË

ÜÒ²Ó

Ñ»Êî

íôåð

åíö

-çàë

à «Ñ

²Ò²Ó

Ñ»Êî

íôåð

åíö

-çàë

à «Ñ

ÏÐ²

ÍÒ»

09:0

0–10

:00

ñ. 8

Ñï³ë

üíå

çàñ³

äàíí

ÿ ªâ

ðîïå

éñüê

îãî

òîâà

ðèñò

âà

ç àò

åðîñ

êëåð

îçó,

Óêð

à¿íñ

üêîã

î òî

âàðè

ñòâà

ç à

òåðî

-ñê

ëåðî

çó òà

Ïîë

üñüê

î¿ ë

³ï³ä

íî¿ à

ñîö³

àö³¿

(÷àñ

òèíà

ïåð

øà)

09:0

0–09

:30

ñ. 8

Ëåê

ö³ÿ

ïðî

ô. Ì

. Áàí

àõ. (

Ëîä

çü, Ï

îëüù

à)09

:30–

09:5

0 ñ.

8Ä

óìêà

ñïå

ö³à

ë³ñò

à10

:00–

13:2

0 ñ.

8–9

Íàó

êîâî

-ïðà

êòè÷

í³ ñ

èìïî

ç³óì

è

9:30

–13:

20 ñ

. 9–1

0Ë

åêö

³ÿ, ì

àéñò

åð-ê

ëà-

ñè, í

àóêî

âî-ï

ðàê-

òè÷í

³ ñèì

ïîç³

óìè,

êðóã

ë³ ñò

îëè

9:00

–12:

50 ñ

. 11

Ñåêö

³éíå

çàñ

³äàí

íÿÌ

àéñò

åð ê

ëàñ

Àðè

òìîë

îã³ÿ

: ùî

ïîâè

-íå

í çí

àòè

êîæ

åí ë

³êàð

äëÿ

ë³êà

ð³â

çà ñ

ïåö

³-àë

üí³ñ

òþ «

Çàãà

ëüíà

ïð

àêòè

êà —

ñ³ì

åéíà

ì

åäèö

èíà»

12:5

0–13

:20

ñ. 1

2Ê

ðóãë

èé ñò

³ë

9:00

–11:

00 ñ

. 13

Ñåêö

³éíå

çàñ

³äàí

íÿÖ

óêðî

âèé

ä³àá

åò11

:00–

11:2

0 ñ.

13

Äóì

êà ñ

ïåö

³àë³

ñòà

11:2

0–13

:20

ñ. 1

3–14

Ñåêö

³éíå

çàñ

³äàí

íÿÀ

êòóà

ëüí³

ïèò

àííÿ

ãå

íäåð

íî¿ ì

åäèö

èíè

9:00

–13:

20 ñ

. 15–

16Ñå

êö³é

íå ç

àñ³ä

àííÿ

Ñåðö

åâî-

ñóäè

ííà

â³-

çóàë

³çàö³

ÿ

9:00

–11:

40 ñ

. 16

Ñåêö

³éíå

çàñ

³äàí

íÿÑò

ðåñà

ñîö³

éîâà

í³ ê

îìîð

á³äí

³ ðî

çëàä

è çä

îðîâ

’ÿ ó

ïîñ

òðàæ

-äà

ëèõ

âíàñ

ë³äî

ê çá

ðîéí

îãî

êîíô

ë³êò

ó11

:40–

13:2

0 ñ.

17–

18Ñå

êö³é

íå ç

àñ³ä

àííÿ

Íàó

êîâî

-ä³à

ãíîñ

òè÷í

³ äî-

ñë³ä

æåí

íÿ â

êàð

ä³îë

îã³÷

íó

ïðàê

òèêó

13:2

0–14

:00

ÏÅÐ

ÅÐÂÀ

14.0

0–14

.40

ñ. 9

Ì³æ

äèñö

èïë³

íàðí

èé ê

ðóãë

èé ñò

³ëÌ

îæëè

âîñò

³ êîì

á³íî

âàíî

¿ àíò

èã³ï

åðòå

íçèâ

íî¿

òåðà

ï³¿ à

ìëî

äèï³

í +

âàë

ñàðò

àí +

ã³äð

îõëî

ðîò³à

çèä

14.4

0–15

.20

ñ. 9

Íàó

êîâî

-ïðà

êòè÷

íèé

ñèì

ïîç³

óìÍ

îâ³ ì

îæëè

âîñò

³ àíò

èêîà

ãóëÿ

íòíî

¿ òåð

àï³¿

ó ïà

ö³ºí

-ò³â

ç Í

ÔÏ

òà Ã

ÊÑ15

.20–

16.5

0 ñ.

9–1

0Í

îâèí

è ç

ªâðî

ïåéñ

üêîã

î êî

íãðå

ñó–2

019

Îãë

ÿä ð

åêîì

åíäà

ö³é

ºâðî

ïåéñ

üêîã

î òî

âàðè

ñòâà

êà

ðä³î

ëîã³â

201

9 ð.

14:0

0–16

:40

ñ. 1

0–11

Íàó

êîâî

-ïðà

êòè÷

í³

ñèì

ïîç³

óìè,

êðó

ãë³

ñòîë

è, ï

ðîáë

åìí³

äî

ïîâ³

ä³

14:0

0–16

:30

ñ. 1

2Ñå

êö³é

íå ç

àñ³ä

àííÿ

Ëåê

ö³¿ ä

ëÿ ë

³êàð

³â

çà ñ

ïåö³

àëüí

³ñòþ

«Çà

-ãà

ëüíà

ïðà

êòèê

à —

ñ³-

ìåé

íà ì

åäèö

èíà»

16:3

0–16

:50

ñ. 1

13Ê

ðóãë

èé ñò

³ë

14:0

0–14

:30

ñ. 1

4Ê

ðóãë

èé ñò

³ë14

:30–

16:5

0 ñ.

14

Ñåêö

³éíå

çàñ

³äàí

íÿ

Êàðä

³îöå

ðåáð

àëüí

³ ïî

ðóø

åííÿ

: ïîø

óêè

êîì

îðá³

äíîñ

ò³

14:0

0–14

:40

ñ. 1

6Ê

ðóãë

èé ñ

ò³ë

Ïàö

³ºíò

ç òÿ

æêî

þ Ñ

Í: ô

îêóñ

íà

àêò

èâí³

é ä³

óðåò

è÷í³

é òå

ðàï³

¿14

:40–

16:4

0 ñ.

16

Ñåêö

³éíå

çàñ

³äàí

íÿÊî

ëåã³à

ëüí³

ð³ø

åííÿ

â ñ

òðà-

òåã³ÿ

õ ïð

îô³ë

àêòè

êè òà

ë³-

êóâà

ííÿ

ñåðö

åâî-

ñóäè

ííèõ

óñ

êëàä

íåíü

ïðè

ïðî

âåäå

íí³

ïðîò

èïóõ

ëèíí

î¿ òå

ðàï³

¿

14:0

0–16

:30

ñ. 1

8–19

Êîíê

óðñ

ìîë

îäèõ

â÷å

íèõ

16:5

0–17

:15

ÒÅÕ

Í²×

ÍÀ

ÏÅÐ

ÅÐÂÀ

ÍÑÊ

«Î

Ë²Ì

Ï²É

ÑÜÊ

ÈÉ

» (Õ

ÎË

×ÅÌ

Ï²Î

Í²Â

)

17:1

5 Óð

î÷èñ

òå â

³äêð

èòòÿ

Êîí

ãðåñ

óÍ

àãîð

îäæ

åííÿ

Ðàóò

äëÿ

âñ³

õ ó÷

àñíè

ê³â

Êîíã

ðåñó

×åòâåð 26 âåðåñíÿ

ÍÑÊ

«Î

Ë²Ì

Ï²É

ÑÜÊ

ÈÉ

»Ãî

òåëü

«Ðó

ñü»

ÕÎË

×ÅÌ

Ï²Î

Í²Â

Êîíô

åðåí

ö-ç

àëà

«ÑÏ

ÀÐÒ

À»

Êîíô

åðåí

ö-ç

àëà

«ÎË

²ÌÏ

²ß»

Êîíô

åðåí

ö-ç

àëà

«ÎÄ

²ÑÑÅ

É»

Êîíô

åðåí

ö-ç

àëà

«ÀË

ÜÒ²Ó

Ñ»Âå

ëèêà

êîí

ôåð

åíö

-çàë

à«E

», «

À»,

«B,

Ñ, D

»

9:00

-11:

20 ñ

. 19

Ïëå

íàðí

å çà

ñ³äà

ííÿ

Ãîñò

ðèé

êîðî

íàðí

èé

ñèíä

ðîì

òà ³í

ø³ í

åâ³ä

-êë

àäí³

ñòà

íè11

:20-

13:2

0 ñ.

20

Ïëå

íàðí

å çà

ñ³äà

ííÿ

Ïðà

êòè÷

í³ à

ñïåê

òè í

å-â³

äêëà

äíî¿

êàð

ä³îë

îã³¿

³ êîì

îðá³

äí³ñ

òü(÷

àñòè

íà ï

åðø

à)

9:00

–11:

30 ñ

. 21–

22Ï

ëåíà

ðíå

çàñ³

äàíí

ÿÑò

àá³ë

üíà

³øåì

³÷íà

õâ

îðîá

à ñå

ðöÿ:

ä³à

-ãí

îñòè

êà, ñ

òðàò

èô³ê

à-ö³

ÿ ðè

çèêó

, ïðî

ô³ë

àê-

òèêà

, ë³ê

óâàí

íÿ11

:30–

13:2

0 ñ.

22

Ëåê

ö³ÿ

, êðó

ãë³ ñ

òîëè

9:00

–13:

20 ñ

. 23–

24Ì

àéñò

åð-ê

ëàñè

, êð

óãë³

ñòîë

è, ë

åêö

³ÿ,

àêòó

àëüí

à äè

ñêóñ

³ÿ

9:00

–11:

40 ñ

. 25

Ñåêö

³éíå

çàñ

³äàí

íÿØ

êîëà

ïðà

êòèê

óþ÷î

ãî

ë³êà

ðÿ (ê

ë³í³

÷í³ â

è-ïà

äêè)

11:4

0–12

:50

ñ. 2

5–26

Ñåêö

³éíå

çàñ

³äàí

íÿÍ

îâ³ ò

åíäå

íö³¿

â ë³

êóâà

íí³ ñ

åðöå

âî-

ñóäè

ííèõ

çàõ

âîðþ

-âà

íü. Ä

îêàç

îâà

ìåä

è-öè

íà òà

ðåê

îìåí

äàö³

¿

9:00

–11:

20 ñ

. 27

Ñåêö

³éíå

çàñ

³äàí

íÿÌ

óëüò

èôàê

òîðí

à êî

ðåêö

³ÿ ñ

åðöå

âî-ñ

óäèí

íîãî

ðèç

èêó

11:2

0–12

:30

ñ. 2

7Ñï

³ëüí

å çà

ñ³äà

ííÿ

ªâðî

ïåéñ

üêîã

î òî

âàðè

ñòâà

ç à

òå-

ðîñê

ëåðî

çó, Ó

êðà¿

íñüê

îãî

òîâà

ðèñò

âà ç

àòå

ðîñê

ëåðî

çó

òà Ï

îëüñ

üêî¿

ë³ï

³äíî

¿ àñî

ö³àö

³¿ (÷

àñòè

íà ä

ðóãà

)12

:30—

12:5

0 ñ.

27

Ïðî

áëåì

íà ä

îïîâ

³äü

12:5

0—13

:20

ñ. 2

7Ì

àéñò

åð ê

ëàñ

9:00

–9:3

0 ñ.

29

Ëåê

ö³ÿ

: Î.Ñ

. Ñè÷

îâ (Ê

è¿â)

9:30

-11:

45 ñ

. 29_

30Ñå

êö³é

íå ç

àñ³ä

àííÿ

Àíò

èòðî

ìáî

òè÷í

à òå

ðàï³

ÿ ó

õâî-

ðèõ

ç ô

³áðè

ëÿö³

ºþ ï

åðåä

ñåðä

ü11

:45-

13:2

0 ñ.

30

Ñï³ë

üíå

çàñ³

äàíí

ÿ êð

à¿í

Ñõ³ä

íî¿

òà Ö

åíòð

àëüí

î¿ ª

âðîï

èÀ

ðèòì

³¿ òà

ðàï

òîâà

ñåð

öåâà

ñì

åðòü

13:2

0–14

:00

ÏÅÐ

ÅÐÂÀ

×åòâåð 26 âåðåñíÿ

ÍÑÊ

«Î

Ë²Ì

Ï²É

ÑÜÊ

ÈÉ

»Ãî

òåëü

«Ðó

ñü»

ÕÎË

×ÅÌ

Ï²Î

Í²Â

Êîíô

åðåí

ö-ç

àëà

«ÑÏ

ÀÐÒ

À»

Êîíô

åðåí

ö-ç

àëà

«ÎË

²ÌÏ

²ß»

Êîíô

åðåí

ö-ç

àëà

«ÎÄ

²ÑÑÅ

É»

Êîíô

åðåí

ö-ç

àëà

«ÀË

ÜÒ²Ó

Ñ»Çà

ëàE,

AÇà

ëàB,

C, D

Çàëà F,

14:0

0–15

:45

ñ. 2

0Ï

ëåí

àðí

å çà

ñ³ä

àíí

ÿÏ

ðàêò

è÷í³

àñï

åêòè

íå-

â³äê

ëàäí

î¿ ê

àðä³

îëîã

³¿ ³ ê

îìîð

á³äí

³ñòü

(÷àñ

òèíà

äðó

ãà)

14:0

0–14

:45

ñ. 2

0Òå

ëåì

³ñò

Óêðà

¿íà

— Ñ

ØÀ

ÃÊÑ

³ öó

êðîâ

èé ä

³àáå

ò14

:45–

15:4

5 ñ.

20

Êðó

ãëè

é ñ

ò³ë,

ëåê

ö³ÿ

15:4

5–18

:15

ñ. 2

0–21

Ïëå

íàð

íå

çàñ³

äàí

íÿ

Ñï³

ëüíå

çàñ

³äàí

íÿ

Âñåó

êðà¿

íñüê

î¿ à

ñî-

ö³àö

³¿ ³í

òåðâ

åíö³

éíèõ

êà

ðä³î

ëîã³

â Óê

ðà¿í

è òà

Àñî

ö³àö

³¿ êà

ðä³î

õ³-

ðóðã

³â Ó

êðà¿

íè

14:0

0–14

:30

ñ. 2

2Ê

ðóãë

èé

ñò³

ëÀ

íòèã

³ïåð

òåíç

èâíà

òå

ðàï³

ÿ ó

õâîð

îãî

íà ö

óêðî

âèé

ä³àá

åò:

åôåê

òèâí

³ñòü

çàð

àäè

æèò

òÿ14

:30–

17:3

0 ñ.

22–

23Ï

ëåí

àðí

å çà

ñ³ä

àíí

ÿÀ

ðòåð

³àëü

íà ã

³ïåð

-òå

íç³ÿ

14:0

0–14

:30

ñ. 2

4Ì

àéñò

åð-ê

ëàñ

Âèïð

àâäà

í³ í

àä³¿

àáî

íîâå

â ë

³êóâ

àíí³

ïàö

³ºíò

³â

³ç õ

ðîí³

÷íîþ

ñåð

öåâî

þ í

å-äî

ñòàò

í³ñò

þ ³

çáåð

åæåí

îþ

ôðà

êö³º

þ â

èêèä

ó14

:30–

18:0

0 ñ.

24–

25Ï

ëåí

àðí

å çà

ñ³ä

àíí

ÿÑ

åðöå

âà í

åäîñ

òàòí

³ñòü

14:0

0–14

:30

ñ. 2

6Ê

ðóãë

èé

ñò³

ë«Ä

²ÀÌ

ÀÍ

Ò» â

ï³ä

õîä³

äî

ïåð

ñîí³

ô³ê

îâàí

î-ãî

ë³ê

óâàí

íÿ ³ø

åì³¿

ì³î

êðàä

à14

:30–

16:3

0 ñ.

26–

27Ï

ëåí

àðí

å çà

ñ³ä

àíí

ÿÊî

ìîð

á³äí

³ ñòà

íè

â êà

ðä³î

ëîã³

¿16

:30–

17:0

0 ñ.

27

Êðó

ãëè

é ñ

ò³ë

Ïåð

èïàð

òàëü

íà ê

àðä³

î-ì

³îïà

ò³ÿ

ç òî

÷êè

çîðó

êà

ðä³î

ëîãà

òà

ã³íå

êî-

ëîãà

: ä³à

ëîã

ïðîô

åñ³-

îíàë

³â17

:00–

17:2

0 ñ.

27

Ïðî

áëåì

íà

äîï

îâ³ä

üC

ó÷àñ

í³ ï

îçèö

³¿ ñò

à-òè

íîòå

ðàï³

¿ ó õ

âîðè

õ ç

êàðä

³îâñ

êóëÿ

ðíîþ

ïà

òîëî

ã³ºþ

14:0

0–17

:50

ñ. 2

8–29

Ïëå

íàð

íå

çàñ³

äàí

íÿ

Ëåã

åíåâ

à ã³

ïåðò

åíç³

ÿ â

êë³í

³÷íè

õ âè

ïàäê

àõ

14:0

0–16

:45

ñ. 3

0–31

Cåê

ö³é

íå

çàñ³

äàí

íÿ

Àðè

òì³¿

³ êîì

îð-

á³äí

³ñòü

16:4

5–17

:45

ñ. 3

1C

åêö

³éí

å çà

ñ³ä

àíÿ

Êë³í

³÷í³

âèï

àäêè

14:0

0–14

:30

ñ. 3

1Ê

ðóãë

èé

ñò³

ëÒå

ðàï³

ÿ ô

³áðè

ëÿ-

ö³¿ ï

åðåä

ñåðä

ü —

ª

âðîï

åéñü

ê³

ðåêî

ìåí

äàö³

¿ òà

âëà

ñíèé

äî-

ñâ³ä

14:3

0–15

:10

ñ. 3

1Ï

ðîáë

åìí

³ äî-

ïîâ³

ä³

15:1

0–17

:45

ñ. 3

2C

åêö

³éí

å çà

ñ³ä

àíÿ

²íòå

ðâåí

ö³éí

à àð

èòì

îëîã

³ÿ

14:0

0–17

:40

ñ. 3

2–33

Ìàé

ñòåð

-êë

àñè

Ïðà

êòè÷

í³

íàâè

÷êè

äëÿ

ë³êó

âàíí

ÿ õâ

îðèõ

³ç

ïîð

óøåí

-íÿ

ìè

ðèòì

ó òà

ïðî

â³ä-

íîñò

³ ñåð

öÿ

Ï’ÿòíèöÿ 27 âåðåñíÿ

ÍÑÊ

«Î

Ë²Ì

Ï²É

ÑÜÊ

ÈÉ

»Õ

ÎË

×ÅÌ

Ï²Î

Í²Â

Êîí

ôåð

åíö

-çàë

à «Î

Ä²Ñ

ÑÅÉ

»Êî

íô

åðåí

ö-ç

àëà

«ÀË

ÜÒ²Ó

Ñ»

9:00

–9:3

0 ñ.

33

Ëåê

ö³ÿ

Î.À

. Êðè

êóíî

â9:

30–1

3:00

ñ. 3

3–34

Ïëå

íàð

íå

çàñ³

äàí

íÿ

Õâî

ðîáè

ì³î

êàðä

à, å

íäîê

àðäà

òà

êëàï

àí³â

ñåð

öÿ

9:00

–11:

30 ñ

. 34–

35Ï

ëåí

àðí

å çà

ñ³ä

àíí

ÿ²í

íîâà

ö³¿ ä

³àãí

îñòè

êè ò

à ë³

êóâà

ííÿ

àðòå

ð³àë

üíî¿

ã³ï

åðòå

íç³¿

10:5

0–11

:20

ñ. 3

5Ì

àéñò

åð-ê

ëàñ

Òåðà

ï³ÿ

õâîð

èõ í

à öó

êðîâ

èé ä

³àáå

ò 2

-ãî

òèïó

: ÿê

ïîêð

àùèò

è ñå

ðöåâ

î-ñó

äèí-

íèé

ïðîã

íîç

11:2

0–11

:30

ñ. 3

5Ä

óìêà

ñïå

ö³à

ë³ñò

àÌ

³ñöå

ïîä

â³éí

î¿ ³

ïîòð

³éíî

¿ êîì

á³íî

âàíî

¿ àíò

èã³ï

åðòå

íçèâ

íî¿ ò

åðàï

³¿ â

ñó÷à

ñ-íè

õ ñõ

åìàõ

ë³ê

óâàí

íÿ11

:30–

13:1

5 ñ.

35–

36Ñ

åêö

³éí

å çà

ñ³ä

àíí

ÿÁ³

îìàð

êåðè

ó ê

àðä³

îëîã

³¿

9:00

–12:

00 ñ

. 36

Ìàñ

òåð-

êëàñ

êàð

ä³î

ëîãà

ç í

åâðî

ëîãî

ì:

âðÿò

óºì

î Óê

ðà¿í

ó â³

ä ³í

ñóëü

ò³â

ðàçî

ì9:

30–1

3:00

ñ. 3

6–37

Ïëå

íàð

íå

çàñ³

äàí

íÿ

Àêò

óàëü

í³ ï

èòàí

íÿ ï

ðåâå

íòèâ

íî¿ ê

àðä³

îëîã

³¿ òà

ðåà

á³ë³

òàö³

¿

ÍÑÊ

«Î

Ë²Ì

Ï²É

ÑÜÊ

ÈÉ

» (Õ

ÎË

×ÅÌ

Ï²Î

Í²Â

)13

:15—

15:3

0 ñ.

34

Ãåí

åðàë

üíà

àñàì

áëåÿ

Çàêð

èòò

ÿ Êî

íãð

åñó


8

25 â

åðåñ

íÿ

(ñåð

åäà)

PROGRAM OF MEETINGS25-TH OF SEPTEMBER (WEDNESDAY)

NSK «OLYMPIYSKIY»

HALL OF CHAMPIONS9:00–10:00 Joint meeting of the European Atherosclerosis Society, Ukrainian Atherosclerosis Society and Polish Lipid AssociationModerators: prof. O.I. Mitchenko, prof. M.I. Lutay, prof.

M. Banach, prof. Z. Petrulioniene Part One

9:00–9:30 Lecture: Prof. M. Banakh., President of the Polish Mother’s Memorial Hospital Research Institute, President of the Polish Lipid Association (PoLA), EAS Advisor in Matters related to EU Relations, (Lodz, Poland)New aspects of hypolipidemic therapy

9:30–9:50 Opinion of the specialistDiagnosis and treatment of family hypercholesterolemia in Ukraine. The role of inhibitors of PCSK9

prof. O.I. Mitchenko (Kyiv) – 20 minDiscussion – 10 min

10:00–10:40 Scientific-practical symposiumPrimary and secondary prevention: is there a difference in approach?Participants: prof. O.Y. Zharinov, L.A. Mishchenko MD (Kyiv)

10:40–11:20 Scientific-practical symposiumAnticoagulation with NOAC in high CV risk: management in CAD and in nvAF patients

Participants: prof. O.S. Sychov (Kyiv), prof. O.A. Koval (Dni-pro)

11:20–12:00 Scientific-practical symposiumThe role of combined neprilysine/angiotensin II receptor blockade in realization of personalized treatment strategy in chronic heart failureParticipauts: prof. L.G. Voronkov, prof. O.M. Parkhomenko

(Kyiv)

12:00–12:40 Scientific-practical symposium 1. AH treatment for patient with T2D: evidence-based

choice

prof. S.A. Tykhonova (Odesa) – 10 min2. Patient with CHD and AH: practical aspects of treat-

mentO.I. Irkin MD (Kyiv) – 10 min

3. Combined antihypertensive therapy in patients with comorbiditiesL.A. Mishchenko MD (Kyiv) — 10 min

Discussion — 10 min

ÏÐÎÃÐÀÌÀ ÇÀÑ²ÄÀÍÜ25 ÂÅÐÅÑÍß (ÑÅÐÅÄÀ)

ÍÑÊ «ÎË²ÌÏ²ÉÑÜÊÈÉ»

ÕÎË ×ÅÌÏ²ÎÍ²Â9:00–10:00 Ñï³ëüíå çàñ³äàííÿ ªâðîïåéñüêîãî òîâàðè-ñòâà ç àòåðîñêëåðîçó, Óêðà¿íñüêîãî òîâàðèñòâà ç àòåðî-ñêëåðîçó òà Ïîëüñüêî¿ ë³ï³äíî¿ àñîö³àö³¿ Ìîäåðàòîðè: ïðîô. Î.². Ì³ò÷åíêî, ïðîô. Ì.². Ëóòàé, ïðîô.

Ì. Áàíàõ, ïðîô. Æ. Ïåòðóë³îí³íå ×àñòèíà ïåðøà

9:00–9:30 Ëåêö³ÿ: ïðîô. Ì. Áàíàõ (Ëîäçü, Ïîëüùà), Presi-dent of Polish Mother’s Memorial Hospital Research Institute, President of Polish Lipid Association (PoLA), EAS Advisor in Mat-ters related to EU Relations, Poland, Lodz

Íîâ³ àñïåêòè ã³ïîë³ï³äåì³÷íî¿ òåðàï³¿

9:30–9:50 Äóìêà ñïåö³àë³ñòàÄ³àãíîñòèêà òà ë³êóâàííÿ ñ³ìåéíèõ ã³ïåðõîëåñòåðèíåì³é â Óêðà¿í³. Ðîëü ³íã³á³òîð³â PCSK9

ïðîô. Î.². Ì³ò÷åíêî (Êè¿â) — 20 õâÎáãîâîðåííÿ — 10 õâ

10:00–10:40 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óìÏåðâèííà ³ âòîðèííà ïðîô³ëàêòèêà: ÷è º ð³çíèöÿ â ï³äõîäàõ?Ó÷àñíèêè: ïðîô. Î.É. Æàð³íîâ, ä.ì.í. Ë.À. Ì³ùåíêî (Êè¿â)

10:40–11:20 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óìÀíòèêîàãóëÿíòíà òåðàï³ÿ ÍÎÀÊ ó ïàö³ºíò³â âèñîêîãî ñåðöåâî-ñóäèííîãî ðèçèêó: îñîáëèâîñò³ çàñòîñóâàííÿ ó õâîðèõ ³ç ñèíóñîâèì ðèòìîì òà çà íàÿâíîñò³ íÔÏ Ó÷àñíèêè: ïðîô. Î.Ñ. Ñè÷îâ (Êè¿â), ïðîô.Î.À. Êîâàëü

(Äí³ïðî)

11:20–12:00 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óìÐîëü êîìá³íîâàíî¿ áëîêàäè íåïðèë³çèíó òà ðåöåïòîð³â àíã³îòåíçèíó ²² ó ðåàë³çàö³¿ ñòðàòåã³¿ ïåðñîí³ô³êîâàíîãî ë³êóâàííÿ ïðè õðîí³÷í³é ñåðöåâ³é íåäîñòàòíîñò³Ó÷àñíèêè: ïðîô. Ë.Ã.Âîðîíêîâ, ïðîô. Î.Ì. Ïàðõîìåíêî

(Êè¿â)

12:00–12:40 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óì1. Àíòèã³ïåðòåíçèâíà òåðàï³ÿ äëÿ ïàö³ºíò³â ç öóêðî-

âèì ä³àáåòîì 2-ãî òèïó: âèá³ð íà äîêàçîâèõ çàñà-äàõïðîô. Ñ.À. Òèõîíîâà (Îäåñà) — 10 õâ

2. Ïàö³ºíò ç ³øåì³÷íîþ õâîðîáîþ ñåðöÿ òà àðòåð³-àëüíîþ ã³ïåðòåíç³ºþ: ïðàêòè÷í³ àñïåêòè ë³êóâàííÿä.ì.í. Î.². ²ðê³í (Êè¿â) — 10 õâ

3. Êîìá³íîâàíà àíòèã³ïåðòåíçèâíà òåðàï³ÿ äëÿ ïàö³-ºíò³â ç êîìîðá³äíèìè ñòàíàìèä.ì.í. Ë.À. Ì³ùåíêî (Êè¿â) — 10 õâ

Îáãîâîðåííÿ — 10 õâ


9

25th

of

Sept

embe

r (W

edne

sday

)

12:40–13:20 Scientific-practical symposium1. Does treatment of AH with beta-blockers depend

on stage of disease?prof. Yu.M. Sirenko (Kyiv) – 20 min

2. Metabolic agents in treatment of ischemic heart dis-ease: how to choose?prof. E.G. Nesukay (Kyiv) – 20 min

13:00–14:00 BREAK

14:00–14:40 Interdisciplinary Round tableFeasibility of combination antihypertensive therapy amlodipine + valsartan + hydrochlorothiazideParticipauts: prof. M. Banach (Poland, Lodz), L.A. Mishchenko

MD (Kyiv), Z.M. Kravchuk PhD (Kyiv)

14:40–15:20 Scientific-practical symposiumNew possibility anticoagulant therapy for treatment of patients with NAF and ACS1. Antithrombotic therapy after Acute Coronary Syn-

drome or PCI in Atrial Fibrillation

prof. O.S. Sychov(Kyiv) – 20 min2. Will the results of the AUGUSTUS study change the

guidelines for the management of patients with AF?O.I. Irkin MD (Kyiv) – 20 min

15:20–16:50 Hotline ESC 20192019 ESC GUIDELINES OVERVIEW

1. 2019 ESC Guidelines on Stable CAD

prof. Yu.M. Sirenko – 15 min2. 2019 ESC/EAS Guidelines on Dyslipidaemias

prof. O.I. Mitchenko – 15 min3. 2019 ESC Guidelines on Supraventricular Tachycardia

prof. O.S. Sychov – 15 min4. 2019 ESC Guidelines on Acute Pulmonary Embolism

prof. O.M. Parkhomenko – 15 min5. 2019 ESC/EASD Guidelines on Diabetes, Pre-diabetes,

and Cardiovascular Diseasesprof. E.G. Nesukay – 15 min

16:50–17:15 TECHNICAL BREAK

17:15 Grand opening of the congressCongratulations to the participants of the ÕX National Congress of Cardiologists of UkraineAwardingProblem lectureComorbidity and cardiovascular continuum — a new paradigm in cardiology Awarding

acad. of NAMS of Ukraine, prof. V.M. KovalenkoRout for all Congress members

CONFERENCE HALL «SPARTA»9:00–9:30 Lecture: prof. M.M. Oros (Uzhhorod)Myofascial syndrome as a cause of heart pain

12:40–13:20 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óì1. ×è çàëåæèòü ë³êóâàííÿ ÀÃ áåòà-áëîêàòîðîì â³ä ñòà-

ä³¿ çàõâîðþâàííÿ? ïðîô. Þ.Ì. Ñ³ðåíêî (Êè¿â) — 20 õâ

2. Ìîäóëÿòîðè ìåòàáîë³çìó ó ë³êóâàíí³ ³øåì³÷íî¿ õâîðîáè ñåðöÿ: ÿê îáðàòè?ïðîô. Î.Ã. Íåñóêàé (Êè¿â) — 20 õâ

13:20–14:00 ÏÅÐÅÐÂÀ

14:00–14:40 Ì³æäèñöèïë³íàðíèé êðóãëèé ñò³ëÌîæëèâîñò³ êîìá³íîâàíî¿ àíòèã³ïåðòåíçèâíî¿ òåðàï³¿ àìëîäèï³í + âàëñàðòàí + ã³äðîõëîðîò³àçèäÓ÷àñíèêè: ïðîô. Ì. Áàíàõ (Ëîäçü, Ïîëüùà), ä.ì.í. Ë.À. Ì³-

ùåíêî, ê.á.í. Æ.Ì. Êðàâ÷óê (Êè¿â)

14:40–15:20 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óìÍîâ³ ìîæëèâîñò³ àíòèêîàãóëÿíòíî¿ òåðàï³¿ ó ïàö³ºíò³â ç ÍÔÏ òà ÃÊÑ1. Àíòèòðîìáîòè÷íà òåðàï³ÿ ïàö³ºíò³â ç ÍÔÏ ï³ñëÿ ãî-

ñòðîãî êîðîíàðíîãî ñèíäðîìó àáî ÷åðåçøê³ðíîãî êîðîíàðíîãî âòðó÷àííÿ ïðîô. Î.Ñ. Ñè÷îâ (Êè¿â) — 20 õâ

2. ×è çì³íÿòü ðåçóëüòàòè äîñë³äæåííÿ AUGUSTUS ðå-êîìåíäàö³¿ ç âåäåííÿ ïàö³ºíò³â ç ÔÏ?ä.ì.í. Î.². ²ðê³í (Êè¿â) — 20 õâ

15:20–16:50 Íîâèíè ç ªâðîïåéñüêîãî êîíãðåñó–2019 ÎÃËßÄ ÐÅÊÎÌÅÍÄÀÖ²É ªÂÐÎÏÅÉÑÜÊÎÃÎ ÒÎÂÀÐÈÑÒÂÀ ÊÀÐÄ²ÎËÎÃ²Â 2019 ð.1. Ðåêîìåíäàö³¿ ùîäî ñòàá³ëüíî¿ ³øåì³÷íî¿ õâîðîáè

ñåðöÿïðîô. Þ.Ì. Ñ³ðåíêî — 15 õâ

2. Ðåêîìåíäàö³¿ ùîäî äèñë³ï³äåì³¿ïðîô. Î.². Ì³ò÷åíêî — 15 õâ

3. Ðåêîìåíäàö³¿ ùîäî íàäøëóíî÷êîâî¿ òàõ³êàðä³¿ïðîô. Î.Ñ. Ñè÷îâ — 15 õâ

4. Ðåêîìåíäàö³¿ ùîäî ãîñòðî¿ ëåãåíåâî¿ åìáîë³¿ïðîô. Î.Ì. Ïàðõîìåíêî — 15 õâ

5. Ðåêîìåíäàö³¿ ùîäî ä³àáåòó, ïåðåää³àáåòó òà ñåðöåâî- ñóäèííèõ çàõâîðþâàíü ïðîô. Î.Ã. Íåñóêàé — 15 õâ

16:50–17:15 ÒÅÕÍ²×ÍÀ ÏÅÐÅÐÂÀ

17:15 Óðî÷èñòå â³äêðèòòÿ êîíãðåñóÂ³òàííÿ ó÷àñíèêàì ÕX Íàö³îíàëüíîãî êîíãðåñó êàðä³îëîã³â Óêðà¿íè ÍàãîðîäæåííÿÏðîáëåìíà äîïîâ³äüÊîìîðá³äí³ñòü òà ñåðöåâî-ñóäèííèé êîíòèíóóì — íîâà ïàðàäèãìà â êàðä³îëîã³¿

àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ì. ÊîâàëåíêîÐàóò äëÿ âñ³õ ó÷àñíèê³â Êîíãðåñó

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÑÏÀÐÒÀ»9:00–9:30 Ëåêö³ÿ: ïðîô. Ì.Ì. Îðîñ (Óæãîðîä) Ì³îôàñö³àëüíèé ñèíäðîì ÿê ïðè÷èíà áîëþ â ä³ëÿíö³ ñåðöÿ


10

25 â

åðåñ

íÿ

(ñåð

åäà)

9:30–10:00 Master class (clinical analysis)Optimization of antithrombotic therapy in patients with NAF and ACSParticipanyts: O.M. Romanova PhD, O.I. Irkin MD (Kyiv)

10:00–10:30 Scientific-practical symposium1. Secondary arterial hypertension and fixed combina-

tions for monitoring blood pressureprof. Yu.M. Sirenko (Kyiv) – 15 min

2. Pseudoreflective hypertension, control of blood pres-sure in Ukraineprof. T.V. Kolesnyk (Dnipro) — 15 min

10:30–11:00 Master classEra of NOACs in anticoagulant treatment of VTE patients: from guidelines to the clinical practice

corr.-member of NAMS of Ukraine, prof. O.M. Parkhomenko (Kyiv)

11:00–11:30 Scientific-practical symposium1. The efficacy of statin therapy for the prevention of car-

diovascular disease: ROSOVOSTATINprof. Yu.M. Sirenko (Kyiv) – 15 min

2. Modern principles of hypolipidemic and antiplatelet therapy, taking into account current international rec-ommendationsL.A.Mishchenko MD (Kyiv) – 15 min

11:30–12:00 Master classAppreciation of the Omega-3 (840 mg) efficacy and safety in patients with heart rhythm disturbances on the IHD backgroundParticipanyts: prof. T.V. Talaeva, O.M. Romanova PhD (Kyiv)

12:00–12:50 Scientific-practical symposium1. Recent recommendations on the use of anticoagulant

therapyprof. O.S. Sychov (Kyiv) – 20 min

2. Clinical pharmacology of anticoagulant therapy

prof A.V. Zaichenko (Kyiv) – 20 minDiscussion — 10 min

12:50–13:20 Scientific-practical symposiumSecondary prevention of cardiovascular diseases: reality and new guidelinesParticipanyts: corr.-member of NAMS of Ukraine, prof.

O.M. Parkhomenko (Kyiv), prof. Î.À. Koval (Dnipro)

13:20–14:00 BREAK

14:00–14:40 Scientific-practical symposiumPreventing of athero-trombotic events in patients with coronary disease1. Adherence in ACS patients: when should we start

to fight?corr.-member of NAMS of Ukraine prof. O.M. Parkhomen-ko (Kyiv) – 20 min

9:30–10:00 Ìàéñòåð-êëàñ (êë³í³÷íèé ðîçá³ð)Îïòèì³çàö³ÿ àíòèòðîìáîòè÷íî¿ òåðàï³¿ ó ïàö³ºíò³â ç ÍÔÏ òà ãîñòðèì êîðîíàðíèì ñèíäðîìîì Ó÷àñíèêè: ê.ì.í. Î.Ì. Ðîìàíîâà, ä.ì.í. Î.². ²ðê³í (Êè¿â)

10:00–10:30 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óì 1. Âòîðèíí³ àðòåð³àëüí³ ã³ïåðòåíç³¿ ³ ô³êñîâàí³ êîìá³-

íàö³¿ äëÿ êîíòðîëþ ÀÒïðîô. Þ.Ì. Ñ³ðåíêî (Êè¿â) — 15 õâ

2. Ïñåâäîðåçèñòåíòí³ ÀÃ, ïðîáëåìè êîíòðîëþ ÀÒ â Óêðà-¿í³ïðîô. Ò.Â. Êîëåñíèê (Äí³ïðî) — 15 õâ

10:30–11:00 Ìàéñòåð-êëàñÅðà ÍÎÀÊ â àíòèêîàãóëÿíòí³é òåðàï³¿ ïàö³ºíò³â ³ç ÂÒÅ: â³ä ðåêîìåíäàö³é äî êë³í³÷íî¿ ïðàêòèêè

÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Î.Ì. Ïàðõîìåíêî (Êè¿â)

11:00–11:30 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óì1. Åôåêòèâí³ñòü òåðàï³¿ ñòàòèíàìè äëÿ ïðîô³ëàêòèêè

ñåðöåâî-ñóäèííèõ çàõâîðþâàíü: ÐÎÇÓÂÀÑÒÀÒÈÍïðîô. Þ.Ì. Ñ³ðåíêî (Êè¿â) — 15 õâ

2. Ïðèíöèïè ã³ïîë³ï³äåì³÷íî¿ òà àíòèòðîìáîöèòàðíî¿ òåðàï³¿ ç óðàõóâàííÿì ñó÷àñíèõ ì³æíàðîäíèõ ðå-êîìåíäàö³éä.ì.í. Ë.À. Ì³ùåíêî (Êè¿â) — 15 õâ

11:30–12:00 Ìàéñòåð-êëàñÎö³íêà êë³í³÷íî¿ åôåêòèâíîñò³ òà áåçïåêè îìåãà-3 (840 ìã) ó õâîðèõ ç ïîðóøåííÿìè ðèòìó ñåðöÿ íà ôîí³ ³øåì³÷íî¿ õâîðîáè ñåðöÿÓ÷àñíèêè: ïðîô. Ò.Â. Òàëàºâà, ê.ì.í. Î.Ì. Ðîìàíîâà (Êè¿â)

12:00–12:50 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óì1. Îñòàíí³ ðåêîìåíäàö³¿ ùîäî çàñòîñóâàííÿ àíòèêîà-

ãóëÿíòíî¿ òåðàï³¿ïðîô. Î.Ñ. Ñè÷îâ (Êè¿â) — 20 õâ

2. Êë³í³÷íà ôàðìàêîëîã³ÿ àíòèêîàãóëÿíòíèõ ïðåïà-ðàò³âïðîô. Ã.Â. Çàé÷åíêî (Êè¿â) — 20 õâ


12:50–13:20 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óì Âòîðèííà ïðîô³ëàêòèêà ñåðöåâî-ñóäèííèõ çàõâîðþâàíü: ðåàëüí³ñòü ³ íîâ³ ðåêîìåíäàö³¿Ó÷àñíèêè: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Î.Ì. Ïàðõîìåíêî

(Êè¿â), ïðîô. Î.À. Êîâàëü (Äí³ïðî)

13:20–14:00 ÏÅÐÅÐÂÀ

14:00–14:40 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óìÇàïîá³ãàííÿ àòåðîòðîìáîòè÷íèì ïîä³ÿì ó ïàö³ºíò³â ç êîðîíàðíîþ õâîðîáîþ1. Ïðèõèëüí³ñòü äî òåðàï³¿ ó ïàö³ºíò³â ç ãîñòðèì êîðî-

íàðíèì ñèíäðîìîì: êîëè ïî÷èíàòè áîðîòüáó÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Î.Ì. Ïàðõîìåíêî (Êè¿â) — 20 õâ


11

25th

of

Sept

embe

r (W

edne

sday

)

2. CAD pts: what should we do for preventing cardio-vascular events

prof. Mikhail Kosiborod (Kansas-city) – 20 min

14:40–15:20 Scientific-practical symposiumÑarnitine synthesis blocade in cardiovascular pathology and comorbid conditionsParticipanyts: prof. Virginijus Sapoka (Vilnius, Lithuania), prof.

L.G. Voronkov (Kyiv)

15:20–15:40 Professional`s point of viewDiastolic HF — a modern view of the problem

D.V. Ryabenko MD (Kyiv)

15:40–16:20 Round tableDonators of the cycle of tricarboxylic acids. Can they help?Participanyts: prof. T.V. Talaeva, O.I. Irkin MD, O.M. Romanova

PhD (Kyiv)

16:20–16:40 Opinion of the specialistVasoprotection in patients with coronary heart disease (CHD): possibilities for controlling the stability of coronary flow

prof. N.M. Seredyuk (Ivano-Frankivsk)

CONFERENCE HALL «ODISSEY»9:00-12:50 Section meetingMaster classARITHMOLOGY: WHAT SHOULD YOU KNOW EVERY DOCTORfor doctors in the specialty «General practice — family medicine»Moderators: G.M. Solovyan PhD, O.I. Frolov PhD

Welcome address – prof. O.S. Sychov (Kyiv) – 10 min1. Atrial fibrillation: diagnostics and features of treat-

mentO.M. Romanova (Kyiv) – 20 min

2. Does left ventricular hypertrophy critical factor for choosing of antiarrhythmic drug?A.O. Borodai (Kyiv) – 20 min

3. Selection of patients for invasive treatment of cardiac arrhythmiasS.V. Lisogub, O.S. Sychov, E.V. Mogilnitskii (Kyiv) — 20 min

4. Syncope caused by cardiac arrhythmias. Diagnosis and treatmentO.I. Frolov (Kyiv) — 20 min

5. Supraventricular tachycardias: modern methods in the diagnosis and treatmentG.M. Solovyan (Kyiv) — 20 min

6. Ventricular arrhythmias. Diagnostics and modern methods of treatment. Sudden cardiac death and its preventionYu.V. Zinchenko (Kyiv) — 20 min

2. Ïàö³ºíòè ç õðîí³÷íîþ êîðîíàðíîþ õâîðîáîþ: ùî ïîòð³áíî çðîáèòè äëÿ ïðîô³ëàêòèêè êàðä³îâàñ-êóëÿðíèõ ïîä³éïðîô. Ì³õà³ë Êîñ³áîðîä (Êàíçàñ-ñ³ò³) — 20 õâ

14:40–15:20 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óì Áëîêàäà ñèíòåçó êàðí³òèíó ïðè êàðä³îâàñêóëÿðí³é ïàòîëîã³¿ òà êîìîðá³äíèõ ñòàíàõÓ÷àñíèêè: ïðîô. Â³ðã³í³þñ Øàïîêà (Â³ëüíþñ, Ëèòâà), ïðîô.

Ë.Ã. Âîðîíêîâ (Êè¿â)

15:20–15:40 Ïîãëÿä ïðîôåñ³îíàëàÄ³àñòîë³÷íà ñåðöåâà íåäîñòàòí³ñòü — ñó÷àñíèé ïîãëÿä íà ïðîáëåìó

ä.ì.í. Ä.Â. Ðÿáåíêî (Êè¿â)

15:40–16:20 Êðóãëèé ñò³ëÄîíàòîðè öèêëó òðèêàðáîíîâèõ êèñëîò. ×è ìîæóòü âîíè äîïîìîãòè?Ó÷àñíèêè: ïðîô. Ò.Â. Òàëàºâà, ä.ì.í. Î.². ²ðê³í, ê.ì.í.

Î.Ì. Ðîìàíîâà (Êè¿â)

16:20–16:40 Äóìêà ñïåö³àë³ñòàÂàçîïðîòåêö³ÿ ó ïàö³ºíò³â ³ç ³øåì³÷íîþ õâîðîáîþ ñåðöÿ (²ÕÑ): ìîæëèâîñò³ êîíòðîëþ ñòàá³ëüíîñò³ êîðîíàðíîãî êðîâîïëèíó

ïðîô. Í.Ì. Ñåðåäþê (²âàíî-Ôðàíê³âñüê)

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÎÄ²ÑÑÅÉ»9:00-12:50 Ñåêö³éíå çàñ³äàííÿÌàéñòåð-êëàñÀÐÈÒÌÎËÎÃ²ß: ÙÎ ÏÎÂÈÍÅÍ ÇÍÀÒÈ ÊÎÆÅÍ Ë²ÊÀÐäëÿ ë³êàð³â çà ñïåö³àëüí³ñòþ «Çàãàëüíà ïðàêòèêà — ñ³ìåéíà ìåäèöèíà»Ìîäåðàòîðè: ê.ì.í. Ã.Ì. Ñîëîâ’ÿí, ê.ì.í. Î.². Ôðîëîâ

Âñòóïíå ñëîâî — ïðîô. Î.Ñ. Ñè÷îâ (Êè¿â) — 10 õâ1. Ô³áðèëÿö³ÿ ïåðåäñåðäü: ä³àãíîñòèêà òà îñîáëèâîñò³

òåðàï³¿ Î.Ì. Ðîìàíîâà (Êè¿â) — 20 õâ

2. Åõîêàðä³îãðàô³ÿ ó õâîðèõ ç àðèòì³ÿìè: çíà÷åííÿ ìåòîäó À.Î. Áîðîäàé (Êè¿â) — 20 õâ

3. Â³äá³ð õâîðèõ äî ³íâàçèâíîãî ë³êóâàííÿ àðèòì³é ñåðöÿ Ñ.Â. Ëèçîãóá, Î.Ñ. Ñè÷îâ, ª.Â. Ìîãèëüíèöüêèé (Êè¿â) — 20 õâ

4. Ñèíêîïàëüí³ ñòàíè ïðè ïîðóøåííÿõ ðèòìó ñåðöÿ. Ä³àãíîñòèêà ³ ë³êóâàííÿ Î.². Ôðîëîâ (Êè¿â) — 20 õâ

5. Ñóïðàâåíòðèêóëÿðí³ òàõ³êàðä³¿: ñó÷àñí³ ìåòîäè ä³à-ãíîñòèêè ³ ë³êóâàííÿÃ.Ì. Ñîëîâ’ÿí (Êè¿â) — 20 õâ

6. Øëóíî÷êîâ³ ïîðóøåííÿ ðèòìó ñåðöÿ. Ä³àãíîñòè-êà ³ ñó÷àñí³ ìåòîäè ë³êóâàííÿ. Ðàïòîâà êàðä³àëüíà ñìåðòü òà ¿¿ ïðîô³ëàêòèêàÞ.Â. Ç³í÷åíêî (Êè¿â) — 20 õâ


12

25 â

åðåñ

íÿ

(ñåð

åäà)

7. Features of arrhythmias management during preg-nancyM.Z. Cherednichenko PhD (Kyiv) – 20 min

8. Antithrombotic therapy for atrial fibrillation

T.V. Hetman (Kyiv) — 20 min9. Guidelines for the management of patients with car-

diac arrhythmias during cancer treatmentE.V. Mogilnitskii (Kyiv) – 20 min

10. Reabilitation of patients with arrhythmiasO.V. Sribna (Kyiv) – 20 min


12:50–13:20 Round tablePatients with ACS, AF and CH: how to treat such patients

Participators: O.I. Irkin MD, O.M. Romanova PhD (Kyiv)

13:20-14:00 BREAK

14:00–16:30 Section meeting LECTURES FOR DOCNORS ON THE SPECIALTY «GENERAL PRACTICE — FAMILY MEDICINE»Moderators: prof. M.M. Dolzhenko, prof. S.O. Andriyevska,

prof. M.M. Seliuk1. Possibilities of organoprotection of the triple com-

bined therapy of hypertensionK.Y. Egorov (Dnipro) – 15 min

2. The modern possibilities of treatment of chronic coro-nary syndrome or new — it is well forgotten oldM.M. Dolzhenko (Kyiv) – 15 min

3. Antihypertensive therapy for patients without a meta-bolic syndromeN.Yu. Osovska (Vinnytsia) – 15 min

4. Patient with AH and T2D: simple choice in complicated situationI.V. Davydova (Kyiv) – 15 min

5. Long-term surveillance programs for patients with high cardiovascular risk according to European guide-lines 2019S.O. Andriyevska (Odesa) – 15 min

6. Important components of T2D patients’ management in family doctor practiceN.M. Zherdiova (Kyiv) – 15 min

7. Modern view on the combination therapy of arterial hypertensionM.M. Seliuk (Kyiv) — 15 min

8. Program «Prostir without Stroke»: how to improve outcomes of anticoagulant therapy in nvAF patients

S.M. Koval (Kharkiv)— 15 min9. Treatment of tobacco dependence in patients with

CVDO.V. Sribna (Kyiv) — 15 min

7. Îñîáëèâîñò³ ë³êóâàííÿ ïîðóøåíü ðèòìó ñåðöÿ ó âà-ã³òíèõÌ.Ç. ×åðåäíè÷åíêî (Êè¿â) — 20 õâ

8. Àíòèòðîìáîòè÷íà òåðàï³ÿ ïðè ô³áðèëÿö³¿ ïåðåä-ñåðäüÒ.Â. Ãåòüìàí (Êè¿â) — 20 õâ

9. Ðåêîìåíäàö³¿ ç âåäåííÿ îíêîëîã³÷íèõ õâîðèõ ç àðèòì³ÿìèª.Â. Ìîãèëüíèöüêèé (Êè¿â) — 20 õâ

10. Ðåàá³ë³òàö³ÿ õâîðèõ ç àðèòì³ÿìèÎ.Â. Ñð³áíà (Êè¿â) — 20 õâ


12:50–13:20 Êðóãëèé ñò³ëÏàö³ºíòè ç ãîñòðèì êîðîíàðíèì ñèíäðîìîì, ô³áðèëÿö³ºþ ïåðåäñåðäü òà ñåðöåâîþ íåäîñòàòí³ñòþ: ÿê ë³êóâàòè òàêèõ ïàö³ºíò³â Ó÷àñíèêè: ä.ì.í. Î.². ²ðê³í, ê.ì.í. Î.Ì. Ðîìàíîâà (Êè¿â)

13:20-14:00 ÏÅÐÅÐÂÀ

14:00-16:30 Ñåêö³éíå çàñ³äàííÿ ËÅÊÖ²¯ ÄËß Ë²ÊÀÐ²Â ÇÀ ÑÏÅÖ²ÀËÜÍ²ÑÒÞ «ÇÀÃÀËÜÍÀ ÏÐÀÊÒÈÊÀ — Ñ²ÌÅÉÍÀ ÌÅÄÈÖÈÍÀ»Ìîäåðàòîðè: ïðîô. Ì.Ì. Äîëæåíêî, ïðîô. Ñ.Î. Àíäð³ºâ-

ñüêà, ïðîô. Ì.Ì. Ñåëþê 1. Ìîæëèâîñò³ îðãàíîïðîòåêòîðíî¿ ä³¿ ïîòð³éíî¿ êîì-

á³íîâàíî¿ òåðàï³¿ àðòåð³àëüíî¿ ã³ïåðòåíç³¿Ê.Þ. ªãîðîâ (Äí³ïðî) — 15 õâ

2. Ñó÷àñí³ ìîæëèâîñò³ ë³êóâàííÿ õðîí³÷íîãî êîðîíàð-íîãî ñèíäðîìó, àáî Íîâå — öå äîáðå çàáóòå ñòàðåÌ.Ì. Äîëæåíêî (Êè¿â) — 15 õâ

3. Àíòèã³ïåðòåíçèâíà òåðàï³ÿ ó ïàö³ºíò³â áåç ìåòàáî-ë³÷íîãî ñèíäðîìóÍ.Þ. Îñîâñüêà (Â³ííèöÿ) — 15 õâ

4. Õâîðèé íà àðòåð³àëüíó ã³ïåðòåíç³þ òà öóêðîâèé ä³-àáåò 2-ãî òèïó: ïðîñòèé âèá³ð ó ñêëàäí³é ñèòóàö³¿².Â. Äàâèäîâà (Êè¿â) — 15 õâ

5. Äîâãîñòðîêîâ³ ïðîãðàìè ñïîñòåðåæåííÿ ïàö³ºíò³â âèñîêîãî êàðä³îâàñêóëÿðíîãî ðèçèêó â ñâ³òë³ ªâðî-ïåéñüêèõ ðåêîìåíäàö³é–2019Ñ.Î. Àíäð³ºâñüêà (Îäåñà) — 15 õâ

6. Âàæëèâ³ êîìïîíåíòè âåäåííÿ ïàö³ºíò³â ç öóêðîâèì ä³àáåòîì 2-ãî òèïó â ïðàêòèö³ ñ³ìåéíîãî ë³êàðÿÍ.Ì. Æåðäüîâà (Êè¿â) — 15 õâ

7. Ñó÷àñí³ ïîãëÿäè íà êîìá³íîâàíó òåðàï³þ àðòåð³-àëüíî¿ ã³ïåðòåíç³¿Ì.Ì. Ñåëþê (Êè¿â) — 15 õâ

8. Ïðîãðàìà «Ïðîñò³ð áåç ³íñóëüòó»: ÿê ï³äâèùèòè ðå-çóëüòàòèâí³ñòü àíòèêîàãóëÿíòíî¿ òåðàï³¿ ó ïàö³ºíò³â ç ô³áðèëÿö³ºþ ïåðåäñåðäüÑ.Ì. Êîâàëü (Õàðê³â) — 15 õâ

9. Ë³êóâàííÿ òþòþíîâî¿ çàëåæíîñò³ ó õâîðèõ ³ç ñåðöåâî- ñóäèííèìè çàõâîðþâàííÿìèÎ.Â. Ñð³áíà (Êè¿â) — 15 õâ


13

25th

of

Sept

embe

r (W

edne

sday

)

16:30–16:50 Round tableContinuum of coronary heart disease: the role of personalized treatment strategiesPartcipants: corr.-member of NAMS of Ukraine, prof.

O.M. Parkhomenko, prof. L.G. Voronkov (Kyiv)

CONFERENCE HALL «ALTIUS»9:30–11:00 Section meeting DIABETES MELLITUSModerators: corr. member of NAMS of Ukraine, prof.

O.M. Parkhomenko, prof. V.M. Zhebel, L.K. Sokolova MD

9:00–9:30 Round tableModern global CaReMe trend: cardiologist and endocrinologist’s perspective on T2D patients with cardiovascular pathologyParticipants: corr. member of NAMS of Ukraine, prof.

O.M. Parkho menko (Kyiv), corr. member of NAMS of Ukraine, prof. B.M. Mankovskiy (Kyiv), prof.M.V. Vlasenko (Vinnytsia)

1. Modern approaches to decreasing of cardiovascular outcomes in patients with T2 diabetes mellitusO.M. Parkhomenko (Kyiv) – 15 min

2. Prognosis and modern correction of cardiovascular risk in patients with pre- and diabetesV.N. Zhebel (Vinnytsia) – 15 min

3. Strategic aspects of CHF treatment in patients with co-morbid conditionsM.M. Dolzhenko (Kyiv) – 15 min

10:15–10:45 Master classHeart failure in T2D patients

Participants: prof. L.G. Voronkov (Kyiv), L.K. Sokolova MD (Kyiv) Discussion — 15 min

11:00–11:20 Opinion of the specialistAchieving blood pressure control in isolated systolic hypertension: a portrait of the patient

prof. E.G. Nesukay (Kyiv)

11:20–13:20 Sectional sessionGENDER MEDICINE — CURRENT ISSUESModerators: prof. O.I. Mitchenko, corr.-Member of the NAMS

of Ukraine, prof. T.F. Tatarchuk1. Correction of insulin resistance at comorbidity with

hypothyroidism in womenV.I. Pankiv (Kyiv) — 15 min

2. Management of women with PCOS in the aspect of prevention of cardiovascular diseaseT.F. Tatarchuk, N.V. Kosey, T.M. Tutchenko (Kyiv) — 15 min

3. Arterial hypertension and insulin resistance in the for-mation of cardiovascular risk in womenO.I. Mitchenko, G.Ya. Ilyushina (Kyiv) — 15 min

16:30–16:50 Êðóãëèé ñò³ëÊîíòèíóóì ³øåì³÷íî¿ õâîðîáè ñåðöÿ: ðîëü ñòðàòåã³¿ ïåðñîí³ô³êîâàíîãî ë³êóâàííÿÓ÷àñíèêè: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Î.Ì. Ïàðõîìåí-

êî, ïðîô. Ë.Ã. Âîðîíêîâ (Êè¿â)

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÀËÜÒ²ÓÑ»9:00–11:00 Ñåêö³éíå çàñ³äàííÿÖÓÊÐÎÂÈÉ Ä²ÀÁÅÒÌîäåðàòîðè: ÷ë.-êîð ÍÀÌÍ Óêðà¿íè, ïðîô. Î.Ì. Ïàðõî-

ìåíêî, ïðîô. Â.Ì. Æåáåëü, ä.ì.í. Ë.Ê. Ñîêîëîâà

9:00–9:30 Êðóãëèé ñò³ëÑó÷àñíà ñâ³òîâà òåíäåíö³ÿ CaReMe: ïîãëÿä êàðä³îëîãà òà åíäîêðèíîëîãà íà ïàö³ºíòà ç ÖÄ 2-ãî òèïó òà íàÿâí³ñòþ ñåðöåâî-ñóäèííî¿ ïàòîëîã³¿Ó÷àñíèêè: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Î.Ì. Ïàðõîìåíêî

(Êè¿â), ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Á.Ì. Ìàíüêîâ-ñüêèé (Êè¿â), ïðîô. Ì.Â. Âëàñåíêî (Â³ííèöÿ)

1. Ñó÷àñí³ ï³äõîäè äî çíèæåííÿ ñåðöåâî-ñóäèííèõ óñêëàäíåíü ó õâîðèõ íà öóêðîâèé ä³àáåò 2-ãî òèïóÎ.Ì. Ïàðõîìåíêî (Êè¿â) — 15 õâ

2. Ïðîãíîç òà ñó÷àñíà êîðåêö³ÿ ñåðöåâî-ñóäèííîãî ðèçèêó ó õâîðèõ íà ïðå- òà ä³àáåòÂ. Ì. Æåáåëü (Â³ííèöÿ) — 15 õâ

3. Ñòðàòåã³÷í³ àñïåêòè ë³êóâàííÿ õðîí³÷íî¿ ñåðöåâî¿ íåäîñòàòíîñò³ ó õâîðîãî ç êîìîðá³äíèìè ñòàíàìèÌ.Ì. Äîëæåíêî (Êè¿â) — 15 õâ

10:15–10:45 Ìàéñòåð-êëàñÑåðöåâà íåäîñòàòí³ñòü ó õâîðèõ íà öóêðîâèé ä³àáåò 2-ãî òèïóÓ÷àñíèêè: ïðîô. Ë.Ã. Âîðîíêîâ, ä.ì.í. Ë.Ê. Ñîêîëîâà (Êè¿â)Îáãîâîðåííÿ — 15 õâ

11:00–11:20 Äóìêà ñïåö³àë³ñòà Øëÿõè äîñÿãíåííÿ êîíòðîëþ àðòåð³àëüíîãî òèñêó ïðè ³çîëüîâàí³é ñèñòîë³÷í³é àðòåð³àëüí³é ã³ïåðòåíç³¿: ïîðòðåò ïàö³ºíòà

ïðîô. Î.Ã. Íåñóêàé (Êè¿â)

11:20–13:20 Ñåêö³éíå çàñ³äàííÿ ÀÊÒÓÀËÜÍ² ÏÈÒÀÍÍß ÃÅÍÄÅÐÍÎ¯ ÌÅÄÈÖÈÍÈÌîäåðàòîðè: ïðîô. Î.². Ì³ò÷åíêî, ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè,

ïðîô. Ò.Ô. Òàòàð÷óê1. Êîðåêö³ÿ ³íñóë³íîðåçèñòåíòíîñò³ ïðè êîìîðá³äíîñò³

ç ã³ïîòèðåîçîì ó æ³íîê Â.². Ïàíüê³â (Êè¿â) — 15 õâ

2. Ìåíåäæìåíò æ³íîê ³ç ñèíäðîìîì ïîë³ê³ñòîçíèõ ÿº÷íèê³â â àñïåêò³ ïðîô³ëàêòèêè êàðä³îâàñêóëÿðíî¿ ïàòîëîã³¿ Ò.Ô. Òàòàð÷óê, Í.Â. Êîcºé, Ò.Ì. Òóò÷åíêî (Êè¿â) — 15 õâ

3. Àðòåð³àëüíà ã³ïåðòåíç³ÿ òà ³íñóë³íîðåçèñòåíòí³ñòü ó ôîðìóâàíí³ ñåðöåâî-ñóäèííîãî ðèçèêó ó æ³íîê Î.². Ì³ò÷åíêî, Ã.ß. ²ëþøèíà (Êè¿â) — 15 õâ


14

25 â

åðåñ

íÿ

(ñåð

åäà)

4. Controversial provisions in the Guidelines of the ESC-2018 concerning the Cardiovascular Diseases during PregnancyV.I. Medvid (Kyiv) — 15 min

5. Prognostic value of sex hormones in women with ische mic heart diseaseG.S. Isayeva, V.I. Volkov (Kharkiv) – 15 min

6. High pulmonary hypertension in pregnant women: cardiological and perinatal aspects K.M. Duda (Kyiv) — 15 min

7. Newest therapeutic tendencies in the treatment of the effects of estrogen deficiencyO.Î. Efimenko (Kyiv) — 15 min

8. Gender features of arterial wall stiffness. Possibilities of correctionK.Yu. Egorov (Dnipro) — 15 min

13:20-14:00 BREAK

14:00–14:30 Round table Treatment of patients with NAF after stroke: a tandem of a neurologist and a cardiologistParticipants: Yu.V. Flomin PhD, T.V. Hetman PhD (Kyiv)

14:30–16:50 Section meetingCARDIOCERBRAL DISORDERS: SEARCH FOR COMORBIDENCE Moderators: L.A. Mishchenko MD, prof. S.M. Kuznetsova,

I.L. Revenko PhD1. Pathogenetic heterogeneity of ischemic stroke (funda-

mental and clinical aspects)S.M. Kuznetsova, N.V. Jumping (Kyiv) — 15 min2. Cardiac disturbances in the problem of cerebral stroke L.A. Dzyak (Dnipro) - 15 min

3. National plan of stroke management in UkraineYu.V. Flomin (Kyiv) — 15 min

4. Arterial hypertension and brain: how to prevent com-plicationsL.A. Mishchenko (Kyiv) — 15 min

5. Arterial hypertension and cognitive disturbancesN.Yu. Bachynska (Kyiv) — 15 min

6. Comparing of secondary prophylaxis after ischemic stroke and myocardial infarctionA.V. Yagenskyi (Lutsk) — 15 min

7. Acute stroke: practical recommendationsH.P. Pasechnic, Yu.M. Martynchuk (Kyiv) — 15 min

8. Emergency care of cardioembolic stroke: opportunities for endovascular technologyD.V. Shcheglov, S.V. Konotopchik, O.E. Sviridyuk (Kyiv) — 15 min

9. Cardioembolic stroke. Work on mistakesI.L. Revenko, V.M. Kornatskyi (Kyiv) — 15 min

10. Low risk atrial fibrillation patients. In which cases is anticoagulation?N.N. Nosånko (Kyiv) — 15 min

4. Êîíòðîâåðñ³éí³ ïîëîæåííÿ â Ðåêîìåíäàö³ÿõ ªâðî-ïåéñüêîãî òîâàðèñòâà êàðä³îëîã³â–2018 ùîäî âå-äåííÿ ñåðöåâî-ñóäèííèõ õâîðîá ó âàã³òíèõ Â.². Ìåäâ³äü (Êè¿â) — 15 õâ

5. Ïðîãíîñòè÷íà çíà÷óù³ñòü ð³âíÿ ñòàòåâèõ ãîðìîí³â ó æ³íîê ç ³øåì³÷íîþ õâîðîáîþ ñåðöÿ Ã.Ñ. ²ñàºâà, Â.². Âîëêîâ (Õàðê³â) — 15 õâ

6. Âèñîêà ëåãåíåâà ã³ïåðòåíç³ÿ ó âàã³òíèõ: êàðä³îëî-ã³÷í³ òà ïåðèíàòàëüí³ àñïåêòè Ê.Ì. Äóäà (Êè¿â) — 15 õâ

7. Íîâ³òí³ òåðàïåâòè÷í³ òåíäåíö³¿ â ë³êóâàíí³ íàñë³ä-ê³â åñòðîãåííîãî äåô³öèòó Î.Î. ªô³ìåíêî (Êè¿â) — 15 õâ

8. Ãåíäåðí³ îñîáëèâîñò³ æîðñòêîñò³ àðòåð³àëüíî¿ ñò³í-êè. Ìîæëèâîñò³ êîðåêö³¿ Ê.Þ. ªãîðîâ (Äí³ïðî) — 15 õâ

13:20-14:00 ÏÅÐÅÐÂÀ

14:00–14:30 Êðóãëèé ñò³ëÂåäåííÿ õâîðèõ ç ÍÔÏ ï³ñëÿ ïåðåíåñåíîãî ³íñóëüòó: òàíäåì íåâðîëîãà òà êàðä³îëîãàÓ÷àñíèêè: ê.ì.í. Þ.Â. Ôëîì³í, ê.ì.í. Ò.Â. Ãåòüìàí (Êè¿â)

14:30–16:50 Ñåêö³éíå çàñ³äàííÿÊÀÐÄ²ÎÖÅÐÅÁÐÀËÜÍ² ÏÎÐÓØÅÍÍß: ÏÎØÓÊÈ ÊÎÌÎÐÁ²ÄÍÎÑÒ²Ìîäåðàòîðè: ïðîô. Ñ.Ì. Êóçíåöîâà, ä.ì.í. Ë.À. Ì³ùåíêî,

ê.ì.í. ².Ë. Ðåâåíüêî1. Ïàòîãåíåòè÷íà ãåòåðîãåíí³ñòü ³øåì³÷íîãî ³íñóëüòó

(ôóíäàìåíòàëüí³ òà êë³í³÷í³ àñïåêòè)Ñ.Ì. Êóçíåöîâà, Í.Â. Ñêà÷êîâà (Êè¿â) — 15 õâ

2. Êàðä³àëüí³ ïîðóøåííÿ â ïðîáëåì³ ìîçêîâîãî ³íñóëüòóË.À. Äçÿê (Äí³ïðî) — 15 õâ

3. Íàö³îíàëüíèé ïëàí ä³é áîðîòüáè ç ³íñóëüòîìÞ.Â. Ôëîì³í (Êè¿â) — 15 õâ

4. Àðòåð³àëüíà ã³ïåðòåíç³ÿ ³ ìîçîê: ÿê çàïîá³ãòè óñêëàäíåííÿìË.À. Ì³ùåíêî (Êè¿â) — 15 õâ

5. Àðòåð³àëüíà ã³ïåðòåíç³ÿ òà êîãí³òèâí³ ïîðóøåííÿÍ.Þ. Áà÷èíñüêà (Êè¿â) — 15 õâ

6. Ïîð³âíÿííÿ åôåêòèâíîñò³ âòîðèííî¿ ïðîô³ëàêòèêè ï³ñëÿ ³øåì³÷íîãî ³íñóëüòó òà ³íôàðêòó ì³îêàðäàÀ.Â. ßãåíñüêèé (Ëóöüê) — 15 õâ

7. Ãîñòðèé ³íñóëüò: ïðàêòè÷í³ ðåêîìåíäàö³¿ Ã.Ï. Ïàñ³÷íèê, Þ.Ì. Ìàðòèí÷óê (Êè¿â) — 15 õâ

8. Íåâ³äêëàäíà äîïîìîãà ïðè êàðä³îåìáîë³÷íîìó ³í-ñóëüò³: ìîæëèâîñò³ åíäîâàñêóëÿðíèõ òåõíîëîã³éÄ.Â. Ùåãëîâ, Ñ.Â. Êîíîòîï÷èê, Î.ª. Ñâèðèäþê (Êè¿â) — 15 õâ

9. Êàðä³îåìáîë³÷íèé ³íñóëüò. Ðîáîòà íàä ïîìèëêàìè².Ë. Ðåâåíüêî, Â.Ì. Êîðíàöüêèé (Êè¿â) — 15 õâ

10. Ïàö³ºíòè ³ç 1 áàëîì ðèçèêó çà øêàëîþ CHA2DS2–VASc. Â ÿêèõ âèïàäêàõ àíòèêîàãóëÿö³ÿ?Í.Ì. Íîñåíêî (Êè¿â) — 15 õâ


15

25th

of

Sept

embe

r (W

edne

sday

)

CONFERENCE HALL «CITIUS»9:00-12:30 Sectional sessionCARDIOVASCULAR VISUALIZATIONModerators: acad. of NAMS of Ukraine, prof. V.M. Kovalenko,

prof. S.V. Fedkiv, prof. S.M.Furkalo, prof. Yu.I.Karpenko, prof. Yu.A. Ivaniv

1. Modern possibilities of MRI in the diagnosis of myo-carditisS.V. Fedkiv (Kyiv) — 15 min

2. Intravascular visualization in the implementation of coronary interventional proceduresS.M. Furkalo (Kyiv) — 15min

3. Radiofrequency ablation of the interventricular sep-tum in patients with hypertrophic cardiomyopathy Yu.I. Karpenko (Odesa) – 15 min

4. Diagnostic peculiarities and treatment of the left ven-tricular pseudoaneurysmsY.A. Ivaniv, L.V. Kulyk (Lviv) — 15 min

5. New methods of functional diagnosis and vizualiza-tion in evaluating specifi non-coronary myocardial pa-thology (cardiac transplant rejection)S.V. Potashev, S.V. Fedkiv, K.V. Rudenko — 15 min

6. Echocardiographic profiles of chronic heart failure with preserved ejection fraction

M.Yu. Kolesnyk (Zaporizhzhya) — 15 min7. The role of multimodality imaging in Fabry disease

E.G. Nesukay (Kyiv) — 15min8. EchoCG of myocardial pathology and ischemia: new pos-

sibilities and clinical experienceS.V. Potashev, S.V. Salo, A.Y. Gavrylishyn (Kyiv) — 15 min

9. Speckle tracking ECG in Non-coronary diseases diag-nosticsN.S. Polenova, E.G. Nesukay, E.Yu. Titov (Kyiv) — 15 õâ

10. Imaging methods in the differential diagnosis of hy-pertrophied myocardium N.D. Oryshchyn (Lviv) – 15 min

11. Preoperative ÑÒ/ÌRI planning for the surgical treat-ment of hypertrophic obstructive cardiomyopathy — contemporary approach S.V. Fedkiv, M.O. Tregubova, K.V. Rudenko (Kyiv) — 15 min

12. Carotid ultrasound: interpretation of conclusion and the keys in the diagnostic search for the cardiolo-gistN.N. Nosenko (Kyiv) — 15 min

13. Evaluation of the right heart in patients with pulmo-nary hypertensionE.Yu. Titov, N.S. Polenova, I.O. Zhyvylo (Kyiv) — 15 min

14. Pits and falls of pulmonary hypertension echocardio-graphic assessment L.Ì. Hrubyak (Kyiv) — 15 min

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «Ñ²Ò²ÓÑ»9:00–13:20 Ñåêö³éíå çàñ³äàííÿÑÅÐÖÅÂÎ-ÑÓÄÈÍÍÀ Â²ÇÓÀË²ÇÀÖ²ßÌîäåðàòîðè: àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ì. Êîâàëåí-

êî, ïðîô. Ñ.Â. Ôåäüê³â, ïðîô. Ñ.Ì. Ôóðêàëî, ïðîô. Þ.². Êàðïåíêî, ïðîô. Þ.À. ²âàí³â

1. Ñó÷àñí³ ìîæëèâîñò³ ÌÐÒ â ä³àãíîñòèö³ ì³îêàðäè-ò³âÑ.Â. Ôåäüê³â (Êè¿â) — 15 õâ

2. Âíóòð³øíüîñóäèííà â³çóàë³çàö³ÿ ïðè çä³éñíåíí³ êî-ðîíàðíèõ ³íòåðâåíö³éíèõ âòðó÷àíüÑ.Ì. Ôóðêàëî (Êè¿â) — 15 õâ

3. Ðàä³î÷àñòîòíà àáëÿö³ÿ ì³æøëóíî÷êîâî¿ ïåðåãîðîä-êè ó õâîðèõ ç ã³ïåðòðîô³÷íîþ êàðä³îì³îïàò³ºþÞ.². Êàðïåíêî (Îäåñà) — 15 õâ

4. Îñîáëèâîñò³ ä³àãíîñòèêè ³ ë³êóâàííÿ ïñåâäîàíåâ-ðèçì ë³âîãî øëóíî÷êàÞ.À. ²âàí³â, Ë.Â. Êóëèê (Ëüâ³â) — 15 õâ

5. Ðîëü íîâèõ ìåòîä³â ôóíêö³îíàëüíî¿ ä³àãíîñòèêè òà â³-çóàë³çàö³¿ â îö³íö³ ñïåöèô³÷íî¿ íåêîðîíàðîãåííî¿ ïà-òîëîã³¿ ì³îêàðäà (â³äòîðãíåííÿ òðàíñïëàíòàòó ñåðöÿ)Ñ.Â. Ïîòàøåâ, Ñ.Â. Ôåäüê³â, Ê.Â. Ðóäåíêî (Êè¿â) — 15 õâ

6. Åõîêàðä³îãðàô³÷í³ ïîðòðåòè õðîí³÷íî¿ ñåðöåâî¿ íå-äîñòàòíîñò³ ç³ çáåðåæåíîþ ôðàêö³ºþ âèêèäó ë³âîãî øëóíî÷êàÌ.Þ. Êîëåñíèê (Çàïîð³ææÿ) — 15 õâ

7. Çíà÷åííÿ ìåòîä³â â³çóàë³çàö³¿ â ä³àãíîñòèö³ õâîðî-áè Ôàáð³Î.Ã. Íåñóêàé (Êè¿â) — 15 õâ

8. ÅõîÊÃ ³øåì³¿ òà ïàòîëîã³¿ ì³îêàðäà: íîâ³ ìîæëèâîñò³ òà äîñâ³ä çàñòîñóâàííÿÑ.Â. Ïîòàøåâ, Ñ.Â. Ñàëî, À.Þ. Ãàâðèëèøèí (Êè¿â) — 15 õâ

9. Ñïåêë-òðåê³íã-åõîÊÃ â ä³àãíîñòèö³ íåêîðîíàðíèõ çàõâîðþâàíü ñåðöÿÍ.Ñ. Ïîëåíîâà, Î.Ã. Íåñóêàé, ª.Þ. Ò³òîâ (Êè¿â) — 15 õâ

10. Ðîëü ìåòîä³â â³çóàë³çàö³¿ ó äèôåðåíö³àö³¿ ã³ïåðòðî-ô³¿ ì³îêàðäà ë³âîãî øëóíî÷êàÍ.Ä. Îðèùèí (Ëüâ³â) — 15 õâ

11. Ïåðåäîïåðàö³éíå ÊÒ/ÌÐÒ ïëàíóâàííÿ â õ³ðóðã³÷-íîìó ë³êóâàíí³ ã³ïåðòðîô³÷íî¿ êàðä³îì³îïàò³¿ — ñó-÷àñíèé ï³äõ³äÑ.Â. Ôåäüê³â, Ì.Î. Òðåãóáîâà, Ê.Â. Ðóäåíêî (Êè¿â) — 15 õâ

12. Óëüòðàçâóêîâå äîñë³äæåííÿ ñóäèí: ³íòåðïðåòàö³ÿ âèñíîâêó òà êëþ÷³ â ä³àãíîñòè÷íîìó ïîøóêó äëÿ êàðä³îëîãàÍ.Ì. Íîñåíêî (Êè¿â) — 15 õâ

13. Îö³íêà ôóíêö³¿ ïðàâèõ â³ää³ë³â ñåðöÿ ó õâîðèõ ç ëå-ãåíåâîþ ã³ïåðòåíç³ºþ ª.Þ. Ò³òîâ, Í.Ñ. Ïîëåíîâà, ².Î. Æèâèëî (Êè¿â) — 15 õâ

14. Ïðîáëåìè åõîêàðä³îãðàô³÷íî¿ îö³íêè ëåãåíåâî¿ ã³-ïåðòåíç³¿Ë. Ì. Ãðóáÿê (Êè¿â) — 15 õâ


16

25 â

åðåñ

íÿ

(ñåð

åäà)

15. Radiology management of patients with congenitally corrected transposition of great arteriesYe.V. Stohova, N.M. Rudenko, T.A. Yalynska, R. Tammo, O.O. Motrechko (Kyiv) — 15 min

16. Äîïîâ³äü

13:20-14:00 BREAK

14:00–14:40 Round table Patient with severe heart failure: the active diuretic treatment in focusParticipants: prof. L.G. Voronkov, N.A.Tkach PhD (Kyiv)

14:40–16:40 Sectional sessionTEAM DECISIONS IN THE STRATEGIES OF PREVENTION AND THERAPY OF CARDIOVASCULAR COMPLICATIONS IN CANCER TREATMENTModerators: S.M. Kozhukhov MD, prof. I.A. Kryachok 1. Cardio-onco-hematology as a part of cardio-oncolo-

gy: current state and perspectivesS.M. Kozhukhov (Kyiv) – 20 min

2. Management strategies in patients with combination of cardiac and hematological toxicity in cancer treat-mentI.A. Kryachok (Kyiv) – 20 min

15:20–15:50 Round table: Thrombosis in cardio-oncology practice: necessity of cardiologist and oncohematologist collaborationÑardiologist’s point of view

S.M. Kozhukhov (Kyiv) Oncohematologist’s point of view

prof. I.A. Kryachok (Kyiv) Discussion

15:50–16:30 Clinical casesManagement of patients with cardiovascular complications of cancer treatment

1. Heart failure in cancer therapy — role of visualization and biomarkers

N.V. Dovganych (Kyiv) – 10 min2. Patient with combination of cardiovascular and he-

matological complications of cancer treatment — team decisionsI.B. Tytorenko (Kyiv) — 10 min

3. Arterial hypertension in cancer therapy

O.A. Yarynkina (Kyiv) – 10 minDiscussion — 10 min

CONFERENCE HALL «SPRINT»9:00–11:40 Section mettengSTRESS-ASSOCIATED COMBINED DISORDERS OF HEALTH IN ADOLESCENT ARMED CONFLICTModerators: prof. V.Ì. Kornatskii, prof. V.I. Osiodlo

15. Ðàä³îëîã³÷íèé ñóïðîâ³ä ïàö³ºíò³â ³ç âðîäæåíîþ êî-ðèãîâàíîþ òðàíñïîçèö³ºþ ìàã³ñòðàëüíèõ àðòåð³éÎ.Â. Ñòîãîâà, Í.Ì. Ðóäåíêî, Ò.À. ßëèíñüêà, Òàììî Ðààä, Î.Î. Ìîòðå÷êî (Êè¿â) — 15 õâ

16. Äîïîâ³äü13:20–14:00 ÏÅÐÅÐÂÀ

14:00–14:40 Êðóãëèé ñò³ëÏàö³ºíò ç òÿæêîþ ÑÍ: ôîêóñ íà àêòèâí³é ä³óðåòè÷í³é òåðàï³¿Ó÷àñíèêè: ïðîô. Ë.Ã. Âîðîíêîâ, ê.ì.í. Í.À. Òêà÷ (Êè¿â)

14:40–16:40 Ñåêö³éíå çàñ³äàííÿÊÎËÅÃ²ÀËÜÍ² Ð²ØÅÍÍß Â ÑÒÐÀÒÅÃ²ßÕ ÏÐÎÔ²ËÀÊÒÈÊÈ ÒÀ Ë²ÊÓÂÀÍÍß ÑÅÐÖÅÂÎ-ÑÓÄÈÍÍÈÕ ÓÑÊËÀÄÍÅÍÜ ÏÐÈ ÏÐÎÂÅÄÅÍÍ² ÏÐÎÒÈÏÓÕËÈÍÍÎ¯ ÒÅÐÀÏ²¯Ìîäåðàòîðè: ä.ì.í. Ñ.Ì. Êîæóõîâ, ïðîô. ².À. Êðÿ÷îê1. Êàðä³îîíêîãåìàòîëîã³ÿ ÿê ðîçä³ë êàðä³îîíêîëîã³¿:

ñó÷àñíèé ñòàí òà ïåðñïåêòèâèÑ.Ì. Êîæóõîâ (Êè¿â) — 20 õâ

2. Îñîáëèâîñò³ êóðàö³¿ ïàö³ºíò³â ç ïîºäíàííÿì ïðî-ÿâ³â êàðä³àëüíî¿ òà ãåìàòîëîã³÷íî¿ òîêñè÷íîñò³ ïðè ïðîâåäåíí³ ë³êóâàííÿ çëîÿê³ñíèõ íîâîóòâîðåíü². À. Êðÿ÷îê (Êè¿â) — 20 õâ

15:20–15:50 Êðóãëèé ñò³ë Òðîìáîçè â êàðä³îîíêîëîã³÷í³é ïðàêòèö³: íåîáõ³äí³ñòü âçàºìîä³¿ êàðä³îëîãà òà îíêîãåìàòîëîãàÏîãëÿä êàðä³îëîãà

ä.ì.í. Ñ.Ì. Êîæóõîâ (Êè¿â) Ïîãëÿä îíêîãåìàòîëîãà

ïðîô. ².À. Êðÿ÷îê (Êè¿â) Äèñêóñ³ÿ

15:50–16:30 Êë³í³÷í³ âèïàäêè Òàêòèêà âåäåííÿ ïàö³ºíò³â ³ç êàðä³îâàñêóëÿðíèìè óñêëàäíåííÿìè ïðè ïðîâåäåíí³ ïðîòèïóõëèííîãî ë³êóâàííÿ 1. Ñåðöåâà íåäîñòàòí³ñòü ïðè ïðîâåäåíí³ ïðîòè-

ïóõëèííîãî ë³êóâàííÿ — ðîëü ìåòîä³â â³çóàë³çàö³¿ òà á³î ìàðêåð³âÍ.Â. Äîâãàíè÷ (Êè¿â) — 10 õâ

2. Ïàö³ºíò ç ïîºäíàííÿì êàðä³îâàñêóëÿðíèõ òà ãåìà-òîëîã³÷íèõ óñêëàäíåíü ïðîòèïóõëèííî¿ òåðàï³¿ — êîìàíäíèé ï³äõ³ä².Á. Òèòîðåíêî (Êè¿â) — 10 õâ

3. Àðòåð³àëüíà ã³ïåðòåíç³ÿ ïðè ïðîâåäåíí³ ïðîòèïóõ-ëèííîãî ë³êóâàííÿÎ.À. ßðèíê³íà (Êè¿â) — 10 õâ


ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÑÏÐ²ÍÒ»9:00–11:40 Ñåêö³éíå çàñ³äàííÿ ÑÒÐÅÑÀÑÎÖ²ÉÎÂÀÍ² ÊÎÌÎÐÁ²ÄÍ² ÐÎÇËÀÄÈ ÇÄÎÐÎÂ’ß Ó ÏÎÑÒÐÀÆÄÀËÈÕ ÂÍÀÑË²ÄÎÊ ÇÁÐÎÉÍÎÃÎ ÊÎÍÔË²ÊÒÓÌîäåðàòîðè: ïðîô. Â.Ì. Êîðíàöüêèé, ïðîô. Â.². Îñüîäëî


17

25th

of

Sept

embe

r (W

edne

sday

)

1. Features of the development and the course of stress-associated comorbid pathology in modern conditions of UkraineV.M. Kornatskyi, D.M. Moroz, L.O. Dyachenko (Kyiv) – 20 min

2. Peculiarities of the effect of combat psychic trauma on the cardiovascular system. Principles of diagnosis and managementA.P. Kazmirchuk, G.V. Myasnikov, A.P. Tchaikovsky (Kyiv) — 15 min

3. Post-traumatic stress disorder and cardiovascular dis-ease in combatantsV.I. Os�odlo (Kyiv) — 15 min

4. Complex analysis of cardiac rhythm variability as a cri-terion for assessing the effectiveness of medical and psychological rehabilitation of servicemen of UkraineV.V. Steblyuk (Kyiv) — 15 min

5. Post-traumatic stress disorder: somatic content

O.S. Chaban (Kyiv) — 15 min6. Rehabilitation of participants in armed conflict: mea-

sures and guaranteesA.H. Kyrychenko (Dnipro) — 15 min

7. Optimization of cardiological care of tertiary level in patients with stress-associated comorbid patho-logyA.M. Dorokhina (Kyiv) — 15 min

8. Psychotherapeutic help in cardiology practice

ZH.H. Adaricheva (Kyiv) — 15 min9. Correction of social-psychological maladjustment

in patients with arrhythmia and alexithymiaO.Y. Polishchuk (Chernivtsi) — 15 min


11:40–13:20 Section meeting SCIENTIFIC AND DIAGNOSTIC RESEARCH IN CARDIOLOGY PRACTICEModerators: prof. T.I. Gavrilenko, prof. O.V. Kuryata, prof.

O.M. Klimova1. The imbalance of cell cytokines in cardiovascular pa-

thologyT.I. Gavrilenko, N.O. Ryzhkova, L.V. Yakushko, O.A. Pid-gaina (Kyiv) – 15 min

2. Regulators of angiogenesis, endothelial dysfunction and activity of matrex metalloproteinases in the blood of patients with atrial fibrillation and chronic heart failureO.V. Kuryata, A.O. Tikhomirov, Y.S. Kushnir (Kyiv) – 15 min

3. Diagnostic criteria of inflammatory reactions in pa-tients with cardiovascular pathology in the context of obstructive pulmonary diseasesO.M. Klimova, O.V. Lovinska, K.O. Bychenko, G.M. Tim-chenko (Kharkiv) – 15 min

1. Îñîáëèâîñò³ ðîçâèòêó òà ïåðåá³ãó ñòðåñàñîö³éîâà-íî¿ êîìîðá³äíî¿ ïàòîëîã³¿ â ñó÷àñíèõ óìîâàõ Óêðà¿-íèÂ.Ì. Êîðíàöüêèé, Ä.Ì. Ìîðîç, Ë.Î. Äÿ÷åíêî (Êè¿â) — 20 õâ

2. Îñîáëèâîñò³ âïëèâó áîéîâî¿ ïñèõ³÷íî¿ òðàâìè íà ñåðöåâî-ñóäèííó ñèñòåìó. Ïðèíöèïè ä³àãíîñòè-êè òà íàäàííÿ äîïîìîãèÀ.Ï. Êàçì³ð÷óê, Ã.Â. Ì’ÿñíèêîâ, À.Ï. ×àéêîâñüêèé (Êè¿â) — 15 õâ

3. Ïîñòòðàâìàòè÷íèé ñòðåñîâèé ðîçëàä ³ ñåðöåâî- ñóäèíí³ çàõâîðþâàííÿ â ó÷àñíèê³â áîéîâèõ ä³éÂ.². Îñüîäëî (Êè¿â) — 15 õâ

4. Êîìïëåêñíèé àíàë³ç âàð³àáåëüíîñò³ ñåðöåâîãî ðèò-ìó ÿê êðèòåð³é îö³íêè åôåêòèâíîñò³ ìåäèêî-ïñèõî-ëîã³÷íî¿ ðåàá³ë³òàö³¿ â³éñüêîâîñëóæáîâö³â Óêðà¿íèÂ.Â. Ñòåáëþê (Êè¿â) — 15 õâ

5. Ïîñòòðàâìàòè÷íèé ñòðåñîâèé ðîçëàä: ñîìàòè÷íå íàïîâíåííÿÎ.Ñ. ×àáàí (Êè¿â) — 15 õâ

6. Ðåàá³ë³òàö³ÿ ó÷àñíèê³â çáðîéíîãî êîíôë³êòó: çàõî-äè òà ãàðàíò³¿À.Ã. Êèðè÷åíêî (Äí³ïðî) — 15 õâ

7. Îïòèì³çàö³ÿ êàðä³îëîã³÷íî¿ äîïîìîãè òðåòèííîãî ð³âíÿ õâîðèì ³ç ñòðåñàñîö³éîâàíîþ êîìîðá³äíîþ ïàòîëîã³ºþ À.Ì. Äîðîõ³íà (Êè¿â) — 15 õâ

8. Ïñèõîòåðàïåâòè÷íà äîïîìîãà ó êàðä³îëîã³÷í³é ïðàêòèö³ Æ.Ã. Àäàð³÷åâà (Êè¿â) — 15 õâ

9. Êîðåêö³ÿ ñîö³àëüíî-ïñèõîëîã³÷íî¿ äåçàäàïòàö³¿ ó ïà-ö³ºíò³â ³ç ïîðóøåííÿìè ðèòìó ñåðöÿ òà àëåêñèòèì³ºþÎ.Þ. Ïîë³ùóê (×åðí³âö³) — 15 õâ


11:40-13:20 Ñåêö³éíå çàñ³äàííÿÍÀÓÊÎÂÎ-Ä²ÀÃÍÎÑÒÈ×Í² ÄÎÑË²ÄÆÅÍÍß Â ÊÀÐÄ²ÎËÎÃ²×ÍÓ ÏÐÀÊÒÈÊÓÌîäåðàòîðè: ïðîô. Ò.². Ãàâðèëåíêî, ïðîô. Î.Â. Êóðÿòà,

ïðîô. Î.Ì. Êë³ìîâà1. Äèñáàëàíñ êë³òèííèõ öèòîê³í³â ïðè ñåðöåâî-

ñóäèíí³é ïàòîëîã³¿Ò.². Ãàâðèëåíêî, Í.Î. Ðèæêîâà, Ë.Â. ßêóøêî, Î.À. Ï³ä-ãàéíà (Êè¿â) — 15 õâ

2. Ðåãóëÿòîðè àíã³îãåíåçó, åíäîòåë³àëüíî¿ äèñôóíêö³¿ òà àêòèâíîñò³ ìàòðèêñíèõ ìåòàëîïðîòå¿íàç ó êðî-â³ õâîðèõ ç ô³áðèëÿö³ºþ ïåðåäñåðäü òà õðîí³÷íîþ ñåðöåâîþ íåäîñòàòí³ñòþÎ.Â. Êóðÿòà, À.Î. Òèõîìèðîâ, Þ.Ñ. Êóøí³ð (Äí³ïðî) — 15 õâ

3. Ä³àãíîñòè÷í³ êðèòåð³¿ çàïàëüíèõ ðåàêö³é ó õâîðèõ ³ç ñåðöåâî-ñóäèííîþ ïàòîëîã³ºþ íà ôîí³ îáñòðóê-òèâíèõ çàõâîðþâàíü ëåãåíüÎ.Ì. Êë³ìîâà, Î.Â. Ëîâèíñüêà, Ê.Î. Áè÷åíêî, Ã.Ì. Òèì-÷åíêî (Õàðê³â) — 15 õâ


18

25 â

åðåñ

íÿ

(ñåð

åäà)

4. The role of immunological biomarkers in predicting the clinical course of myocarditisS.V. Chernyuk, T.I. Gavrilenko, L.V. Yakushko, O.A. Pid-gaina (Kyiv) – 15 min

5. Influence of immunopathological reactions on the ef-fectiveness of resynchronization therapy in patients with heart failureO.V. Rasputnyak, V.P. Zalevsky, O.M. Lomakovsky, N.O. Rizhkova – 15 min

6. Use of laboratory research in the complex treatment of patients with ischemic heart disease, which pro-ceeds against the background of allergic dermatitisL.V. Kuznetsova (Kyiv) – 15 min


13:20–14:00 BREAK

14:00–16:30 Competition of the young investigatorsModerators: prof. M.I. Lytay, prof. L.M. Babii, prof. I.E. Maly-

novska, S.M. Kozhukhov MD, S.V. Chernyuk PhD 1. The biomarker growth differentiation factor 15 in the

5-year adverse events prediction in patients with acute coronary syndromeI.R. Vyshnevska (Kharkiv)

2. Clinical and functional predictors of quality of life in patients with stable ischemic heart disease and con-comitant chronic obstructive pulmonary disease

D.V. Didenko (Vinnytsia)3. Weight loss in patients with chronic heart failure: pre-

dictors and clinical and prognostic significance

K.V. Voitsekhovska (Kyiv)4. Predictors of atrial fibrillation recurrence after radio-

frequency ablation in patients with chronic heart fai-lureV.T. Zolotarova (Kharkiv)

5. The relationship between uric acid level with risk fac-tor in essential hypertensionL.S. Tymoshchuk (Kyiv)

6. Analysis of the hospitalization causes in patients with a permanent form of atrial fibrillation, arterial hyper-tension, stable coronary artery disease and heart fai-lureM.I. Yalovenko (Dnipro)

7. Predictors of renal function impairment in patients with resistant arterial hypertensionK.I. Serbeniuk (Kyiv)

8. Features of the reactions of individual leukocyte popu-lations to acute ischemic injury and the development of complications of acute myocardial infarctionO.V. Dovhan (Kyiv)

9. 10-rdichny dosv³d imposition of total cavalp-posses-sion at the party with functionally one slut sertsya

Yu.V. Poznyak (Kyiv)

4. Ðîëü ³ìóíîëîã³÷íèõ á³îìàðêåð³â ó ïðîãíîçóâàíí³ êë³í³÷íîãî ïåðåá³ãó ì³îêàðäèòóÑ.Â. ×åðíþê, Ò.². Ãàâðèëåíêî, Ë.Â. ßêóøêî, Î.À. Ï³ä-ãàéíà (Êè¿â) — 15 õâ

5. Âïëèâ ³ìóíîïàòîëîã³÷íèõ ðåàêö³é íà åôåêòèâí³ñòü ðåñèíõðîí³çàö³éíî¿ òåðàï³¿ ó ïàö³ºíò³â ³ç ñåðöåâîþ íåäîñòàòí³ñòþÎ.Â. Ðàñïóòíÿê, Â.Ï. Çàëåâñüêèé, Î.Ì. Ëîìàêîâñüêèé, Í.Ð. Ðèæêîâà (Êè¿â) — 15 õâ

6. Âèêîðèñòàííÿ ëàáîðàòîðíèõ äîñë³äæåíü ïðè êîìï-ëåêñíîìó ë³êóâàíí³ õâîðèõ ç ³øåì³÷íîþ õâîðîáîþ ñåðöÿ íà ôîí³ àëåðãîäåðìàòîç³âË.Â. Êóçíºöîâà (Êè¿â) — 15 õâ


13:20–14:00 ÏÅÐÅÐÂÀ

14:00–16:30 Êîíêóðñ ìîëîäèõ â÷åíèõÌîäåðàòîðè: ïðîô. Ì.². Ëóòàé, ïðîô. Ë.Ì. Áàá³é, ïðîô.

².Å. Ìàëèíîâñüêà, ä.ì.í. Ñ.Ì. Êîæóõîâ, ê.ì.í. Ñ.Â. ×åðíþê1. Á³îìàðêåð ðîñòîâèé ôàêòîð äèôåðåíö³àö³¿ 15

â 5-ð³÷íîìó ïðîãíîçóâàíí³ íàñòàííÿ íåñïðèÿòëèâèõ ïîä³é ó ïàö³ºíò³â ³ç ãîñòðèì êîðîíàðíèì ñèíäðîìîì².Ð. Âèøíåâñüêà (Õàðê³â)

2. Êë³í³êî-ôóíêö³îíàëüí³ ïðåäèêòîðè ÿêîñò³ æèòòÿ ó ïàö³ºíò³â ³ç ñòàá³ëüíîþ ³øåì³÷íîþ õâîðîáîþ ñåð-öÿ òà ñóïóòí³ì õðîí³÷íèì îáñòðóêòèâíèì çàõâîðþ-âàííÿì ëåãåíüÄ.Â. Ä³äåíêî (Â³ííèöÿ)

3. Âòðàòà ìàñè ò³ëà ó ïàö³ºíò³â ³ç õðîí³÷íîþ ñåðöåâîþ íåäîñòàòí³ñòþ: ïðåäèêòîðè òà êë³í³êî-ïðîãíîñòè÷-íå çíà÷åííÿÊ.Â. Âîéöåõîâñüêà (Êè¿â)

4. Ïðåäèêòîðè ðåöèäèâó ô³áðèëÿö³¿ ïåðåäñåðäü ï³ñ-ëÿ ðàä³î÷àñòîòíî¿ àáëÿö³¿ ó ïàö³ºíò³â ³ç õðîí³÷íîþ ñåðöåâîþ íåäîñòàòí³ñòþÒ.Â. Çîëîòàðüîâà (Õàðê³â)

5. Âçàºìîçâ’ÿçîê ð³âíÿ ñå÷îâî¿ êèñëîòè ç ôàêòîðàìè ðèçèêó ïðè åñåíö³àëüí³é àðòåð³àëüí³é ã³ïåðòåíç³¿Ë.Ñ. Òèìîùóê (Êè¿â)

6. Ôàêòîðè ðèçèêó ðåãîñï³òàë³çàö³é ó õâîðèõ ³ç ô³á-ðèëÿö³ºþ ïåðåäñåðäü, àðòåð³àëüíîþ ã³ïåðòåíç³ºþ, ³øåì³÷íîþ õâîðîáîþ ñåðöÿ òà õðîí³÷íîþ ñåðöå-âîþ íåäîñòàòí³ñòþÌ.². ßëîâåíêî (Äí³ïðî)

7. Ïðåäèêòîðè ïîã³ðøåííÿ ôóíêö³¿ íèðîê ó õâîðèõ íà ðåçèñòåíòíó àðòåð³àëüíó ã³ïåðòåíç³þÊ.². Ñåðáåíþê (Êè¿â)

8. Îñîáëèâîñò³ ðåàêö³¿ îêðåìèõ ïîïóëÿö³é ëåéêîöèò³â íà ãîñòðå ³øåì³÷íå óøêîäæåííÿ ³ ðîçâèòîê óñêëàä-íåíü ãîñòðîãî ³íôàðêòó ì³îêàðäàÎ.Â. Äîâãàíü (Êè¿â)

9. 10-ð³÷íèé äîñâ³ä íàêëàäàííÿ òîòàëüíîãî êàâà-ïóëüìîíàëüíîãî ñïîëó÷åííÿ ó ïàö³ºíò³â ³ç ôóíêö³î-íàëüíî ºäèíèì øëóíî÷êîì ñåðöÿÞ.Â. Ïîçíÿê (Êè¿â)


19

26th

of

Sept

embe

r (T

hurs

day)

10. Arterial hypertension and connective tissue dysplasia

N.O. Rak (Lviv)11. Modern views and perspectives of the use of meta-

bolic therapy in patients with arterial hypertensionM.I. Prokosa (Lviv)

12. Role changes intestine micribiom in the pathogenesis of paroxysmal forms of AF in patients with CADI.O. Melnychuk (Kiev)

26-TH OF SEPTEMBER (THURSDAY)NSC «OLYMPIYSKIY»

HALL OF CHAMPIONS9:00-11:20 Plenary sessionACUTE CORONARY SYNDROME AND OTHER URGENT STATESModerators: corr. member of NAMS of Ukraine, prof.

O.M. Parkhomenko, prof. T.V. Talaeva, prof. V.K. Tashchuk 1. ACS in young patients: clinical and instrumental pecu-

liaritiesO.M. Parkhomenko, Ya.M. Lutay, O.I. Irkin, D.O. Belyi (Kyiv) – 20 min

2. Clinical realization of modern treatment pathways correction in ACS patients

V.K. Tashchuk (Chernivtsi) — 15 õâ3. Decongestion as a main goal of acute decompensated

HF treatmentK.M. Amosova, A.B. Bezrodnyi, Yu.V. Rudenko (Kyiv) – 15 min

4. Traditional and additional criteria for risk stratification of ACS patientsO.A. Koval, O.S. Schukina, A.S. Skoromna (Dnipro) – 15 min

5. ACS in elderly and senile patients. Diagnosis and treat-mentV.Z. Netiazhenko (Kyiv) – 15 min

6. Clinical and prognostic value of atrial fibrillation in ACS patientsV.Yo. Tseluyko, F. Ben Salem, O.E. Matuzok (Kharkiv) – 15 min

7. Influence of individual cardiorehabilitation program on atherosclerosis dynamics and restoration of work capacity after myocardial infarctionV.O. Shumakov, I.E. Malynovska, L.M. Babii, N.P. Teresh-chenko, A.Yu. Rybak, O.B. Kuchmenko (Kyiv) – 15 min

8. Role of blood monocytes subpopulations assessment in patients with acute myocardial infarctionT.V. Talaeva, O.M. Parkhomenko, I.V. Tretiak, O.M. Dov-gan (Kyiv) – 15 min

9. Risk Factor Stratification is a strategic stage in the treatment of NSTEMI patientsYu.M. Sokolov, M.Yu. Sokolov, Yu.V. Nechiporenko, I.V. Tarapon (Kyiv) – 15 min

10. Àðòåð³àëüíà ã³ïåðòåíç³ÿ òà äèñïëàç³ÿ ñïîëó÷íî¿ òêàíèíèÍ.Î. Ðàê (Ëüâ³â)

11. Ñó÷àñí³ ïîãëÿäè òà ïåðñïåêòèâè çàñòîñóâàííÿ ìåòà-áîë³÷íî¿ òåðàï³¿ ó õâîðèõ íà àðòåð³àëüíó ã³ïåðòåíç³þÌ.². Ïðîêîñà (Ëüâ³â)

12. Ðîëü çì³í ì³êðîá³îìó êèøå÷íèêó â ïàòîãåíåç³ ïà-ðîêñèçìàëüíî¿ ôîðìè ÔÏ ó õâîðèõ íà ²ÕÑ².Î. Ìåëüíè÷óê (Êè¿â)

26 ÂÅÐÅÑÍß (×ÅÒÂÅÐ)ÍÑÊ «ÎË²ÌÏ²ÉÑÜÊÈÉ»

ÕÎË ×ÅÌÏIÎÍIÂ09:00–11:20 Ïëåíàðíå çàñ³äàííÿÃÎÑÒÐÈÉ ÊÎÐÎÍÀÐÍÈÉ ÑÈÍÄÐÎÌ ÒÀ ²ÍØ² ÍÅÂ²ÄÊËÀÄÍ² ÑÒÀÍÈÌîäåðàòîðè: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Î.Ì. Ïàðõî-

ìåíêî, ïðîô. Ò.Â. Òàëàºâà, ïðîô. Â.Ê. Òàùóê1. Ãîñòðèé êîðîíàðíèé ñèíäðîì ó îñ³á ìîëîäîãî â³êó:

êë³í³êî-³íñòðóìåíòàëüí³ õàðàêòåðèñòèêèÎ.Ì. Ïàðõîìåíêî, ß.Ì. Ëóòàé, Î.². ²ðê³í, Ä.Î. Á³ëèé (Êè¿â) — 20 õâ

2. Êë³í³÷íà ðåàë³çàö³ÿ ïàòîãåíåòè÷íèõ åôåêò³â ñó-÷àñíîãî ë³êóâàííÿ õâîðèõ íà ãîñòðèé êîðîíàðíèé ñèíä ðîìÂ.Ê. Òàùóê (×åðí³âö³) — 15 õâ

3. Äåêîíãåñò³ÿ ÿê òåðàïåâòè÷íà ö³ëü ë³êóâàííÿ ãîñòðî¿ äåêîìïåíñîâàíî¿ ñåðöåâî¿ íåäîñòàòíîñò³Ê.Ì. Àìîñîâà, À.Á. Áåçðîäíèé, Þ.Â. Ðóäåíêî (Êè¿â) — 15 õâ

4. Òðàäèö³éí³ òà äîäàòêîâ³ êðèòåð³¿ ñòðàòèô³êàö³¿ õâî-ðèõ íà ãîñòðèé êîðîíàðíèé ñèíäðîìÎ.À. Êîâàëü, Î.Ñ. Ùóê³íà, À.Ñ. Ñêîðîìíà (Äí³ïðî) — 15 õâ

5. Ãîñòðèé êîðîíàðíèé ñèíäðîì â îñ³á ïîõèëîãî ³ ñòà-ðå÷îãî â³êó. Ä³àãíîñòèêà òà ë³êóâàííÿÂ.Ç. Íåòÿæåíêî (Êè¿â) — 15 õâ

6. Êë³í³÷íå ³ ïðîãíîñòè÷íå çíà÷åííÿ ô³áðèëÿö³¿ ïå-ðåäñåðäü ó õâîðèõ íà ãîñòðèé êîðîíàðíèé ñèíäðîìÂ.É. Öåëóéêî, Ô. Áåí Ñàëåì, Î.Å. Ìàòóçîê (Õàðê³â) — 15 õâ

7. Âïëèâ ³íäèâ³äóàëüíèõ ïðîãðàì êàðä³îðåàá³ë³òàö³¿ íà äèíàì³êó àòåðîñêëåðîçó ³ â³äíîâëåííÿ ïðàöå-çäàòíîñò³ ï³ñëÿ ïåðåíåñåíîãî ³íôàðêòó ì³îêàðäàÂ.Î. Øóìàêîâ, ².Å. Ìàëèíîâñüêà, Ë.Ì. Áàá³é, Í.Ï. Òå-ðåùåíêî, À.Þ. Ðèáàê, Î.Á. Êó÷ìåíêî (Êè¿â) — 15 õâ

8. Çíà÷èì³ñòü âèçíà÷åííÿ ñóáïîïóëÿö³é ìîíîöèò³â êðîâ³ ó õâîðèõ íà ãîñòðèé ³íôàðêò ì³îêàðäàÒ.Â. Òàëàºâà, Î.Ì. Ïàðõîìåíêî, ².Â. Òðåòÿê, Î.Ì. Äîâ-ãàíü (Êè¿â) — 15 õâ

9. Ñòðàòèô³êàö³ÿ çà ôàêòîðàìè ðèçèêó — ñòðàòåã³÷íèé åòàï ë³êóâàííÿ NSTEMI ïàö³ºíò³âÞ.Ì. Ñîêîëîâ, Ì.Þ. Ñîêîëîâ, Þ.Â. Íå÷èïîðåíêî, ².Â. Òàðàïîí — 15 õâ


20

26 â

åðåñ

íÿ

(÷åò

âåð)

11:20-13:20 Plenary sessionPRACTICAL ASPECTS OF EMERGENCY CARDIOLOGY AND COMORBIDITY Part OneModerators: corr. member of NAMS of Ukraine, prof.

O.M. Parkhomenko, corr. member of NAMS of Ukraine, prof. V.Z. Netiazhenko, O.I. Irkin MD

11:20–12:20 Round tableACS without ST elevation: modern possibilities of diagnostics and treatment in patients with comorbiditiesParticipants: O.M. Parkhomenko, O.I. Irkin, Ya.M. Lutay (Kyiv)

12:20–13:20 Scientific-practical symposiumFrom emergency treatment to secondary prevention in heart failure patientsParticipants: O.I. Irkin, Ya.M. Lutay, O.M. Parkhomenko (Kyiv)

13:20–14:00 BREAK

14:00–15:45 Plenary sessionPRACTICAL ASPECTS OF EMERGENCY CARDIOLOGY AND COMORBIDITY Part Two

14:00–14:45 Bridge Ukraine — USA ACS and diabetes mellitusParticipants: M. Kosiborod (USA), O.M. Parkhomenko (Kyiv)

14:45–15:15 Round table Updated ESC recommendations 2019 on management of Pulmonary Embolism

Participants: Ya.M. Lutay (Kyiv), V.Yo. Tseluyko (Kharkiv)

15:15–15:45 Lecture: corr. member of NAMS of Ukraine, prof. V.Z. Netiazhenko (Kyiv)Emergency care management strategy in patients with ACS, PE, Stroke and comorbidities

15:45–18:15 Plenary session JOINT SESSION OF THE ALL-UKRAINIAN ASSOCIATION OF INTERVENTIONAL CARDIOLOGISTS OF UKRAINE AND ASSOCIATION OF CARDIOCSURGES OF UKRAINEÌîäåðàòîðè: corr. member of NAMS of Ukraine, prof. Y.M. So-

kolov, acad. of NAMS of Ukraine, prof. A.V. Rudenko, prof. M.Yu. Sokolov

1. Prospects for the development of Interventional Car-diology in the world and in UkraineYu.M. Sokolov (Kyiv) — 20 min

2. Coronary Surgery. Trends in development, joint con-cept with interventional cardiologyA.V. Rudenko (Kyiv) — 20 min

11:20–13:20 Ïëåíàðíå çàñ³äàííÿÏÐÀÊÒÈ×Í² ÀÑÏÅÊÒÈ ÍÅÂ²ÄÊËÀÄÍÎ¯ ÊÀÐÄ²ÎËÎÃ²¯ ² ÊÎÌÎÐÁ²ÄÍ²ÑÒÜ ×àñòèíà ïåðøà Ìîäåðàòîðè: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Î.Ì. Ïàðõî-

ìåíêî, ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ç. Íåòÿæåíêî, ä.ì.í. Î.². ²ðê³í

11:20–12:20 Êðóãëèé ñò³ëÃîñòðèé êîðîíàðíèé ñèíäðîì áåç åëåâàö³¿ ñåãìåíòà ST: ñó÷àñí³ ìîæëèâîñò³ ä³àãíîñòèêè òà ë³êóâàííÿ â óìîâàõ êîìîðá³äíîñò³Ó÷àñíèêè: Î.Ì. Ïàðõîìåíêî, Î.². ²ðê³í, ß.Ì. Ëóòàé (Êè¿â)

12:20–13:20 Íàóêîâî-ïðàêòè÷íèé ñèìïîç³óìÂ³ä ë³êóâàííÿ ãîñòðîãî ñòàíó äî âòîðèííî¿ ïðîô³ëàêòèêè ñåðöåâî¿ íåäîñòàòíîñò³Ó÷àñíèêè: Î.². ²ðê³í, ß.Ì. Ëóòàé, Î.Ì. Ïàðõîìåíêî (Êè¿â)

13:20–14:00 ÏÅÐÅÐÂÀ

14:00–15:45 Ïëåíàðíå çàñ³äàííÿÏÐÀÊÒÈ×Í² ÀÑÏÅÊÒÈ ÍÅÂ²ÄÊËÀÄÍÎ¯ ÊÀÐÄ²ÎËÎÃ²¯ ² ÊÎÌÎÐÁ²ÄÍ²ÑÒÜ×àñòèíà äðóãà

14:00-14:45 Òåëåì³ñò Óêðà¿íà — ÑØÀÃÊÑ ³ öóêðîâèé ä³àáåòÓ÷àñíèêè: Ì. Êîñ³áîðîä (ÑØÀ), Î.Ì. Ïàðõîìåíêî (Êè¿â)

14:45–15:15 Êðóãëèé ñò³ëÎíîâëåí³ ðåêîìåíäàö³¿ ªâðîïåéñüêîãî òîâàðèñòâà êàðä³îëîã³â 2019 ðîêó ùîäî âåäåííÿ õâîðèõ íà òðîìáîåìáîë³þ ëåãåíåâî¿ àðòåð³¿Ó÷àñíèêè: ß.Ì. Ëóòàé (Êè¿â), Â.É. Öåëóéêî (Õàðê³â)

15:15–15:45 Ëåêö³ÿ: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ç. Íå-òÿæåíêî (Êè¿â)Ïîñë³äîâí³ñòü ë³êàðñüêèõ çàõîä³â ïðè íàäàíí³ óðãåíòíî¿ ìåäè÷íî¿ äîïîìîãè õâîðèì ç ãîñòðèì êîðîíàðíèì ñèíäðîìîì, òðîìáîåìáîë³ºþ ëåãåíåâî¿ àðòåð³¿ òà ãîñòð³ ïîðóøåííÿ ìîçêîâîãî êðîâîîá³ãó ïðè êîìîðá³äíèõ ñòàíàõ

15:45–18:15 Ïëåíàðíå çàñ³äàííÿ ÑÏ²ËÜÍÅ ÇÀÑ²ÄÀÍÍß ÂÑÅÓÊÐÀ¯ÍÑÜÊÎ¯ ÀÑÎÖ²ÀÖ²¯ ²ÍÒÅÐÂÅÍÖ²ÉÍÈÕ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ ÒÀ ÀÑÎÖ²ÀÖ²¯ ÊÀÐÄ²ÎÕ²ÐÓÐÃ²Â ÓÊÐÀ¯ÍÈÌîäåðàòîðè: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Þ.Ì. Ñîêîëîâ,

àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. À.Â. Ðóäåíêî, ïðîô. Ì.Þ. Ñî-êîëîâ

1. Ïåðñïåêòèâè ðîçâèòêó ³íòåðâåíö³éíî¿ êàðä³îëîã³¿ â ñâ³ò³ òà Óêðà¿í³Þ.Ì. Ñîêîëîâ (Êè¿â) — 20 õâ

2. Êîðîíàðíà õ³ðóðã³ÿ. Òåíäåíö³¿ ðîçâèòêó, ñï³ëüíà êîíöåïö³ÿ ç ³íòåðâåíö³éíî¿ êàðä³îëîã³ºþÀ.Â. Ðóäåíêî (Êè¿â) — 20 õâ


21

26th

of

Sept

embe

r (T

hurs

day)

3. Development dynamics of Regional Reperfusion Net-works in Ukraine. Data of PCI Registry and analysis of the last three years activity (2015–2018)

M.Yu. Sokolov (Kyiv) — 20 min4. Successful experience of organization of Regional re-

perfusion network. Where to begin the program in the clinic for percutaneous reperfusion therapy of AMII.V. Danilchuk (Vinnytsia) — 15 min

5. Organization of Reperfusion Center with a large vo-lume of patients. Experience of Kharkiv and Kharkiv regionV.P. Konos (Kharkiv) — 15 min

6. Features of the intracoronary thrombus structure in STEMI patients. Morphology and Clinical PracticeD.I. Besh (Lviv) — 15 min

7. Experience of work of Donetsk and Lugansk regions on extraterritorial principle in the treatment of pa-tients with acute ST segment elevation myocardial in-farction (STEMI): the development of a program of ur-gent stentingS.M. Getman (Kramatorsk) — 15 min

8. Current options for using FFR in clinical practice

A.V. Khokhlov (Kyiv) — 15 min9. Grafts stenting: The role of antiembolic devices

M.V. Shimanko (Kyiv) — 15 min

CONFERENCE HALL «SPARTA»9:00-11:30 Plenary sessionSTABLE ISCHEMIC HEART DISEASE: DIAGNOSIS, RISK STRATIFICATION, PREVENTION, TREATMENTModerators: prof. M.I. Lutay, prof. T.V. Talaeva, Yu.S. Ru-

dik MD

9:00-9:30 Lecture: prof. M.I. Lutay (Kyiv)Principles of rational pharmacotherapy for patients with stable coronary heart disease according to new recommendations1. Role of blood monocytes in atherogenesis

T.V. Talaeva (Kyiv) – 15 min2. Control of heart rate and blood pressure in patients

with coronary artery disease and arterial hyperten-sion. Experience of ambulatory treatment in Ukraine

M.I. Lutay (Kyiv) – 15 min 3. Diagnosis of stable forms coronary heart disease in pa-

tients with kidneys function reduction, the possibility of coronary arteries index calcificationO.V. Kuryata, V.G. Stryzheniy, O.V. Gorshkova, V.V. Se-menov (Dnipro) – 15 min

3. Äèíàì³êà ðîçâèòêó ðåã³îíàëüíèõ ðåïåðôóç³éíèõ ìåðåæ â Óêðà¿í³. Äàí³ Ðåºñòðó ïåðêóòàííèõ êîðî-íàðíèõ âòðó÷àíü òà àíàë³ç îñòàíí³õ òðüîõ ðîê³â ðî-áîòè (2015–2018 ðð.)Ì.Þ. Ñîêîëîâ (Êè¿â) — 20 õâ

4. Óñï³øíèé äîñâ³ä îðãàí³çàö³¿ Ðåã³îíàëüíî¿ ðåïåð-ôóç³éíî¿ ìåðåæ³. Ç ÷îãî ïî÷àòè ïðîãðàìó â êë³í³ö³ ç ïåðêóòàííî¿ ðåïåðôóç³éíî¿ òåðàï³¿ Ã²Ì².Â. Äàíèëü÷óê (Â³ííèöÿ) — 15 õâ

5. Ñèñòåìà îðãàí³çàö³¿ ðåïåðôóç³éíîãî öåíòðó ç âåëè-êèì îáñÿãîì ïàö³ºíò³â. Äîñâ³ä Õàðêîâà ³ Õàðê³âñüêî¿ îáëàñò³Â.Ï. Êîíîñ (Õàðê³â) — 15 õâ

6. Îñîáëèâîñò³ áóäîâè âíóòð³øíüîêîðîíàðíîãî òðîìáó ó STEMI ïàö³ºíò³â. Ìîðôîëîã³ÿ òà êë³í³÷íà ïðàêòèêàÄ.². Áåø (Ëüâ³â) — 15 õâ

7. Äîñâ³ä ðîáîòè Äîíåöüêî¿ òà Ëóãàíñüêî¿ îáëàñòåé çà åêñòðàòåðèòîð³àëüíèì ïðèíöèïîì ïðè ë³êóâàíí³ ïàö³ºíò³â ç ãîñòðèì ³íôàðêòîì ì³îêàðäà ç åëåâà-ö³ºþ ñåãìåíòà ST (STEMI): ðîçâèòîê ïðîãðàìè óð-ãåíòíîãî ñòåíòóâàííÿÑ.Ì. Ãåòüìàí (Êðàìàòîðñüê) — 15 õâ

8. Ôðàêö³éíèé ðåçåðâ êðîâîïëèíó: ñó÷àñíèé ñòàí ïðîáëåìè À.Â. Õîõëîâ (Êè¿â) — 15 õâ

9. Ïðèñòðî¿ ïðîòèåìáîë³÷íîãî çàõèñòó ïðè ñòåíòóâàí-í³ âåíîçíèõ øóíò³âÌ.Â. Øèìàíêî (Êè¿â) — 15 õâ

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÑÏÀÐÒÀ»9:00-11:30 Ïëåíàðíå çàñ³äàííÿÑÒÀÁ²ËÜÍÀ ²ØÅÌ²×ÍÀ ÕÂÎÐÎÁÀ ÑÅÐÖß: Ä²ÀÃÍÎÑÒÈÊÀ, ÑÒÐÀÒÈÔ²ÊÀÖ²ß ÐÈÇÈÊÓ, ÏÐÎÔ²ËÀÊÒÈÊÀ, Ë²ÊÓÂÀÍÍßÌîäåðàòîðè: ïðîô. Ì.². Ëóòàé, ïðîô. Ò.Â. Òàëàºâà, ä.ì.í.

Þ.Ñ. Ðóäèê

9:00–9:30 Ëåêö³ÿ: ïðîô. Ì.². Ëóòàé (Êè¿â)Ïðèíöèïè ðàö³îíàëüíî¿ ìåäèêàìåíòîçíî¿ òåðàï³¿ ïàö³ºíò³â ç³ ñòàá³ëüíîþ ³øåì³÷íîþ õâîðîáîþ ñåðöÿ ç îãëÿäó íà íîâ³ ðåêîìåíäàö³¿1. Ðîëü ìîíîöèò³â êðîâ³ â àòåðîãåíåç³

Ò.Â. Òàëàºâà (Êè¿â) — 15 õâ2. Êîíòðîëü ÷àñòîòè ñåðöåâèõ ñêîðî÷åíü òà àðòåð³àëü-

íîãî òèñêó ó ïàö³ºíò³â ç ³øåì³÷íîþ õâîðîáîþ ñåðöÿ ³ àðòåð³àëüíîþ ã³ïåðòåíç³ºþ. Äîñâ³ä àìáóëàòîðíîãî ë³êóâàííÿ â Óêðà¿í³Ì.². Ëóòàé (Êè¿â) — 15 õâ

3. Ä³àãíîñòèêà ñòàá³ëüíèõ ôîðì ³øåì³÷íî¿ õâîðîáè ñåðöÿ ïðè çíèæåíí³ ôóíêö³¿ íèðîê, ìîæëèâîñò³ ³í-äåêñó êàëüöèô³êàö³¿ êîðîíàðíèõ àðòåð³éÎ.Â. Êóðÿòà, Â.Ã. Ñòðèæåíèé, Î.Â. Ãîðøêîâà, Â.Â. Ñå-ìåíîâ (Äí³ïðî) — 15 õâ


22

26 â

åðåñ

íÿ

(÷åò

âåð)

4. IHD and low triiodothyronine syndrome

Yu.S. Rudik, S.M. Brewer (Kharkiv) – 15 min5. Criteria for diagnosis, risk stratification in patients

with coronary artery calcinosisI.P. Golikova (Kyiv) – 15 min

6. Arterial myocardial revascularization. Modern view. The experience of the one centerO.O. Zhurba (Cherkasy) – 15 min

7. Coronary artery disease without significant hemody-namic atherosclerotic lesions: strategies and tactics of the treatment O.O. Yakymenko, D.M. Sebov, V.A. Korotaieva (Odesa) — 15 min

8. Complete myocardium revascularization as a safe and effective method of coronary bypass surgery in pa-tients with multivessel coronary artery lesions

S.V. Verbanets, O.Yu. Pukass, G.I. Emets, O.S. Gurjeva, I.M. Emets (Kyiv) – 15 min

11:30–12:00 Round table1. Portrait of a cardiologic patient with resistant arterial

hypertension and metabolic syndromeprof. N.Y. Osovska (Vinnytsia)

2. Problematic issues for treatment of arterial hyperten-sion in oblique and agingprof. L.M. Yena (Kyiv)

12:00-12:20 Lecture: prof. V.Yo.Tseluyko (Kharkiv)The comorbid patient in cardiology – how to find answers on unresolved questions

12:20–12:50 Round tableCardioprotection of coronary artery disease from stable angina pectoris to myocardial infarctionParticipants: prof. V.K. Tashchuk (Chernivtsi), prof.

V.O. Shumakov (Kyiv)

12:50–13:20 Round table1. Place of cardioprotective therapy in the treatment

of acute forms of coronary artery disease and the pos-sibility of its intensification in modern timesprof. V.V. Batushkin (Kyiv)

2. Features of pharmacotherapy for arterial hypertension in elderly patientsprof. O.M. Barna (Kyiv)

13:20–14:00 BREAK

14:00-14:30 Round TableAntihypertensive treatment in T2D patient: efficacy for lifeParticipants: L.K.Sokolova MD (Kyiv), prof. S.A. Tikhonova (Odessa)

14:30–17:30 Plenary sessionARTERIAL HYPERTENSIONModerators: L.A. Mishchenko MD, prof. S.M. Koval, prof.

O.Y. Zharinov

4. ²øåì³÷íà õâîðîáà ñåðöÿ òà ñèíäðîì íèçüêîãî òðè-éîäòèðîí³íóÞ.Ñ. Ðóäèê, Ñ.Ì. Ïèâîâàð (Õàðê³â) — 15 õâ

5. Êðèòåð³¿ ä³àãíîñòèêè, ñòðàòèô³êàö³¿ ðèçèêó ó ïàö³-ºíò³â ç êàëüöèíîçîì êîðîíàðíèõ àðòåð³é².Ï. Ãîë³êîâà (Êè¿â) — 15 õâ

6. Àðòåð³àëüíà ðåâàñêóëÿðèçàö³ÿ ì³îêàðäà. Ñó÷àñíèé ïîãëÿä. Äîñâ³ä îäíîãî öåíòðóÎ.Î. Æóðáà (×åðêàñè) — 15 õâ

7. ²øåì³÷íà õâîðîáà ñåðöÿ áåç ãåìîäèíàì³÷íî çíà-÷óùîãî àòåðîñêëåðîòè÷íîãî óðàæåííÿ êîðîíàðíèõ àðòåð³é: ñòðàòåã³ÿ ³ òàêòèêà ë³êóâàííÿÎ.Î. ßêèìåíêî, Ä.Ì. Ñåáîâ, Â.À. Êîðîòàºâà (Îäåñà) — 15 õâ

8. Ïîâíà àðòåð³àëüíà ðåâàñêóëÿðèçàö³ÿ ì³îêàðäà ÿê áåçïå÷íèé òà åôåêòèâíèé ìåòîä êîðîíàðíîãî øóíòóâàííÿ ó ïàö³ºíò³â ³ç áàãàòîñóäèííèì óðàæåí-íÿì â³íöåâèõ ñóäèí Ñ.Â. Âåðáàíåöü, Î.Þ. Ïóêàñ, Ã.². ªìåöü, Î.Ñ. Ãóð’ºâà, ².Ì. ªìåöü (Êè¿â) — 15 õâ

11:30-12:00 Êðóãëèé ñò³ë1. Ïîðòðåò êàðä³îëîã³÷íîãî ïàö³ºíòà ³ç ðåçèñòåíòíîþ àð-

òåð³àëüíîþ ã³ïåðòåíç³ºþ òà ìåòàáîë³÷íèì ñèíä ðîìîìïðîô. Í.Þ. Îñîâñüêà (Â³ííèöÿ)

2. Ïðîáëåìí³ ïèòàííÿ ë³êóâàííÿ àðòåð³àëüíî¿ ã³ïåð-òåíç³¿ â ïîõèëîìó òà ñòàðå÷îìó â³ö³ïðîô. Ë.Ì. ªíà (Êè¿â)

12:00–12:20 Ëåêö³ÿ: ïðîô. Â.É. Öåëóéêî (Õàðê³â)Êîìîðá³äíèé ïàö³ºíò â êàðä³îëîã³¿ — â³äïîâ³ä³ íà íåâèð³øåí³ ïèòàííÿ

12:20–12:50 Êðóãëèé ñò³ëÊàðä³îïðîòåêö³ÿ ³øåì³÷íî¿ õâîðîáè ñåðöÿ â³ä ñòàá³ëüíî¿ ñòåíîêàðä³¿ äî ³íôàðêòó ì³îêàðäàÓ÷àñíèêè: ïðîô. Â.Ê. Òàùóê (×åðí³âö³), ïðîô. Â.Î. Øóìà-

êîâ (Êè¿â)

12:50–13:20 Êðóãëèé ñò³ë1. Ì³ñöå êàðä³îïðîòåêòîðíî¿ òåðàï³¿ â ë³êóâàíí³ ãî-

ñòðèõ ôîðì ³øåì³÷íî¿ õâîðîáè ñåðöÿ ³ ìîæëèâîñò³ ¿¿ ³íòåíñèô³êàö³¿ â ñó÷àñíèé ÷àñïðîô. Â.Â. Áàòóøê³í (Êè¿â)

2. Îñîáëèâîñò³ ôàðìàêîòåðàï³¿ àðòåð³àëüíî¿ ã³ïåð-òåíç³¿ ó ïàö³ºíò³â ë³òíüîãî â³êóïðîô. Î.Ì. Áàðíà (Êè¿â)

13:20–14:00 ÏÅÐÅÐÂÀ

14:00–14:30 Êðóãëèé ñò³ëÀíòèã³ïåðòåíçèâíà òåðàï³ÿ ó õâîðîãî íà öóêðîâèé ä³àáåò: åôåêòèâí³ñòü çàðàäè æèòòÿÓ÷àñíèêè: ä.ì.í. Ë.Ê. Ñîêîëîâà (Êè¿â), ïðîô. Ñ.À. Òèõîíîâà (Îäåñà)

14:30–17:30 Ïëåíàðíå çàñ³äàííÿÀÐÒÅÐ²ÀËÜÍÀ Ã²ÏÅÐÒÅÍÇ²ßÌîäåðàòîðè: ä.ì.í. Ë.À. Ì³ùåíêî, ïðîô. Ñ.Ì. Êîâàëü,

ïðîô. Î.É. Æàð³íîâ


23

26th

of

Sept

embe

r (T

hurs

day)

1. Micro-RNA and problems of pathogenesis and treat-ment of essential arterial hypertensionS.M. Koval, I.O. Snigurska, K.O. Yushko (Kharkiv) — 15 min

2. Masked arterial hypertension – myth or reality? Re-sults of Ukrainian MAHNAT trial

L.A. Mishchenko (Kyiv) — 15 min3. Arterial hypertension and atrial fibrillation

O.Y. Zharinov (Kyiv) — 15 min4. New opportunities in treatment hypertensive and dia-

betic patientsL.K. Sokolova (Kyiv) — 15 min

5. Ñrisis management: arterial hypertension and women`s healthYu.V. Davydova (Kyiv) — 15 min

6. Gender aspects of arterial hypertensionM.M. Dolzhenko (Kyiv) — 15 min

7. International clinical protocols and own experience of hypertension management in pregnancyA.Yu. Limanska (Kyiv) — 15 min

8. Hypertensive damage of the organ of vision

Ya.A. Diomin, O.V. Nedzvetska (Kharkiv) — 15 min9. Secondary stroke prevention: What? How? When?

I.L. Revenko, V.M. Kornatskyi (Kyiv) — 15 min10. Nephroprotection in patients with arterial hyperten-

sionS.V. Kushnirenko (Kyiv) — 15 min

11. Treatment of patients with resistant arterial hyper-tension and kidney damage – does universal approach exist?O.O. Matova (Kyiv) -— 15 min

Discussion – 15 min

CONFERENCE HALL «OLYMPIA»9:00–9:30 Master classNew opportunities in antithrombotic treatment of patients with multifocal atherosclerosis

prof. V.Yo. Tseluyko (Kharkiv)

9:30–10:00 Lecture: prof. L.G. Voronkov (Kyiv)Patient with Chronic Heart Failure and Concomitant Anemia

10:00–10:30 Round table Actual questions of treatment of cardiac patients with concomitant endocrine pathologyParticipants: L.A. Mishchenko MD, L.K. Sokolova MD (Kyiv)

10:30–11:00 Actual discussionAntiplatelet and antithrombotic therapy in patients with stable coronary artery disease. Which way to choose?

1. Ì³êðî-ÐÍÊ ³ ïðîáëåìè ïàòîãåíåçó òà ë³êóâàííÿ ïåðâèííî¿ àðòåð³àëüíî¿ ã³ïåðòåíç³¿Ñ.Ì. Êîâàëü, ².Î. Ñí³ãóðñüêà, Ê.Î. Þøêî (Õàðê³â) — 15 õâ

2. Ìàñêîâàíà àðòåð³àëüíà ã³ïåðòåíç³ÿ — ì³ô ÷è ðå-àëüí³ñòü? Ðåçóëüòàòè âñåóêðà¿íñüêîãî äîñë³äæåííÿ ÌÀÃÍÀÒË.À. Ì³ùåíêî (Êè¿â) — 15 õâ

3. Àðòåð³àëüíà ã³ïåðòåíç³ÿ ³ ô³áðèëÿö³ÿ ïåðåäñåðäüÎ.É. Æàð³íîâ (Êè¿â) — 15 õâ

4. Íîâ³ ìîæëèâîñò³ â ë³êóâàíí³ õâîðèõ íà àðòåð³àëüíó ã³ïåðòåíç³þ òà öóêðîâèé ä³àáåòË.Ê. Ñîêîëîâà (Êè¿â) — 15 õâ

5. Àíòèêðèçîâèé ìåíåäæìåíò: àðòåð³àëüíà ã³ïåðòåí-ç³ÿ ³ æ³íî÷å çäîðîâ’ÿÞ.Â. Äàâèäîâà (Êè¿â) — 15 õâ

6. Ãåíäåðí³ àñïåêòè àðòåð³àëüíî¿ ã³ïåðòåíç³¿Ì.Ì. Äîëæåíêî (Êè¿â) — 15 õâ

7. Ì³æíàðîäí³ êë³í³÷í³ ïðîòîêîëè òà âëàñíèé äîñâ³ä â ë³êóâàíí³ ã³ïåðòåíç³¿ ó âàã³òíèõÀ.Þ. Ë³ìàíñüêà (Êè¿â) — 15 õâ

8. Óðàæåííÿ îðãàíà çîðó ïðè àðòåð³àëüí³é ã³ïåð-òåíç³¿Þ.À. Äüîì³í, Î.Â. Íåäçâåöüêà (Õàðê³â) — 15 õâ

9. Âòîðèííà ïðîô³ëàêòèêà ³íñóëüòó: Ùî? ßê? Êîëè?².Ë. Ðåâåíüêî, Â.Ì. Êîðíàöüêèé (Êè¿â) — 15 õâ

10. Çàõèñò íèðîê ó ïàö³ºíò³â ç àðòåð³àëüíîþ ã³ïåðòåí-ç³ºþÑ.Â. Êóøí³ðåíêî (Êè¿â) — 15 õâ

11. Ë³êóâàííÿ õâîðèõ íà ðåçèñòåíòíó àðòåð³àëüíó ã³-ïåðòåíç³þ ç óðàæåííÿì íèðîê — ÷è ³ñíóº óí³âåð-ñàëüíèé ï³äõ³ä?Î.Î. Ìàòîâà (Êè¿â) — 15 õâ


ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÎË²ÌÏ²ß»9:00–9:30 Ìàéñòåð-êëàñÍîâ³ ìîæëèâîñò³ àíòèòðîìáîòè÷íî¿ òåðàï³¿ ïàö³ºíò³â ³ç ìóëüòèôîêàëüíèì àòåðîñêëåðîçîì

ïðîô. Â.É Öåëóéêî (Õàðê³â)

9:30–10:00 Ëåêö³ÿ: ïðîô. Ë.Ã. Âîðîíêîâ (Êè¿â)Ïàö³ºíò ³ç õðîí³÷íîþ ñåðöåâîþ íåäîñòàòí³ñòþ òà ñóïóòíüîþ àíåì³ºþ

10:00–10:30 Êðóãëèé ñò³ë�Àêòóàëüí³ ïèòàííÿ ë³êóâàííÿ êàðä³îëîã³÷íèõ ïàö³ºíò³â ³ç ñóïóòíüîþ åíäîêðèííîþ ïàòîëîã³ºþÓ÷àñíèêè: ä.ì.í. Ë.À. Ì³ùåíêî, ä.ì.í. Ë.Ê. Ñîêîëîâà (Êè¿â)

10:30–11:00 Àêòóàëüíà äèñêóñ³ÿÀíòèòðîìáîöèòàðíà é àíòèòðîìáîòè÷íà òåðàï³ÿ ó õâîðèõ ç³ ñòàá³ëüíîþ õâîðîáîþ êîðîíàðíèõ àðòåð³é. ßêèé øëÿõ îáðàòè?


24

26 â

åðåñ

íÿ

(÷åò

âåð)

ASA, clopidogrel. Dual therapy: ASA + clopidogrel, ASA + ticagrelor

Participants: prof. M.I. Lutay, corr. member of NAMS of Ukraine, prof. O.M. Parkhomenko (Kyiv)

11:00–11:30 Master classAntihypertensive therapy choice in chronic heart failure patient with preserved ejection fraction

prof. Radchenko D.M (Kyiv)

11:30–12:10 Round tableFeatures of diuretic therapy in comorbid patients with cardiac pathologyParticipants: prof. L.G. Voronkov, L.A. Mishchenko MD (Kyiv)

12:10–12:50 Round tableEmpowering your clinical decisions in treating patients with D2T

Participants: L.K. Sokolova MD (Kyiv), prof. B.N. Mankovsky (Kyiv), prof. O.A. Koval (Dnipro)

12:50–13:20 Master classDouble or triple antihypertensive therapy: who to whom?Participants: L.A. Mishchenko MD, O.O.Matova PhD (Kyiv)

13:20–14:00 BREAK

14:00–14:30 Master classJustified expectations or new in the treatment of patients with chronic heart failure with preserved ejection fractionParticipants: prof. V.Yo. Tseluyko (Kharkiv), prof. O.A. Koval

(Dnipro)*With the scientific support of the ACINO company.

14:30–18:00 Plenary session HEART FAILUREPresidium: prof. L.G. Voronkov, corr. member of NAMS

of Ukraine, prof. K.M. Amosova, corr.member of NAMS of Ukraine, prof. B.M. Todurov

14:00-15:00 Lecture: corr. member of NAMS of Ukraine, prof. K.M. Amosova (Kyiv) Heart failure with preserved ejection fraction: phantom or real syndrome with «own face»?

15:00-15:30 Lecture: corr.member of NAMS of Ukraine prof. B.M. Todurov (Kyiv)Contemporary approaches to cardiosurgical treatment of chronic heart failure patients

15:30-18:00 1. Cognitive dysfunction in chronic heart failure patients:

clinical, prognostic significance and rationale for cor-rectionL.G. Voronkov, A.S. Solonovich (Kyiv) –20 min

Àöåòèëñàë³öèëîâà êèñëîòà, êëîï³äîãðåëü. Ïîäâ³éíà òåðàï³ÿ: àöåòèëñàë³öèëîâà êèñëîòà + êëîï³äîãðåëü, àöåòèëñàë³öèëîâà êèñëîòà + ò³êàãðåëîðÓ÷àñíèêè: ïðîô. Ì.². Ëóòàé, ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô.

Î.Ì. Ïàðõîìåíêî (Êè¿â)

11:00–11:30 Ìàéñòåð-êëàñÂèá³ð àíòèã³ïåðòåíçèâíî¿ òåðàï³¿ ó ïàö³ºíòà ³ç ñåðöåâîþ íåäîñòàòí³ñòþ òà çáåðåæåíîþ ôðàêö³ºþ âèêèäó

ïðîô. Ã.Ä. Ðàä÷åíêî (Êè¿â)

11:30–12:10 Êðóãëèé ñò³ëÎñîáëèâîñò³ ä³óðåòè÷íî¿ òåðàï³¿ ó êîìîðá³äíèõ ïàö³ºíò³â ç êàðä³àëüíîþ ïàòîëîã³ºþÓ÷àñíèêè: ïðîô. Ë.Ã. Âîðîíêîâ, ä.ì.í. Ë.À. Ì³ùåíêî (Êè¿â)

12:10–12:50 Êðóãëèé ñò³ëÐîçøèðåííÿ ìîæëèâîñòåé äëÿ âàøèõ êë³í³÷íèõ ð³øåíü ï³ä ÷àñ ë³êóâàííÿ ïàö³ºíò³â ³ç öóêðîâèì ä³àáåòîì 2-ãî òèïóÓ÷àñíèêè: ä.ì.í. Ë.Ê. Ñîêîëîâà (Êè¿â), ïðîô. Á.Í. Ìàíü-

êîâñüêèé (Êè¿â), ïðîô. Å.À. Êîâàëü (Äí³ïðî)

12:50–13:20 Ìàéñòåð-êëàñÏîäâ³éíà ÷è ïîòð³éíà àíòèã³ïåðòåíçèâíà òåðàï³ÿ: ùî êîìó?Ó÷àñíèêè: ä.ì.í. Ë.À. Ì³ùåíêî, ê.ì.í. Î.Î. Ìàòîâà (Êè¿â)

13:20–14:00 ÏÅÐÅÐÂÀ

14:00–14:30 Ìàéñòåð-êëàñÂèïðàâäàí³ íàä³¿ àáî íîâå â ë³êóâàíí³ ïàö³ºíò³â ³ç õðîí³÷íîþ ñåðöåâîþ íåäîñòàòí³ñòþ ³ çáåðåæåíîþ ôðàêö³ºþ âèêèäóÓ÷àñíèêè: ïðîô. Â.². Öåëóéêî (Õàðê³â), ïðîô. Î.À. Êîâàëü

(Ä³ïðî)�*Çà íàóêîâî¿ ï³äòðèìêè êîìïàí³¿ ACINO.

14:30–18:00 Ïëåíàðíå çàñ³äàííÿÑÅÐÖÅÂÀ ÍÅÄÎÑÒÀÒÍ²ÑÒÜÏðåçèä³ÿ: ïðîô. Ë.Ã. Âîðîíêîâ, ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè,

ïðîô. Ê.Ì. Àìîñîâà, ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Á.Ì. Òîäóðîâ

14:30-15:00 Ëåêö³ÿ: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Ê.Ì. Àìîñîâà (Êè¿â)Ñåðöåâà íåäîñòàòí³ñòü ç³ çáåðåæåíîþ ôðàêö³ºþ âèêèäó: ôàíòîì ÷è ðåàëüíèé ñèíäðîì ³ç «âëàñíèì îáëè÷÷ÿì»?

15:00-15:30 Ëåêö³ÿ: ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Á.Ì. Òîäóðîâ (Êè¿â)Ñó÷àñí³ ï³äõîäè äî íàäàííÿ êàðä³îõ³ðóðã³÷íî¿ äîïîìîãè ïàö³ºíòàì ³ç õðîí³÷íîþ ñåðöåâîþ íåäîñòàòí³ñòþ

15:30-18:001. Êîãí³òèâíà äèñôóíêö³ÿ ó ïàö³ºíò³â ³ç õðîí³÷íîþ

ñåðöåâîþ íåäîñòàòí³ñòþ: êë³í³êî-ïðîãíîñòè÷íå çíà÷åííÿ òà îá´ðóíòóâàííÿ êîðåêö³¿Ë.Ã. Âîðîíêîâ, À.Ñ. Ñîëîíîâè÷ (Êè¿â) — 20 õâ


25

26th

of

Sept

embe

r (T

hurs

day)

2. Transcatheter method of aortic valve stenosisB.M. Todurov, M.V. Stan, A.V. Khokhlov (Kyiv) – 20 min

3. Practical aspects of biomarker diagnostics in chronic heart failureO.E. Berezin (Zaporizhia) – 20 min

4. Heart failure with left ventricular ejection fraction in intermediary rangeO.Y. Zharinov (Kyiv) – 20 min

5. Heart failure phenotype and renal dysfunctionO.V. Kuryata (Dnipro) – 20 min

6. The phenotypes of chronic heart failure in patients with ischemic heart disease and comorbidities with chronic obstructive pulmonary diseaseV.A. Potabashniy (Kriviy Rig) – 20 min

7. Catheter treatment of atrial fibrillation in patients with left ventricular systolic dysfunction

Y.V. Zinchenko, T.V. Mikhaleva (Kyiv) – 20 min

CONFERENCE HALL «ODISSEY»9:00–11:40 Section meeting SCHOOL FOR PRACTICING DOCTORS (Clinical cases)Moderators: prof. T.V. Kolesnyk, prof. M.M. Dolzhenko1. The new paradigms of treatment of patients with arte-

rial hypertension after revaskularisation of myocardiumM.M. Dolzhenko (Kyiv ) – 20 min

2. Anticoagulation therapy for atrial fibrillation. Clinical caseanalysisO.M. Romanova (Kyiv) – 20 min

3. Can a patient with ACS be «simple»? Realities and myths based on analysis of a clinical casesD.I. Besh (Lviv) – 20 min

4. Anxiety and depression in cardiologic patients: how to see an genuine face and who has to treat?T.V. Kolesnyk (Dnipro) – 20 min

5. Hypertension and the brain. Cerebroprotective effects of blockade of angiotensin receptors (and not only): world experience and own observationsS.O. Andriyevska (Odessa) – 20 min

6. The multiple dimensions of anti-ischemic therapy and the possibilities of a family doctor at the present stage: clinical analysisM.M. Seliuk (Kyiv) – 20 min

7. Features of the course and treatment of complete AV-blockade L.P. Soleiko, O.V. Soleiko, O.O. Krukova (Vinnytsia) — 20 min


11:40–12:50 Section meeting NEW TRENDS IN TREATMENT OF CARDIOVASCULAR DISEASES. PROOF MEDICINE AND RECOMMENDATIONS

Moderators: prof. M.I. Lutay, prof. V.Yo. Tseluyko

2. Òðàíñêàòåòåðíà ìåòîäèêà ñòåíîçó àîðòàëüíîãî êëàïàíàÁ.Ì. Òîäóðîâ, Ì.Â. Ñòàí, À.Â. Õîõëîâ (Êè¿â) — 20 õâ

3. Ïðàêòè÷í³ àñïåêòè á³îìàðêåðíî¿ ä³àãíîñòèêè ïðè ñåðöåâ³é íåäîñòàòíîñò³Î.ª. Áåðåç³í (Çàïîð³ææÿ) — 20 õâ

4. Ñåðöåâà íåäîñòàòí³ñòü ç ôðàêö³ºþ âèêèäó ë³âîãî øëóíî÷êà ó ïðîì³æíîìó ä³àïàçîí³Î.É. Æàð³íîâ, Î.À. ªïàí÷³íöåâà (Êè¿â) — 20 õâ

5. Ôåíîòèï ñåðöåâî¿ íåäîñòàòíîñò³ òà äèñôóíêö³ÿ íèðîê Î.Â. Êóðÿòà (Äí³ïðî) — 20 õâ

6. Ôåíîòèïè õðîí³÷íî¿ ñåðöåâî¿ íåäîñòàòíîñò³ ó ïàö³-ºíò³â ç ³øåì³÷íîþ õâîðîáîþ ñåðöÿ ³ êîìîðá³äíèì õðîí³÷íèì îáñòðóêòèâíèì çàõâîðþâàííÿì ëåãåíüÂ.À. Ïîòàáàøí³é (Êðèâèé Ð³ã) — 20 õâ

7. Åôåêòèâí³ñòü êàòåòåðíîãî ë³êóâàííÿ ô³áðèëÿö³¿ ïå-ðåäñåðäü ó õâîðèõ ³ç ñèñòîë³÷íîþ äèñôóíêö³ºþ ë³-âîãî øëóíî÷êàÞ.Â. Ç³í÷åíêî, Ò.Â. Ì³õàëºâà (Êè¿â) — 20 õâ

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÎÄ²ÑÑÅÉ» 9:00–11:40 Ñåêö³éíå çàñ³äàííÿØÊÎËÀ ÏÐÀÊÒÈÊÓÞ×ÎÃÎ Ë²ÊÀÐß (êë³í³÷í³ âèïàäêè)Ìîäåðàòîðè: ïðîô. Ò.Â. Êîëåñíèê, ïðîô. Ì.Ì. Äîë æåíêî1. Íîâ³ ïàðàäèãìè ë³êóâàííÿ õâîðèõ íà àðòåð³àëüíó

ã³ïåðòåíç³þ ï³ñëÿ ðåâàñêóëÿðèçàö³¿ ì³îêàðäàÌ.Ì. Äîëæåíêî (Êè¿â) — 20 õâ

2. Àíòèêîàãóëÿíòíà òåðàï³ÿ ïðè ô³áðèëÿö³¿ ïåðåä-ñåðäü. Êë³í³÷íèé ðîçá³ðÎ.Ì. Ðîìàíîâà (Êè¿â) — 20 õâ

3. ×è ìîæå ïàö³ºíò ç ÃÊÑ áóòè «ïðîñòèì»? Ðåàë³¿ òà ì³ôè íà ïðèêëàä³ êë³í³÷íîãî âèïàäêóÄ.². Áåø (Ëüâ³â) — 20 õâ

4. Òðèâîãà ³ äåïðåñ³ÿ ó êàðä³îëîã³÷íîãî ïàö³ºíòà: ÿê ïî-áà÷èòè ñïðàâæíº îáëè÷÷ÿ ³ õòî ïîâèíåí ë³êóâàòè?Ò.Â. Êîëåñíèê (Äí³ïðî) — 20 õâ

5. Ã³ïåðòåíç³ÿ òà ìîçîê. Öåðåáðîïðîòåêòîðí³ åôåêòè áëîêàäè ðåöåïòîð³â àíã³îòåíçèíó (³ íå ò³ëüêè): ñâ³-òîâèé äîñâ³ä òà âëàñí³ ñïîñòåðåæåííÿÑ.Î. Àíäð³ºâñüêà (Îäåñà) — 20 õâ

6. Áàãàòîãðàíí³ñòü àíòè³øåì³÷íî¿ òåðàï³¿: êë³í³÷íèé ðîçá³ð

Ì.Ì. Ñåëþê (Êè¿â) — 20 õâ7. Îñîáëèâîñò³ ïåðåá³ãó òà ë³êóâàííÿ ïîâíî¿ ÀV-

áëîêàäèË.Ï. Ñîëåéêî, Î.Â. Ñîëåéêî, Î.Î. Êðþêîâà (Â³ííèöÿ) — 20 õâ


11:40-12:50 Ñåêö³éíå çàñ³äàííÿÍÎÂ² ÒÅÍÄÅÍÖ²¯ Â Ë²ÊÓÂÀÍÍ² ÑÅÐÖÅÂÎ-ÑÓÄÈÍÍÈÕ ÇÀÕÂÎÐÞÂÀÍÜ. ÄÎÊÀÇÎÂÀ ÌÅÄÈÖÈÍÀ ÒÀ ÐÅÊÎÌÅÍÄÀÖ²¯Ìîäåðàòîðè: ïðîô. Ì.². Ëóòàé, ïðîô. Â.É. Öåëóéêî


26

26 â

åðåñ

íÿ

(÷åò

âåð)

1. Recommendations for antithrombotic therapy in patients with stable coronary artery disease. Focus on high-risk patients, place of anticoagulantsM.I. Lutay (Kyiv) – 15 min

2. Systolic arterial hypertension, current approaches for treatmentV.Yo. Tseluyko (Kharkiv) – 15 min

3. A contemporary view on statin use for the prevention and treatment of cardiovascular diseasesO.O. Khanukov (Dnipro) – 15 min

4. Positions of bisoprolol in modern guidelines for the management of patients with CVD

L.N. Yakovleva (Kharkiv) – 15 min

12:50–13:20 Lecture: prof. L.G. Voronkov (Kyiv)Anticoagulant therapy in chronic stable ischemic heart disease

13:20–14:00 BREAK

14:00–14:30 Round table «DIAMOND» approach to personalized miokardial ischemia treatmentParticipants: O.M. Romanova PhD, O.I. Irkin MD (Kyiv)*With the scientific support of the ACINO company.

14:30–16:30 Plenary session COMMERCIAL STATES IN CARDIOLOGYModerators: acad. of NAMS Ukraine, prof. V.M. Kovalen-

ko, corr. member of NAMS of Ukraine, prof. V.Z. Neti-azhenko, prof. T.V. Talaeva

1. Comorbidity — announce a problemV.M. Kovalenko (Kyiv) – 10 min

2. Efficacy of treatment of patients with high coronary risk in Ukraine M.I. Lutay (Kyiv) – 15 min

3. Pathogenetic mechanisms of development of comor-bid conditionsT.V. Talaeva (Kyiv) – 15 min

4. Diagnosis and correction of hemostasis disorders in co-morbid conditionsV.Z. Netiazhenko (Kyiv) – 15 min

5. Comorbid state in patients with hypertension: strategy and tactics of patient’s management M.M. Dolzhenko (Kyiv) – 15 min

6. Hidden and obvious manifestations of iron deficiency anemiaA.Y. Lymanska (Kyiv) – 15 min

7. Problems of gastrointestinal safety in patients receiv-ing antiplatelet therapyM.Yu. Zak (Mykolaiv)– 15 min

1. Ðåêîìåíäàö³¿ ç àíòèòðîìáîòè÷íî¿ òåðàï³¿ ïàö³ºíò³â ç³ ñòàá³ëüíîþ ³øåì³÷íîþ õâîðîáîþ ñåðöÿ. Ôîêóñ íà ïàö³ºíò³â âèñîêîãî ðèçèêó, ì³ñöå àíòèêîàãóëÿíò³âÌ.². Ëóòàé (Êè¿â) — 15 õâ

2. Ñèñòîë³÷íà àðòåð³àëüíà ã³ïåðòåíç³ÿ, ñó÷àñí³ ï³äõîäè äî ë³êóâàííÿÂ.É. Öåëóéêî (Õàðê³â) — 15 õâ

3. Ñó÷àñí³ óÿâëåííÿ ïðî ðîëü ñòàòèí³â ó ïðîô³ëàêòèö³ òà ë³êóâàíí³ ñåðöåâî-ñóäèííèõ çàõâîðþâàíüÎ.Î. Õàíþêîâ (Äí³ïðî) — 15 õâ

4. Ïîçèö³¿ á³ñîïðîëîëó â ñó÷àñíèõ ðåêîìåíäàö³ÿõ ç âå-äåííÿ ïàö³ºíò³â ³ç ñåðöåâî-ñóäèííèìè çàõâîðþ-âàííÿìè�Ë.Ì. ßêîâëºâà (Õàðê³â) — 15 õâ

12:50–13:20 Ëåêö³ÿ: ïðîô. Ë.Ã. Âîðîíêîâ (Êè¿â)Àíòèêîàãóëÿíòíà òåðàï³ÿ ó ïàö³ºíò³â ³ç õðîí³÷íîþ ñòàá³ëüíîþ ³øåì³÷íîþ õâîðîáîþ ñåðöÿ

13:20–14:00 ÏÅÐÅÐÂÀ

14:00–14:30 Êðóãëèé ñò³ë«Ä²ÀÌÀÍÒ» ó ï³äõîä³ äî ïåðñîí³ô³êîâàíîãî ë³êóâàííÿ ³øåì³¿ ì³îêàðäàÓ÷àñíèêè: ê.ì.í. Î.Ì. Ðîìàíîâà, ä.ì.í. Î.². ²ðê³í (Êè¿â) ��*Çà íàóêîâî¿ ï³äòðèìêè êîìïàí³¿ ACINO.

14:30–16:30 Ïëåíàðíå çàñ³äàííÿÊÎÌÎÐÁ²ÄÍ² ÑÒÀÍÈ Â ÊÀÐÄ²ÎËÎÃ²¯Ìîäåðàòîðè: àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ì. Êîâàëåíêî,

÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ç. Íåòÿæåíêî, ïðîô. Ò.Â. Òàëàºâà

1. Êîìîðá³äí³ñòü — àíîíñ ïðîáëåìèÂ.Ì. Êîâàëåíêî (Êè¿â) — 10 õâ

2. Åôåêòèâí³ñòü ë³êóâàííÿ õâîðèõ âèñîêîãî êîðîíàð-íîãî ðèçèêó â Óêðà¿í³Ì.². Ëóòàé (Êè¿â) — 15 õâ

3. Ïàòîãåíåòè÷í³ ìåõàí³çìè ðîçâèòêó êîìîðá³äíèõ ñòàí³âÒ.Â. Òàëàºâà (Êè¿â) — 15 õâ

4. Ä³àãíîñòèêà òà êîðåêö³ÿ ïîðóøåíü ãåìîñòàçó ïðè êîìîðá³äíèõ ñòàíàõÂ.Ç. Íåòÿæåíêî (Êè¿â) — 15 õâ

5. Êîìîðá³äíèé ñòàí: ñòðàòåã³ÿ ³ òàêòèêà âåäåííÿ ïàö³-ºíòà ç àðòåð³àëüíîþ ã³ïåðòåíç³ºþÌ.Ì. Äîëæåíêî (Êè¿â) — 15 õâ

6. Ïðèõîâàí³ òà íàÿâí³ ïðîÿâè çàë³çîäåô³öèòíî¿ àíå-ì³¿ À.Þ. Ëèìàíñüêà (Êè¿â) — 15 õâ

7. Ïðîáëåìè ãàñòðî³íòåñòèíàëüíî¿ áåçïåêè ó ïàö³ºí-ò³â, ÿê³ îòðèìóþòü àíòèòðîìáîöèòàðíó òåðàï³þÌ.Þ. Çàê (Ìèêîëà¿â) — 15 õâ


27

26th

of

Sept

embe

r (T

hurs

day)

8. Cardiotoxicity in patients with solid tumors during treatment with the use of different polychemotherapy schemesL.A. Ilnytska, V.E.Zhylchuk (Rivne) — 15 min

9. Arterial hypertension in rheumatoid arthritis as a clini-cal problemV.E. Kondratiuk (Kyiv) – 15 min


16:30–17:00 Round TablePeripartum cardiomyopathy from the point of view of a cardiologist and gynecologist: a dialogue of professionals

V.Y. Tseluyko (Kharkiv), Yu.V. Davydova (Kyiv)

17:00–17:20 Problem reportModern positions of statinoterapy for heart disease patients

prof. T.V. Kolesnyk (Dnipro)

CONFERENCE HALL «ALTIUS»9:00–11:20 Sectional sessionMULTIFACTORIAL CORRECTION OF CARDIOVASCULAR RISKModerators: prof. O.I. Mitchenko, acad. of NAMS of Ukraine

A.V. Rudenko, prof. T.V. Kolesnyk 1. Modern approaches to the treatment of patients with

arterial hypertension and obesityT.V. Kolesnyk (Dnipro) — 15 min

2. The surgical treatment of acquired heart disease of ischemic genesisA.V. Rudenko, S.A. Rudenko (Kyiv) — 15 min

3. The problem of resistance to therapy of cardiovascular diseases in the European recommendationsO.I. Mitchenko (Kyiv) — 15 min

4. Factors of cardiovascular risk and premature aging: are there points of contact?O.V. Kolesnikova, O.E. Zaprovalna (Kharkiv) — 15 min

5. The influence of individual and group medical patients education on the control of cardiovascular risk factors

G.S. Isayeva, L.A. Reznik, O.O. Buryakivska, M.M. Vovchenko, A.S. Shalimova (Kharkiv) — 15 min

6. Congestion of alpha-lipid acid in patients with high cardiovascular rhizic L.V. Zhuravlova (Kharkiv) — 15 hv

7. Arterial hypertension and brain. The view of the neu-rologistM.A. Treschinskaya (Kyiv) — 15 min

8. Circulating micro-RNA in coronary artery disease and type 2 diabetesS.A. Serik (Kharkiv) — 15 min

9. Cardiovascular and nephroprotective effects of block-ers renin-angiotensin system in clinical practiceV.Yu. Romanov (Kyiv) — 15 min

8. Êàðä³îòîêñè÷í³ñòü ó õâîðèõ ³ç ñîë³äíèìè ïóõëèíà-ìè ïðè ë³êóâàíí³ ³ç çàñòîñóâàííÿì ð³çíèõ ñõåì ïî-ë³õ³ì³îòåðàï³¿Ë.À. ²ëüíèöüêà, Â.ª. Æèëü÷óê (Ð³âíå) — 15 õâ

9. Àðòåð³àëüíà ã³ïåðòåíç³ÿ ïðè ðåâìàòî¿äíîìó àðò-ðèò³ ÿê êë³í³÷íà ïðîáëåìàÂ.ª. Êîíäðàòþê (Êè¿â) — 15 õâ


16:30–17:00 Êðóãëèé ñò³ëÏåðèïàðòàëüíà êàðä³îì³îïàò³ÿ ç òî÷êè çîðó êàðä³îëîãà òà ã³íåêîëîãà: ä³àëîã ïðîôåñ³îíàë³â

Â.É. Öåëóéêî (Õàðê³â), Þ.Â. Äàâèäîâà (Êè¿â)

17:00–17:20 Ïðîáëåìíà äîïîâ³äüCó÷àñí³ ïîçèö³¿ ñòàòèíîòåðàï³¿ ó õâîðèõ ³ç êàðä³îâàñêóëÿðíîþ ïàòîëîã³ºþ

ïðîô. Ò.Â. Êîëåñíèê (Äí³ïðî)

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÀËÜÒ²ÓÑ»9:00–11:20 Ñåêö³éíå çàñ³äàííÿÌÓËÜÒÈÔÀÊÒÎÐÍÀ ÊÎÐÅÊÖ²ß ÑÅÐÖÅÂÎ-ÑÓÄÈÍÍÎÃÎ ÐÈÇÈÊÓÌîäåðàòîðè: ïðîô. Î.². Ì³ò÷åíêî, àêàä. ÍÀÌÍ Óêðà¿íè

À.Â. Ðóäåíêî, ïðîô. Ò.Â. Êîëåñíèê 1. Ñó÷àñí³ ï³äõîäè äî ë³êóâàííÿ ïàö³ºíò³â ç àðòåð³àëü-

íîþ ã³ïåðòåíç³ºþ òà îæèð³ííÿì Ò.Â. Êîëåñíèê (Äí³ïðî) — 15 õâ

2. Õ³ðóðã³÷íå ë³êóâàííÿ íàáóòèõ âàä ñåðöÿ ³øåì³÷íîãî ãåíåçó À.Â. Ðóäåíêî, Ñ.À. Ðóäåíêî (Êè¿â) — 15 õâ

3. Ïðîáëåìà ðåçèñòåíòíîñò³ äî òåðàï³¿ ñåðöåâî-ñóäèí-íèõ çàõâîðþâàíü ó ñâ³òë³ ªâðîïåéñüêèõ ðåêîìåíäàö³éÎ.². Ì³ò÷åíêî (Êè¿â) — 15 õâ

4. Ôàêòîðè ñåðöåâî-ñóäèííîãî ðèçèêó ³ ïåðåä÷àñíå ñòàð³ííÿ: ÷è º òî÷êè äîòèêó?Î.Â. Êîëåñí³êîâà, Î.ª. Çàïðîâàëüíà (Õàðê³â) — 15 õâ

5. Âïëèâ ³íäèâ³äóàëüíîãî ³ ãðóïîâîãî íàâ÷àííÿ ïàö³-ºíò³â îñíîâàì ìåäè÷íèõ çíàíü íà êîíòðîëü ôàêòî-ð³â ñåðöåâî-ñóäèííîãî ðèçèêóÃ.Ñ. ²ñàºâà, Ë.À. Ðåçí³ê, Î.Î. Áóðÿê³âñüêà, Ì.Ì. Âîâ-÷åíêî, À.Ñ. Øàë³ìîâà (Õàðê³â) — 15 õâ

6. Çàñòîñóâàííÿ àëüôà-ë³ïîºâî¿ êèñëîòè ó ïàö³ºíò³â ç âèñîêèì êàðä³îâàñêóëÿðíèì ðèçèêîìË.Â. Æóðàâëüîâà (Õàðê³â) — 15 õâ

7. Àðòåð³àëüíà ã³ïåðòåíç³ÿ òà ìîçîê. Ïîãëÿä íåâðî-ëîãàÌ.À. Òðåù³íñüêà (Êè¿â) — 15 õâ

8. Öèðêóëþþ÷³ ì³êðî-ÐÍÊ ïðè ³øåì³÷í³é õâîðîá³ ñåð-öÿ òà öóêðîâîìó ä³àáåò³ 2-ãî òèïóÑ.À. Ñåð³ê (Õàðê³â) — 15 õâ

9. Êàðä³î- òà íåôðîïðîòåêòîðíèé åôåêò áëîêàòîð³â ðåí³í-àíã³îòåíçèíîâî¿ ñèñòåìè â êë³í³÷í³é ïðàêòèö³Â.Þ. Ðîìàíîâ (Êè¿â) — 15 õâ


28

26 â

åðåñ

íÿ

(÷åò

âåð)

11:20–12:30 Joint meeting of the European Atheroscle-rosis Society , Ukrainian Atherosclerosis Society and Polish Lipid AssociationModerators: prof. O.I. Mitchenko, prof. M.I. Lutay, prof. Z. Pe-

trulioniene Part Two1. Actual questions of diagnosis and treatment of dyslip-

idemia in LithuaniaZ. Petrulioniene (Vilnius) – 15 min

2. The current strategy of prevention of atherosclerotic cardiovascular diseasesM.I. Lutay (Kyiv) — 15 min

3. Effect of ASK gastropathy on the effectiveness of hy-polipidemic therapy in patients with high cardiovascu-lar riskO.O. Klekot (Vinnytsia) — 15 min

4. Place of combined hypolipidemic therapy in the treat-ment of hypercholesterolemia in patients with high cardiovascular riskV.Yu. Romanov (Kyiv) – 15 min


12:30–12:50 Problem reportRamipril and treatment of high cardio-vascular risk patients

prof. Yu.M. Sirenko (Kyiv)

12:50–13:30 Master classCommon errors in the treatment of patients with atrial fibrillation

O.M. Romanova (Kyiv)

13:20–14:00 BREAK

14:00–17:50 Plenary sessionPULMONARY HYPERTENSION IN CLINICAL CASESModerators: prof. Yu.M. Sirenko, prof. G.D. Radchenko1. Idiopathic pulmonary arterial hypertension: clinical

case Yu.M. Sirenko (Kyiv) — 30 min

2. SAUDI Pulmonary Hypertension Registry: Compared to west registriesAbdullah Aldalaan (Riyadh, Kingdom of Saudi Arabia) — 40 min

3. Indication and contraindication to surgical treatment of congenital heart diseases: clinical cases

I.G. Lebid (Kyiv) — 30 min4. Pulmonary hypertension associated with left heart

diseases: clinical caseG.D. Radchenko (Kyiv) — 30 min

5. Pulmonary hypertension associated with lung dise-ases: clinical casesE.O. Merinkov (Kyiv) — 30 min

11:20–12:30 Ñï³ëüíå çàñ³äàííÿ ªâðîïåéñüêîãî òîâàðè-ñòâà ç àòåðîñêëåðîçó, Óêðà¿íñüêîãî òîâàðèñòâà ç àòåðî-ñêëåðîçó òà Ïîëüñüêî¿ ë³ï³äíî¿ àñîö³àö³¿ Ìîäåðàòîðè: ïðîô. Î.². Ì³ò÷åíêî, ïðîô. Ì.². Ëóòàé, ïðîô.

Æ. Ïåòðóë³îí³íå ×àñòèíà äðóãà 1. Àêòóàëüí³ ïèòàííÿ ä³àãíîñòèêè òà ë³êóâàííÿ äèñë³-

ï³äåì³¿ â Ëèòâ³Æ. Ïåòðóë³îí³íå (Â³ëüíþñ) — 15 õâ

2. Ñó÷àñíà ñòðàòåã³ÿ ïîïåðåäæåííÿ àòåðîñêëåðîòè÷-íèõ ñåðöåâî-ñóäèííèõ çàõâîðþâàíü Ì.². Ëóòàé (Êè¿â) — 15 õâ

3. Âïëèâ àñï³ðèí-³íäóêîâàíèõ ãàñòðîïàò³é íà åôåê-òèâí³ñòü ã³ïîë³ï³äåì³÷íî¿ òåðàï³¿ ó õâîðèõ ç âèñî-êèì ñåðöåâî-ñóäèííèì ðèçèêîìÎ.Î. Êëåêîò (Â³ííèöÿ) — 15 õâ

4. Ì³ñöå êîìá³íîâàíî¿ ã³ïîë³ï³äåì³÷íî¿ òåðàï³¿ â ë³êó-âàíí³ ã³ïåðõîëåñòåðèíåì³é ó õâîðèõ âèñîêîãî ñåð-öåâî-ñóäèííîãî ðèçèêóÂ.Þ. Ðîìàíîâ (Êè¿â) — 15 õâ


12:30–12:50 Ïðîáëåìíà äîïîâ³äüÐàì³ïðèë ³ ë³êóâàííÿ õâîðèõ ç âèñîêèì ñåðöåâî-ñóäèííèì ðèçèêîì

ïðîô. Þ.Ì. Ñ³ðåíêî (Êè¿â)

12:50–13:20 Ìàéñòåð-êëàñÍàé÷àñò³ø³ ïîìèëêè ïðè êóðàö³¿ õâîðèõ ³ç ô³áðèëÿö³ºþ ïåðåäñåðäü

Î.Ì. Ðîìàíîâà (Êè¿â)

13:20–14:00 ÏÅÐÅÐÂÀ

14:00–17:50 Ïëåíàðíå çàñ³äàííÿËÅÃÅÍÅÂÀ Ã²ÏÅÐÒÅÍÇ²ß Â ÊË²Í²×ÍÈÕ ÂÈÏÀÄÊÀÕÌîäåðàòîðè: ïðîô. Þ.Ì. Ñ³ðåíêî, ïðîô. Ã.Ä. Ðàä÷åíêî1. ²ä³îïàòè÷íà ëåãåíåâà àðòåð³àëüíà ã³ïåðòåíç³ÿ: êë³-

í³÷íèé âèïàäîêÞ.Ì. Ñ³ðåíêî (Êè¿â) — 30 õâ

2. Ñàóä³âñüêèé ðåã³ñòð ëåãåíåâî¿ ã³ïåðòåíç³¿: ïîð³â-íÿííÿ ³ç ðåã³ñòðàìè çàõ³äíèõ êðà¿íÀáäóëà Àëäàëààí (Ð³ÿä, Êîðîë³âñòâî Ñàóä³âñüêî¿ Àðà-â³¿) — 40 õâ

3. Ïîêàçàííÿ òà ïðîòèïîêàçàííÿ äëÿ îïåðàòèâíî-ãî ë³êóâàííÿ âðîäæåíèõ âàä ñåðöÿ: êë³í³÷í³ ïðè-êëàäè².Ã. Ëåá³äü (Êè¿â) — 30 õâ

4. Ëåãåíåâà ã³ïåðòåíç³ÿ, àñîö³éîâàíà ç ë³âèìè â³ää³-ëàìè ñåðöÿ: êë³í³÷íèé âèïàäîêÃ.Ä. Ðàä÷åíêî (Êè¿â) — 30 õâ

5. Ëåãåíåâà ã³ïåðòåíç³ÿ, àñîö³éîâàíà ³ç çàõâîðþâàí-íÿì ëåãåíü: êë³í³÷í³ âèïàäêè ª.Î. Ìåðèíêîâà (Êè¿â) — 30 õâ


29

26th

of

Sept

embe

r (T

hurs

day)

16:40–17:20 Master classChronic thromboembolic pulmonary hypertension: treatment options in clinical casesParticipants: I.O. Zhyvilo PhD (Kyiv), prof. L.V. Kulik (Lviv)

17:20–17:50 Satellite symposium Modern options of pharmacological treatment of pulmonary arterial hypertension patients1. Actual questions of pharmacological treatment of pul-

monary arterial hypertension in Ukraineprof. Yu.M. Sirenko (Kyiv) – 15 min

2. Riociguat – new possibilities in treatment of pulmo-nary arterial hypertension I.O. Zhyvilo PhD (Kyiv) – 15 min

*With the scientific support of the BAYER company.

HOTEL «RUS» (LARGE HALL)CONFERENCE-HALL «E», «À», «Â, Ñ, D»

9:00-9:30 Lecture: prof. Sychov O.S. (Kyiv)Management of patients with atrial fibrillation

9:30-11:45 Sectional sessionANTITHROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILATIONModerators: prof. O.Y. Zharinov, prof. S.M. Koval, prof.

V.K. Taschuk, prof. O.O. Khanukov, prof. V.Yo. Tseluyko, O.I. Irkin MD

1. Contemporary antithrombotic treatment in patients with diabetes mellitus and AFV.Yo. Tseluyko (Kharkiv) – 15 min

2. Peculiarities of anticoagulation in patients with non-valvular AF and chronic kidney disease

V.K. Taschuk (Chernivtsi), L.L. Vavilova (Kyiv) — 15 min3. Practical issues of management of patients with atrial

fibrillation and CAD with high ischemic and hemor-rhagic risksO.O. Khanukov (Dnipro) – 15 min

4. Solving of clinical issues with frail patients and non valvular AFO.Y. Zharinov (Kyiv) – 15 min

5. First results of implementation of the programme «Space without stroke» in KharkivS.M. Koval, I.O. Snigurska, T.G. Starchenko, M.Y. Penko-va, O.V. Mysnychenko, K.O. Yushko (Kharkiv) — 15 min

6. Results of studies of real clinical practice for NOAC: how to interpret correctly and implement in different clinical situations

O.I. Irkin (Kyiv) — 15 min

16:40–17:20 Ìàéñòåð-êëàñ Xðîí³÷íà òðîìáîåìáîë³÷íà ëåãåíåâà ã³ïåðòåíç³ÿ: âàð³àíòè ë³êóâàííÿ â êë³í³÷íèõ ïðèêëàäàõ Ó÷àñíèêè: ê.ì.í. I.O. Æèâèëî (Êè¿â), ïðîô. Ë.Â. Êóëèê (Ëüâ³â)

17:20–17:50 Ñàòåë³òíèé ñèìïîç³óì�Ñó÷àñí³ ìîæëèâîñò³ òà àêòóàëüí³ ïèòàííÿ ôàðìàêîòåðàï³¿ ïàö³ºíò³â ç ËÀÃ1. Àêòóàëüí³ ïèòàííÿ ôàðìàêîòåðàï³¿ ëåãåíåâî¿ àðòå-

ð³àëüíî¿ ã³ïåðòåíç³¿ â Óêðà¿í³ïðîô. Þ.Ì. Ñ³ðåíêî (Êè¿â) — 15 õâ

2. Ð³îöèãóàò — íîâ³ ìîæëèâîñò³ â ë³êóâàíí³ ïàö³ºíò³â ç ëåãåíåâîþ àðòåð³àëüíîþ ã³ïåðòåíç³ºþê.ì.í. ².Î. Æèâèëî (Êè¿â) — 15 õâ

*�Çà íàóêîâî¿ ï³äòðèìêè êîìïàí³¿ BAYER.

ÃÎÒÅËÜ «ÐÓÑÜ» (ÂÅËÈÊÀ ÇÀËÀ)ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «E», «À», «B, Ñ, D»

9:00-9:30 Ëåêö³ÿ: ïðîô. Î.Ñ. Ñè÷îâ (Êè¿â)Òåðàï³ÿ õâîðèõ ³ç ô³áðèëÿö³ºþ ïåðåäñåðäü

9:30-11:45 Ñåêö³éíå çàñ³äàííÿÀÍÒÈÒÐÎÌÁÎÒÈ×ÍÀ ÒÅÐÀÏ²ß Ó ÕÂÎÐÈÕ ²Ç Ô²ÁÐÈËßÖ²ªÞ ÏÅÐÅÄÑÅÐÄÜÌîäåðàòîðè: ïðîô. Î.É. Æàð³íîâ, ïðîô. Ñ.Ì. Êîâàëü,

ïðîô. Â.Ê. Òàùóê, ïðîô. Î.Î. Õàíþêîâ, ïðîô. Â.É. Öå-ëóéêî, ä.ì.í. Î.². ²ðê³í

1. Ñó÷àñíà àíòèòðîìáîòè÷íà òåðàï³ÿ ó õâîðèõ íà ä³à-áåò ³ç ô³áðèëÿö³ºþ ïåðåäñåðäüÂ.É. Öåëóéêî (Õàðê³â) — 15 õâ

2. Îñîáëèâîñò³ àíòèêîàãóëÿíòíî¿ òåðàï³¿ ó ïàö³ºíò³â ç íåêëàïàííîþ ô³áðèëÿö³ºþ ïåðåäñåðäü òà ïîðó-øåíîþ ôóíêö³ºþ íèðîêÂ.Ê. Òàùóê (×åðí³âö³), Ë.Ë. Âàâ³ëîâà (Êè¿â) — 15 õâ

3. Ïðàêòè÷í³ ïèòàííÿ âåäåííÿ ïàö³ºíò³â ³ç íåêëàïàííîþ ô³áðèëÿö³ºþ ïåðåäñåðäü òà ³øåì³÷íîþ õâîðîáîþ ñåðöÿ âèñîêîãî ³øåì³÷íîãî òà ãåìîðàã³÷íîãî ðèçèêóÎ.Î. Õàíþêîâ (Äí³ïðî) — 15 õâ

4. Âèð³øåííÿ êë³í³÷íèõ ïèòàíü âåäåííÿ îñëàáëåíèõ ïàö³ºíò³â ³ç íåêëàïàííîþ ô³áðèëÿö³ºþ ïåðåäñåðäüÎ.É. Æàð³íîâ (Êè¿â) — 15 õâ

5. Ïåðø³ ðåçóëüòàòè ðåàë³çàö³¿ Ïðîãðàìè «Ïðîñò³ð áåç ³íñóëüòó» â Õàðêîâ³Ñ.Ì. Êîâàëü, ².Î. Ñí³ãóðñüêà, Ò.Ã. Ñòàð÷åíêî, Ì.Þ. Ïåíü-êîâà, Î.Â. Ìèñíè÷åíêî, Ê.Î. Þøêî (Õàðê³â) — 15 õâ

6. Ðåçóëüòàòè äîñë³äæåíü ðåàëüíî¿ ïðàêòèêè çàñòî-ñóâàííÿ íîâèõ îðàëüíèõ àíòèêîàãóëÿíò³â: ÿê ïðà-âèëüíî ³íòåðïðåòóâàòè òà âèêîðèñòîâóâàòè â ð³çíî-ìàí³òíèõ êë³í³÷íèõ ñèòóàö³ÿõÎ.². ²ðê³í (Êè¿â) — 15 õâ


30

26 â

åðåñ

íÿ

(÷åò

âåð)

7. Prevention of thromboembolic complications during radiofrequency catheter destruction of atrial fibrilla-tionO.V. Doronin, Yu.I. Suslina, A.Ñ. Reznik, M.Ñ. Meshkova (Kyiv) – 15 min

8. Anticoagulant administration in patients with NAF and coronary heart diseaseT.V. Hetman (Kyiv)


11:45-13:20 Joint session of the Central and Eastern Eu-rope countriesARRHYTHMIAS AND SUDDEN CARDIAC DEATHModerators: ðrof. O.S. Sychov (Êyiv), ðrof. M. Chudzik

(Poland), K.V. Rudenko MD (Kyiv), M.P. Kopytsya MD (Kharkiv)

1. Profilactics of sudenn cardiac death: status of prob-leme in UkraineO.S. Sychov (Êyiv) – 20 min

2. Prophylactic of sudden cardiac death — practical recom mendationM. Chudzik (Poland) – 20 min

3. Stratification risk of sudden cardiac death in patient with HCM. What’s new? K.V. Rudenko (Kyiv) – 20 min

4. The role of biochemical and electrophysiological mar-kers in prognostication of ventricular arrhythmias af-ter myocardial infarction

M.P. Kopytsya (Kharkiv) – 20 minDiscussion – 15 min

13:20-14:00 BREAK

HOTEL «RUS» (HALL Å, À)

14:00-16:45 Sectional sessionARRHYTHMIAS AND COMORBIDITYModerators: prof. A.M. Vasylenko, prof. M.V. Grebenik, prof.

I.P. Katerenchuk, prof. V.A. Potabashniy, prof. N.M. Sere-duk, M.P. Kopytsya

1. Rate-dependent complete left bundle branch block on the background of an abnormal origin of the left circumflex arteryN.M. Seredyuk (Ivano-Frankivsk) – 15 min

2. Disorders of rhythm and their treatment in comorbid patients with acute coronary syndromeM.V. Hrebenyk (Ternopil) – 15 min

3. Supraventricular and ventricular arrhythmias in critical ill and post-surgery – consensus EHRA 2019

V.A. Potabashniy, V.I. Fesenko (Kryvyi Rih) – 15 min4. Heart ritting and consequences in patients who have

adults infection myocardityA.M. Vasylenko, S.O. Sheyko (Kryvyi Rih) – 15 min

7. Ïðîô³ëàêòèêà òðîìáîåìáîë³÷íèõ óñêëàäíåíü ï³ä ÷àñ ïðîâåäåííÿ ðàä³î÷àñòîòíî¿ êàòåòåðíî¿ äåñòðóê-ö³¿ ô³áðèëÿö³¿ ïåðåäñåðäüÎ.Â. Äîðîí³í, Þ.². Ñóñëèíà, À.Ñ. Ðåçí³ê, Ì.Ñ. Ìºøêîâà (Êè¿â) — 15 õâ

8. Ïðèçíà÷åííÿ àíòèêîàãóëÿíòà ó ïàö³ºíò³â ç ÍÔÏ òà ²ÕÑÒ.Â. Ãåòüìàí (Êè¿â)


11:45–13:20 Ñï³ëüíå çàñ³äàííÿ êðà¿í Ñõ³äíî¿ òà Öåíò-ðàëüíî¿ ªâðîïèÀÐÈÒÌ²¯ ÒÀ ÐÀÏÒÎÂÀ ÑÅÐÖÅÂÀ ÑÌÅÐÒÜÌîäåðàòîðè: ïðîô. Î.Ñ. Ñè÷îâ (Êè¿â), ïðîô. Ì. Õóäçèê

(Ïîëüùà), ä.ì.í. Ê.Â. Ðóäåíêî (Êè¿â ) ä.ì.í. Ì.Ï. Êîïè-öÿ (Õàðê³â)

1. Ïðîô³ëàêòèêà ðàïòîâî¿ ñåðöåâî¿ ñìåðò³: ñòàí ïðî-áëåìè â Óêðà¿í³Î.Ñ. Ñè÷îâ (Êè¿â) — 20 õâ

2. Ïðîô³ëàêòèêà ðàïòîâî¿ ñåðöåâî¿ ñìåðò³ — ïðàêòè÷-í³ ðåêîìåíäàö³¿Ì. Õóäçèê (Ïîëüùà) — 20 õâ

3. Ñòðàòèô³êàö³ÿ ðèçèêó ðàïòîâî¿ ñåðöåâî¿ ñìåðò³ ïðè ã³ïåðòðîô³÷í³é êàðä³îì³îïàò³¿. Ùî íîâîãî? Ê.Â. Ðóäåíêî (Êè¿â) — 20 õâ

4. Ðîëü á³îõ³ì³÷íèõ òà íå³íâàçèâíèõ åëåêòðîô³ç³îëî-ã³÷íèõ ìàðêåð³â â ïðîãíîçóâàíí³ âèíèêíåííÿ æèò-òºâî íåáåçïå÷íèõ øëóíî÷êîâèõ àðèòì³é ó õâîðèõ ï³ñëÿ ïåðåíåñåíîãî ³íôàðêòó ì³îêàðäàÌ.Ï. Êîïèöÿ (Õàðê³â) — 20 õâ

Îáãîâîðåííÿ – 15 õâ

13:20–14:00 ÏÅÐÅÐÂÀ

ÃÎÒÅËÜ «ÐÓÑÜ» (ÇÀËÀ Å, À)

14:00-16:45 Cåêö³éíå çàñ³äàííÿÀÐÈÒÌ²¯ ² ÊÎÌÎÐÁ²ÄÍ²ÑÒÜÌîäåðàòîðè: ïðîô. À.Ì. Âàñèëåíêî, ïðîô. Ì.Â. Ãðåáåíèê,

ïðîô. ².Ï. Êàòåðåí÷óê, ïðîô. Â.À. Ïîòàáàøí³é, ïðîô. Í.Ì. Ñåðåäþê, ä.ì.í. Ì.Ï. Êîïèöÿ

1. ×àñòîòíî-çàëåæíà ïîâíà áëîêàäà ë³âî¿ í³æêè ïó÷êà Ã³ñà çà íàÿâíîñò³ àíîìàëüíîãî â³äõîäæåííÿ îãèíà-þ÷î¿ ã³ëêè ë³âî¿ êîðîíàðíî¿ àðòåð³¿Í.Ì. Ñåðåäþê (²âàíî-Ôðàíê³âñüê) — 15 õâ

2. Ïîðóøåííÿ ðèòìó òà ¿õ ë³êóâàííÿ ó êîìîðá³äíèõ õâîðèõ ç ãîñòðèì êîðîíàðíèì ñèíäðîìîìÌ.Â. Ãðåáåíèê (Òåðíîï³ëü) — 15 õâ

3. Ñóïðàâåíòðèêóëÿðí³ òà âåíòðèêóëÿðí³ àðèòì³¿ ïðè êðèòè÷íèõ ñòàíàõ ³ ï³ñëÿîïåðàö³éíîìó ïåð³îä³ — ðåêîìåíäàö³¿ EHRA 2019 ð.Â.À. Ïîòàáàøí³é, Â.². Ôåñåíêî (Êðèâèé Ð³ã) — 15 õâ

4. Ïîðóøåííÿ ðèòìó ñåðöÿ òà ïðîâ³äíîñò³ ó ïàö³ºíò³â, ÿê³ ïåðåíåñëè ³íôåêö³éíèé ì³îêàðäèòÀ.Ì. Âàñèëåíêî, Ñ.Î. Øåéêî (Êðèâèé Ð³ã) — 15 õâ


31

26th

of

Sept

embe

r (T

hurs

day)

5. Effectiveness of the long term treatment with propafe-none in management of ventricular extrasystoliaI.P. Katerenchuk, O.I. Katerenchuk (Poltava) – 15 min

6. Application of anti-arrhythmic drugs 1 C class for an-tirecession therapy in patients with atrial fibrillation and comorbid statesO.M. Romanova (Kyiv) – 15 min

7. Assessment of cardiac arrhythmias and heart rate variability in patients with myocarditisV.M. Kovalenko, E.G. Nesukay, R.M. Kirichenko (Kyiv) – 15 min

8. Effect of asymptomatic hyperuricemia correction in patients with atrial fibrillationD.M. Sebov, V.A. Korotaieva, O.M. Kobeleva (Odesa) – 15 min

9. New predictors of ventricular fibrillation and sudden cardiac death A.I. Vytrichovski (Ivano-Frankivsk) – 15 min

10. Òhe effect of antiretroviral therapy on cardiac arrhyth-mias in HIV-infected patientsV.A. Vasylenko, A.M. Vasylenko (Kryvyi Rih) – 15 min


16:45-17:45 Sectional sessionCLINICAL CASESModerators: L.I. Vasilieva PhD, S.O. Pravosudovich PhD1. Brugada Syndrom

S.V. Lyzohub, E.V. Mogilnitskii, L.O. Shabilianova (Kyiv) – 15 min

2. Transcatheter destruction of substrate of left ventricu-lar tachycardia in patient with aortic and mitral me-chanical prosthetic valves with the use of transseptal approachS.O. Pravosudovich, O.B. Bondarenko, L.L. Belmas, D.A. Misiura, L.D. Sushenko (Dnipro) – 15 min

3. Can we use MRI to determine final diagnosis in pa-tient with long term interventricular conduction dis-orders?L.I. Vasilieva, I.V. Marchuk (Dnipro) – 15 min


HOTEL «RUS» (HALL B, C, D)

14:00-14:30 Round table Management of atrial fibrillation — European guidelines and personal experienceParticipants: prof. O.S. Sychov (Kyiv), prof. O.O. Khanukov

(Dnipro)

14:30-14:50 Problem reportTreatment of atrial fibrillation in routine clinical practice

Participants: prof. V.Yo. Tseluyko, O.O. Romanenko (Kharkiv)

14:50-15:10 Problem reportMeldonium application åxperience in patients with ventricular arrhythmias of ischemic genesis

prof. S.V. Grigoryan (Yerevan, Armenia)

5. Åôåêòèâí³ñòü òðèâàëîãî ïðèéîìó ïðîïàôåíîíó ó ë³êóâàíí³ øëóíî÷êîâî¿ åêñòðàñèñòîë³¿².Ï. Êàòåðåí÷óê, Î.². Êàòåðåí÷óê (Ïîëòàâà) — 15 õâ

6. Çàñòîñóâàííÿ àíòèàðèòì³÷íèõ ïðåïàðàò³â 1Ñ êëàñó äëÿ ïðîòèðåöèäèâíî¿ òåðàï³¿ ó ïàö³ºíò³â ³ç ô³áðè-ëÿö³ºþ ïåðåäñåðäü òà êîìîðá³äíèìè ñòàíàìèÎ.Ì. Ðîìàíîâà (Êè¿â) — 15 õâ

7. Îö³íêà àðèòì³é ñåðöÿ òà âàð³àáåëüíîñò³ ñåðöåâîãî ðèòìó â ïàö³ºíò³â ç ì³îêàðäèòîìÂ.Ì. Êîâàëåíêî, Î.Ã. Íåñóêàé, Ð.Ì. Êèðè÷åíêî (Êè¿â) — 15 õâ

8. Âïëèâ êîðåêö³¿ àñèìïòîìàòè÷íî¿ ã³ïåðóðèêåì³¿ ó ïàö³ºíò³â ç ô³áðèëÿö³ºþ ïåðåäñåðäüÄ.Ì. Ñåáîâ, Â.À. Êîðîòàºâà, Î.Ì. Êîáåëåâà (Îäåñà) — 15 õâ

9. Íîâ³òí³ ïðåäèêòîðè ïîÿâè ô³áðèëÿö³¿ øëóíî÷ê³â òà ðàïòîâî¿ ñåðöåâî¿ ñìåðò³À.². Âèòðèõîâñüêèé (²âàíî-Ôðàíê³âñüê) — 15 õâ

10. Âïëèâ àíòèðåòðîâ³ðóñíî¿ òåðàï³¿ íà ïîðóøåííÿ ðèòìó ñåðöÿ ó Â²Ë-³íô³êîâàíèõ ïàö³ºíò³âÂ.À. Âàñèëåíêî, À.Ì. Âàñèëåíêî (Êðèâèé Ð³ã) — 15 õâ


16:45-17:45 Cåêö³éíå çàñ³äàííÿÊË²Í²×Í² ÂÈÏÀÄÊÈÌîäåðàòîðè: ê.ì.í. Ë.². Âàñèëüºâà, ê.ì.í. Ñ.Î. Ïðàâîñóäîâè÷ 1. Ñèíäðîì Áðóãàäà

Ñ.Â. Ëèçîãóá, ª.Â. Ìîãèëüíèöüêèé, Ë.Î. Øàá³ëüÿíîâà (Êè¿â) — 15 õâ

2. Òðàíñêàòåòåðíà äåñòðóêö³ÿ ñóáñòðàòó ë³âîøëóíî÷-êîâî¿ òàõ³êàðä³¿ ó ïàö³ºíòà ç ìåõàí³÷íèìè ïðîòåçà-ìè àîðòàëüíîãî òà ì³òðàëüíîãî êëàïàí³â ç âèêîðèñ-òàííÿì òðàíññåïòàëüíîãî äîñòóïóÑ.Î. Ïðàâîñóäîâè÷, Î.Á. Áîíäàðåíêî, Ë.Ë. Áåëüìàñ, Ä.À. Ìèñþðà, Ë.Ä. Ñóùåíêî (Äí³ïðî) — 15 õâ

3. ×è ìîæëèâî âñòàíîâèòè ê³íöåâèé ä³àãíîç çà äîïî-ìîãîþ ÌÐÒ õâîðîìó ç äîâãîòðèâàëèì ïîðóøåííÿì âíóòð³øíüîøëóíî÷êîâî¿ ïðîâ³äíîñò³ ñåðöÿ?Ë.². Âàñèëüºâà, ².Â. Ìàð÷óê (Äí³ïðî) — 15 õâ


ÃÎÒÅËÜ «ÐÓÑÜ» (ÇÀËÀ B, C, D)

14:00-14:30 Êðóãëèé ñò³ëÒåðàï³ÿ ô³áðèëÿö³¿ ïåðåäñåðäü — ªâðîïåéñüê³ ðåêîìåíäàö³¿ òà âëàñíèé äîñâ³äÓ÷àñíèêè: ïðîô. Î.Ñ. Ñè÷îâ (Êè¿â), ïðîô. Î.Î. Õàíþêîâ

(Äí³ïðî)

14:30-14:50 Ïðîáëåìíà äîïîâ³äüË³êóâàííÿ ô³áðèëÿö³¿ ïåðåäñåðäü ó ïîâñÿêäåíí³é êë³í³÷í³é ïðàêòèö³Ó÷àñíèêè: ïðîô. Â.É. Öåëóéêî, Î.Î. Ðîìàíåíêî (Õàðê³â)

14:50-15:10 Ïðîáëåìíà äîïîâ³äüÄîñâ³ä çàñòîñóâàííÿ ìåëüäîí³þ ó õâîðèõ ³ç øëóíî÷êîâîþ àðèòì³ºþ ³øåì³÷íîãî ãåíåçó

ïðîô. Ñ.Â. Ãðèãîðÿí (ªðåâàí, Â³ðìåí³ÿ)


32

26 â

åðåñ

íÿ

(÷åò

âåð)

15:10-17:45 Sectional sessionINTERVENTIONAL ARRHYTHMOLOGYModerators: prof. O.V. Bilchenko, prof. Yu.I. Karpenko, prof.

O.S. Stychinski, V.P. Zalevski

15:10-15:30 Problem reportPhysiological stimulation of the heart in patients with heart failure. Modern approaches

B.B. Kravchuk PhD (Kyiv), prof. Y.I. Karpenko (Odessa)1. Catheter treatment of atrial tachycardias in patients

with congenital heart diseasesP.A. Almis, O.S. Stychinski, N.V. Melnik, A.V. Topchii, A.V. Pokanevich, A.V. Kovalchuk, O.S. Didus (Kyiv) – 15 min

2. Clinical features and pharmacotherapy in two-years prognosis in patients after atrial fibrillation and atrial flutter radiofrequency ablationO.V. Bilchenko (Kharkiv) – 15 min

3. Cryo-balloon ablation in elderly, in whom is it appro-priateA. Berkowitsch, E. Akkaya, S. Zaltsberg, A. Hain, J. Hjut-ter, K. Weipert, T. Neumann, M. Kuniss (Bad Nauheim, Germany) – 15 min

4. Anticoagulant treatment in rhythm restoring proce-duresY.I. Karpenko (Odessa) – 15 min

5. Ablation of atrial fibrillation is effective, but how to improve its result?D.E. Volkov, D.O. Lopin (Kharkiv) – 15 min

6. Treatment of atrial macro-reentry tachycardiasT.V. Kravchenko, E.S. Akobirov, S.I. Estrin (Kharkiv) – 15 min

7. Predictors of atrial fibrillation in patients after ablation of typical atrial flutter

S.V. Lyzohub, A.O. Borodai, S.I. Deyak, O.S. Sychov (Kyiv) – 15 min

8. Transcatheter left atrial appendage occlusion as an al-ternative for stroke prevention for patients with atrial fibrillationK. Boyko (Kyiv) – 15 min


HOTEL «RUS» (HALL F)

14:00–17:40 Master-classesPRACTICAL SKILLS FOR MANAGEMENT OF PATIENTS WITH RHYTHM AND CONDUCTION DISORDERS

14:00-14:40 Management of patients with pacemakers and defibrillators

S.V. Lisogub (Kyiv) – 40 min

14:40–14:45 BREAK

14:45–15:25 Anticoagulation in patients with non-valvu-lar atrial fibrillation

prof. O.S. Sychov (Kyiv) – 40 min

15:10-17:45 Cåêö³éíå çàñ³äàííÿ²ÍÒÅÐÂÅÍÖ²ÉÍÀ ÀÐÈÒÌÎËÎÃ²ß Ìîäåðàòîðè: ïðîô. Î.Â. Á³ëü÷åíêî, ïðîô. Þ.². Êàðïåíêî,

ïðîô. Î.Ñ. Ñòè÷èíñüêèé, Â.Ï. Çàëåâñüêèé

15:10-15:30 Ïðîáëåìíà äîïîâ³äüÔ³ç³îëîã³÷íà ñòèìóëÿö³ÿ ñåðöÿ ó õâîðèõ ³ç ñåðöåâîþ íåäîñòàòí³ñòþ. Ñó÷àñí³ ìîæëèâîñò³

ê.ì.í. Á.Á. Êðàâ÷óê (Êè¿â), ïðîô. Þ.². Êàðïåíêî (Îäåñà)1. Êàòåòåðíå ë³êóâàííÿ ïåðåäñåðäíèõ òàõ³êàðä³é

ó õâîðèõ ³ç âðîäæåíèìè âàäàìè ñåðöÿÏ.À. Àëüì³ç, Î.Ñ. Ñòè÷èíñüêèé, Í.Â. Ìåëüíèê, À.Â. Òîï÷³é, À.Â. Ïîêàíåâè÷, À.Â. Êîâàëü÷óê, Î.Ñ. Ä³-äóñü (Êè¿â) — 15 õâ

2. Êë³í³÷í³ õàðàêòåðèñòèêè òà ôàðìàêîòåðàï³ÿ ó äâî-ð³÷íîìó ïðîãíîç³ ñòàíó ïàö³ºíò³â ï³ñëÿ ðàä³î÷àñòîò-íî¿ àáëÿö³¿ ô³áðèëÿö³¿ òà òð³ïîò³ííÿ ïåðåäñåðäüÎ.Â. Á³ëü÷åíêî(Õàðê³â) — 15 õâ

3. Êð³îáàëîííà àáëÿö³ÿ â ïàö³ºíò³â ïîõèëîãî â³êó, êîìó âîíà ïîêàçàíàÀ. Áåðêîâè÷, Å. Àêàÿ, Ñ. Çàëüöáåðã, À. Õåéí, É. Õþò-òåð, Ê. Âàéïåðò, Ò. Íîéìàí, Ì. Êóíí³ñ (Áàä Íàóõàéì, Í³ìå÷÷èíà) — 15 õâ

4. Àíòèêîàãóëÿíòíà òåðàï³ÿ ïðè ïðîöåäóðàõ â³äíîâ-ëåííÿ ðèòìó Þ.². Êàðïåíêî (Îäåñà) — 15 õâ

5. Àáëÿö³ÿ ô³áðèëÿö³¿ ïåðåäñåðäü åôåêòèâíà, àëå ÿê ïîë³ïøèòè ¿¿ ðåçóëüòàò?Ä.ª. Âîëêîâ, Ä.Î. Ëîï³í (Õàðê³â) — 15 õâ

6. Ë³êóâàííÿ ïåðåäñåðäíèõ macro-reentry òàõ³êàðä³éÒ.Â. Êðàâ÷åíêî, ª.Ñ. Àêîá³ðîâ, Ñ.². Åñòð³í (Õàðê³â) — 15 õâ

7. Ïðåäèêòîðè âèíèêíåííÿ ô³áðèëÿö³¿ ïåðåäñåðäü ó ïàö³ºíò³â ï³ñëÿ àáëÿö³¿ òèïîâîãî òð³ïîò³ííÿ ïå-ðåäñåðäüÑ.Â. Ëèçîãóá, À.Î. Áîðîäàé, Ñ.². Äåÿê, Î.Ñ. Ñè÷îâ (Êè¿â) — 15 õâ

8. Òðàíñêàòåòåðíå çàêðèòòÿ âóøêà ë³âîãî ïåðåäñåðäÿ ÿê àëüòåðíàòèâà â ïðîô³ëàêòèö³ ³íñóëüòó ó ïàö³ºíò³â ³ç ô³áðèëÿö³ºþ ïåðåäñåðäüÊ.Ñ. Áîéêî (Êè¿â) — 15 õâ


ÃÎÒÅËÜ «ÐÓÑÜ» (ÇÀËÀ F)

14:00–17:40 Ìàéñòåð-êëàñèÏÐÀÊÒÈ×Í² ÍÀÂÈ×ÊÈ ÄËß Ë²ÊÓÂÀÍÍß ÕÂÎÐÈÕ ²Ç ÏÎÐÓØÅÍÍßÌÈ ÐÈÒÌÓ ÒÀ ÏÐÎÂ²ÄÍÎÑÒ² ÑÅÐÖß

14:00–14:40 Âåäåííÿ õâîðèõ ³ç êàðä³îñòèìóëÿòîðàìè òà äåô³áðèëÿòîðàìè

Ñ.Â. Ëèçîãóá (Êè¿â) — 40 õâ

14:40–14:45 ÏÅÐÅÐÂÀ

14:45–15:25 Àíòèêîàãóëÿíòíà òåðàï³ÿ ó õâîðèõ ³ç íå-êëàïàííîþ ô³áðèëÿö³ºþ ïåðåäñåðäü

ïðîô. Î.Ñ. Ñè÷îâ (Êè¿â) — 40 õâ


33

26th

of

Sept

embe

r (T

hurs

day)

15:25-15:30 BREAK

15:30–16:10 Cardiopulmonary resuscitationO.I. Irkin MD (Kyiv) – 40 min

16:10–16:15 BREAK

16:15–16:55 Arrhythmias and comorbidityO.M. Romanova PhD (Kyiv) – 40 min

16:55–17:00 BREAK

17:00–17:40 Should we treat patients with asymptomatic cardiac arrthythmias?

A.O. Borodai MD (Kyiv) – 40 min

27-TH OF SEPTEMBER (FRIDAY)

CHAMPIONS HALL 9:00–9:30 Lecture: prof. O.A. Krikunov (Kyiv)Principles of antibiotic therapy of infective endocarditis

9:30–13:00 Plenary sessionDISEASESS OF MYOCARDIUM, ENDOCARDIUM AND HEART VALVESPresidium: acad. of NAMS of Ukraine, prof. V.M. Kovalenko,

prof. I.M. Emets, prof. E.G. Nesukay, prof.V.Y. Tseluyko, O.A. Krikunov MD

1. Myocarditis — problems and possible ways to resolve themV.M. Kovalenko (Kyiv) – 25 min

2. X-PANT Aortic Valve: TAVI’s first experience in Ukraine

I.M. Emets (Kyiv) – 20 min3. Mechanisms of formation and ways of overcoming

cardiac failure in cardiomyopathies: European recom-mendations 2019 E.G. Nesukay (Kyiv) – 15 min

4. The clinical case: myocarditisprof. V.Yo. Tseluyko, assoc. N.Ye. Mishchuk (Kharkiv) – 15 min

5. Clinical manifestations and treatment of infective en-docarditis caused by antibiotic-resistant pathogens

O.A. Krikunov (Kyiv) – 15 min6. Dilatational cardiomyopathy: forgotten illness

D.V. Ryabenko (Kyiv) – 15 min7. Morfofunctional bases for the formation of cardiac

output V.P. Zakharova, O.M. Trembovetska, O.V. Rudenko (Kyiv) – 15 min

8. Modern possibilities of diagnosis of myocarditis in UkraineS.V. Chernyuk (Kyiv) – 15 min

9. Problems of differential diagnostics of left ventricular hypertrophy in modern cardiologyN.S. Titova (Kyiv) – 15 min

15:25–15:30 ÏÅÐÅÐÂÀ

15:30–16:10 Êàðä³îðåàí³ìàö³ÿä.ì.í. Î.². ²ðê³í (Êè¿â) — 40 õâ

16:10–16:15 ÏÅÐÅÐÂÀ

16:15–16:55 Àðèòì³¿ ³ êîìîðá³äí³ñòüê.ì.í. Î.Ì. Ðîìàíîâà (Êè¿â) — 40 õâ

16:55–17:00 ÏÅÐÅÐÂÀ

17:00–17:40 ×è ïîòð³áíî ë³êóâàòè áåçñèìïòîìí³ àðèò-ì³¿ ñåðöÿ

ä.ì.í. À.Î. Áîðîäàé (Êè¿â) — 40 õâ

27 ÂÅÐÅÑÍß (Ï’ßÒÍÈÖß)

ÕÎË ×ÅÌÏ²ÎÍ²Â 9:00–9:30 Ëåêö³ÿ: ïðîô. Î.À. Êðèêóíîâ (Êè¿â) Ïðèíöèïè àíòèá³îòèêîòåðàï³¿ ³íôåêö³éíîãî åíäîêàðäèòó

9:30–13:00 Ïëåíàðíå çàñ³äàííÿÕÂÎÐÎÁÈ Ì²ÎÊÀÐÄÀ, ÅÍÄÎÊÀÐÄÀ ÒÀ ÊËÀÏÀÍ²Â ÑÅÐÖß Ïðåçèä³ÿ: àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ì. Êîâàëåíêî,

ïðîô. ².Ì. ªìåöü, ïðîô. Î.Ã. Íåñóêàé, ïðîô. Â.É. Öå-ëóéêî, ä.ì.í. Î.À. Êðèêóíîâ

1. Ì³îêàðäèò — ïðîáëåìè òà ìîæëèâ³ øëÿõè ¿õ âèð³-øåííÿÂ.Ì. Êîâàëåíêî (Êè¿â) — 25 õâ

2. Àîðòàëüíèé êëàïàí X-PANT: ïåðøèé äîñâ³ä TAVI â Óêðà¿í³ ².Ì. ªìåöü (Êè¿â) — 20 õâ

3. Ìåõàí³çìè ôîðìóâàííÿ òà øëÿõè ïîäîëàííÿ ñåð-öåâî¿ íåäîñòàòíîñò³ ïðè êàðä³îì³îïàò³ÿõ: ªâðîïåé-ñüê³ ðåêîìåíäàö³¿–2019Î.Ã. Íåñóêàé (Êè¿â) — 15 õâ

4. Êë³í³÷íèé âèïàäîê: ì³îêàðäèòïðîô. Â.É. Öåëóéêî, äîö. Í.ª. Ì³ùóê (Õàðê³â) — 20 õâ

5. Êë³í³÷í³ ïðîÿâè òà ë³êóâàííÿ ³íôåêö³éíîãî åíäî-êàðäèòó, ùî âèêëèêàíèé ðåçèñòåíòíèìè äî àíòè-á³îòèê³â çáóäíèêàìèÎ.À. Êðèêóíîâ (Êè¿â) — 15 õâ

6. Äèëàòàö³éíà êàðä³îì³îïàò³ÿ: çàáóòà õâîðîáàÄ.Â. Ðÿáåíêî (Êè¿â) — 15 õâ

7. Ìîðôîôóíêö³îíàëüí³ îñíîâè ôîðìóâàííÿ ñåðöå-âîãî âèêèäóÂ.Ï. Çàõàðîâà, Î.Ì. Òðåìáîâåöüêà, Î.Â. Ðóäåíêî (Êè¿â) — 15 õâ

8. Ñó÷àñí³ ìîæëèâîñò³ ä³àãíîñòèêè ì³îêàðäèòó â Óêðà-¿í³Ñ.Â. ×åðíþê (Êè¿â) — 15 õâ

9. Ïðîáëåìè äèôåðåíö³éíî¿ ä³àãíîñòèêè ã³ïåðòðîô³¿ ë³âîãî øëóíî÷êà ó ñó÷àñí³é êàðä³îëîã³¿Í.Ñ. Ò³òîâà (Êè¿â) — 15 õâ


34

27 â

åðåñ

íÿ

(ï’ÿ

òíè

öÿ)

10. AL amyloidosis in the practice of a cardiologist: diag-nostic possibilities and prospects for treatmentA.S. Kozlyuk, Y.Y. Giresh, Ye.B. Yershova (Kyiv) – 15 min

11. Short- and long-term outcomes of surgical treatment of aortic valve disease: which strategy to prefer?

O.S. Gurjeva, S.V. Varbanets, O.M. Romaniuk, Yu.I. Klymyshyn, Ye.O. Artemenko, Z. Abdurahmanov, N.M. Rudenko, I.M. Emets (Kyiv) – 15 min

13:15-15:30 General assambly with the participation of Ministry of Health of Ukraine, NAMS of Ukraine, Ukrainian Association of Cardiology and Ukrainian Association of Cardio-Surgeons, Main Specialists of NAMS of Ukraine and Experts of Ministry of Health of UkrainePresidium: acad. of NAMS of Ukraine, prof. V.M. Kovalen-

ko, acad. of NAMS of Ukraine, prof. V.I. Tsymbalyuk, acad. of NAMS of Ukraine, prof. V.V. Lazorishinets, acad. of NAMS of Ukraine O.M. Bilovol, acad. of NAMS of Ukraine, prof. Yu.V. Voronenko, prof. I.D. Shkro-banetz, N.A. Ostropoletz, corr.-member of NAMS of Ukraine, prof. K.M. Amosova, corr.-member of NAMS of Ukraine, prof. B.M. Todurov, prof. I.M. Emetz, prof. Yu.M. Sirenko, prof. O.S. Sychov, prof. M.Yu. Sokolov, prof. S.O. Andriyevska, K.V. Rudenko MD, S.S. Pavlik, I.F. Shumeyko PhD, L.G. Pumpinets

1. Problem ReportNational strategy for the prevention and treatment of cardiovascular disease: new perspectives

Acad. of NAMS of Ukraine, prof. V.M. Kovalenko2. Report of the President of the Ukrainian Association of Cardiology3. Awarding4. Approval of new regulatory documents5. Adoption of the resolutionClosing of the Congress

CONFERENCE HALL «ODISSEY»9:00-11:30 Plenary sessionACTUAL QUESTIONS IN DIAGNOSIS AND TREATMENT OF ARTERIAL HYPERTENSIONModerators: prof. Yu.M. Sirenko, prof. S.M. Koval

9:00-10:501. Combination antihypertensive therapy — basis for

treatment of hypertensive patientsYu.M. Sirenko (Kyiv) — 20 min

2. If it possible to increase the treatment effectiveness in patients with arterial hypertension and decrease the drug adverse effect rate in the same time?S.M. Koval, I.O. Snigurska, K.O. Yushko, M.Y. Penkova, O.V. Mysnychenko (Kharkiv) — 15 õâ

3. Resistant and refractory hypertension: differences in treatment strategyO.L. Rekovetz (Kyiv) — 15min

10. AL àì³ëî¿äîç ó ïðàêòèö³ êàðä³îëîãà: ìîæëèâîñò³ ä³àãíîñòèêè ³ ïåðñïåêòèâè ë³êóâàííÿÀ.Ñ. Êîçëþê, É.É. Ã³ðåø, ª.Á. ªðøîâà (Êè¿â) — 15 õâ

11. Áåçïîñåðåäí³ òà â³ääàëåí³ ðåçóëüòàòè õ³ðóðã³÷íèõ âòðó÷àíü íà àîðòàëüíîìó êëàïàí³: ÿê³é òàêòèö³ íà-äàòè ïåðåâàãó? Î.Ñ. Ãóð’ºâà, Ñ.Â. Âàðáàíåöü, Î.Ì. Ðîìàíþê, Þ.². Êëè-ìèøèí, ª.Î. Àðòåìåíêî, Ç. Àáäóðàõìàíîâ, Í.Ì. Ðó-äåíêî, ².Ì. ªìåöü (Êè¿â) — 15 õâ

13:15-15:30 Ãåíåðàëüíà àñàìáëåÿçà ó÷àñòþ ÌÎÇ Óêðà¿íè, ÍÀÌÍ Óêðà¿íè, Âñåóêðà¿íñüêî¿ àñîö³àö³¿ êàðä³îëîã³â Óêðà¿íè òà Àñîö³àö³¿ ñåðöåâî-ñóäèííèõ õ³ðóðã³â, ãîëîâíèõ ñïåö³àë³ñò³â ÍÀÌÍ Óêðà¿íè òà åêñïåðò³â ÌÎÇ Óêðà¿íè

Ïðåçèä³ÿ: àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ì. Êîâàëåí-êî, àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.². Öèìáàëþê, àêàä. ÍÀÌÍ, ïðîô. Â.Â. Ëàçîðèøèíåöü, àêàä. ÍÀÌÍ Óêðà¿íè Î.Ì. Á³ëîâîë, àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. Þ.Â. Âîðîíåíêî, ïðîô. ².Ä. Øêðîáàíåöü, Í.À. Îñòðî-ïîëåöü, ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Ê.Ì. Àìîñîâà, ÷ë.-êîð. ÍÀÌÍ Óêðà¿íè, ïðîô. Á.Ì. Òîäóðîâ, ïðîô. ².Ì. ªìåöü, ïðîô. Þ.Ì. Ñ³ðåíêî, ïðîô. Î.Ñ. Ñè-÷îâ, ïðîô. Ì.Þ. Ñîêîëîâ, ïðîô. Ñ.Î. Àíäð³ºâñüêà, ä.ì.í. Ê.Â. Ðóäåíêî, Ñ.Ñ. Ïàâëèê, ê.ì.í. ².Ô. Øóìåéêî, Ë.Ã. Ïóìïèíåöü

1. Ïðîáëåìíà äîïîâ³äüÍàö³îíàëüíà ñòðàòåã³ÿ ïîïåðåäæåííÿ ³ ë³êóâàííÿ ñåðöåâî-ñóäèííèõ çàõâîðþâàíü: íîâ³ ïîãëÿäè

àêàä. ÍÀÌÍ Óêðà¿íè, ïðîô. Â.Ì. Êîâàëåíêî2. Çâ³ò Ïðåçèäåíòà Âñåóêðà¿íñüêî¿ àñîö³àö³¿ êàðä³îëîã³â Óêðà¿íè3. Íàãîðîäæåííÿ4. Çàòâåðäæåííÿ íîâèõ íîðìàòèâíèõ äîêóìåíò³â5. Ïðèéíÿòòÿ ðåçîëþö³¿Çàêðèòòÿ Êîíãðåñó

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÎÄ²ÑÑÅÉ»9:00–11:30 Ïëåíàðíå çàñ³äàííÿ²ÍÍÎÂÀÖ²¯ Ä²ÀÃÍÎÑÒÈÊÈ ÒÀ Ë²ÊÓÂÀÍÍß ÀÐÒÅÐ²ÀËÜÍÎ¯ Ã²ÏÅÐÒÅÍÇ²¯Ìîäåðàòîðè: ïðîô. Þ.Ì. Ñ³ðåíêî, ïðîô. Ñ.Ì. Êîâàëü

9:00–10:50 1. Êîìá³íîâàíà àíòèã³ïåðòåíçèâíà òåðàï³ÿ — îñíîâà

ë³êóâàííÿ ïàö³ºíò³â ç àðòåð³àëüíîþ ã³ïåðòåíç³ºþÞ.Ì. Ñ³ðåíêî (Êè¿â) — 20 õâ

2. ×è ìîæëèâî ï³äâèùèòè åôåêòèâí³ñòü ë³êóâàííÿ õâîðèõ íà àðòåð³àëüíó ã³ïåðòåíç³þ é îäíî÷àñíî çíèçèòè ÷àñòîòó ïîá³÷íèõ åôåêò³â ïðåïàðàò³â? Ñ.Ì. Êîâàëü, ².Î. Ñí³ãóðñüêà, Ê.Î. Þøêî, Ì.Þ. Ïåíü-êîâà, Î.Â. Ìèñíè÷åíêî (Õàðê³â) — 15 õâ

3. Ðåçèñòåíòíà òà ðåôðàêòåðíà ã³ïåðòåíç³ÿ: â³äì³ííîñ-ò³ òàêòèêè ë³êóâàííÿÎ.Ë. Ðåêîâåöü (Êè¿â) — 15 õâ


35

27th

of

Sept

embe

r (F

rida

y)

4. Women vs men: differences in arterial hypertension

G.D. Radchenko (Kyiv) – 15 min5. LV diastolic dysfunction in patients with AH and its

clinical consequencesO.O. Torbas (Kyiv) – 15 min

6. Evaluations of EchoCG data in patients with arterial hypertension

N.N. Nosenko (Kyiv) – 15 min7. Syndrome of obstructive sleep apnea

N.A. Krushynska (Kyiv) – 15 min

10:50-11:20 Master classTherapy for type 2 diabetes mellitus: how to improve cardiovascular outcome1. Diabetes and cardiovascular risks

Yu.M. Sirenko (Kyiv) — 15 min2. GLP-1 receptor agonist in cardiology practice: about

what can not be silent O. V. Zinich (Kyiv) — 15 min

10:50-11:30 Opinion of the specialistThe place of double and triple combined antihypertensive therapy in modern treatment regimens

prof. Yu.M. Sirenko (Kyiv) — 10 min

11:20–13:15 Section MettengBIOMARKERS IN CARDIOLOGYPresidium: prof. O.E. Berezin, prof. L.G. Voronkov, prof.

V.M. Zhebel1. The level of NT-proBNP as a predictor of atrial fibrilla-

tion in patients with acute coronary syndrome

V.I. Tseluyko, F. Ben Salem, Î.Å. Matuzok (Kharkiv) – 15 min

2. Chronic heart failure and «low triodothyronine» syn-drome: features of beta blockers treatment

I.S. Rudyk, S.M. Pyvovar, V.I. Galchynska, T.O. Chenchyk (Kharkiv) – 15 min

3. Diagnostic value of ST 2 in essential hypertension and the polymorphism of the encoding gene

V.M. Zhebel, O.M. Starzhynska, D.A. Bahrii, T.M. Kali-novska, A.O. Donec (Vinnitsya) – 15 min

4. Contemporary opportunities in IHD treatment person-alization by biomarker useV.Y. Zharinova, D.A. Bodretska, V.O. Tabakovich-Vazeba, I.S. Shapovalenko, G.G. Voinarovska (Kyiv) – 15 min

5. Apoptotic endothelial microvesicles as a predictor of CHF phenotypeO.E. Berezin, O.O. Kremzer, T.A. Samura (Zaporizhia) – 15 min

4. Æ³íêè ïðîòè ÷îëîâ³ê³â: îñîáëèâîñò³ àðòåð³àëüíî¿ ã³-ïåðòåíç³¿Ã.Ä. Ðàä÷åíêî (Êè¿â) — 15 õâ

5. Ä³àñòîë³÷íà äèñôóíêö³ÿ ËØ ó ïàö³ºíò³â ³ç ÀÃ òà ¿¿ êë³-í³÷í³ íàñë³äêèÎ.Î. Òîðáàñ (Êè¿â) — 15 õâ

6. Ïðîòîêîë âèñíîâêó åõîÊÃ ó ïàö³ºíòà ç àðòåð³àëüíîþ ã³ïåðòåíç³ºþ — ùî ïîòð³áíî çíàòè ïðàêòèêóþ÷îìó ë³êàðþ Í.Í. Íîñåíêî (Êè¿â) — 15 õâ

7. Ñèíäðîì îáñòðóêòèâíîãî í³÷íîãî àïíîå ñíóÍ.À. Êðóøèíñüêà (Êè¿â) — 15 õâ

10:50–11:20 Ìàéñòåð-êëàñ Òåðàï³ÿ õâîðèõ íà öóêðîâèé ä³àáåò 2-ãî òèïó: ÿê ïîêðàùèòè ñåðöåâî-ñóäèííèé ïðîãíîç1. Öóêðîâèé ä³àáåò ³ ñåðöåâî-ñóäèíí³ ðèçèêè

Þ.Ì. Ñ³ðåíêî (Êè¿â) — 15 õâ2. àðÃÏÏ-1 â ïðàêòèö³ êàðä³îëîãà: ïðî ùî íå ìîæíà

ìîâ÷àòè Î.Â. Ç³íè÷ (Êè¿â) — 15 õâ

11:20–11:30 Äóìêà ñïåö³àë³ñòàÌ³ñöå ïîäâ³éíî¿ ³ ïîòð³éíî¿ êîìá³íîâàíî¿ àíòèã³ïåðòåíçèâíî¿ òåðàï³¿ â ñó÷àñíèõ ñõåìàõ ë³êóâàííÿ

ïðîô. Þ.Ì. Ñ³ðåíêî (Êè¿â) — 10õâ

11:30-13:15 Ñåêö³éíå çàñ³äàííÿÁ²ÎÌÀÐÊÅÐÈ Ó ÊÀÐÄ²ÎËÎÃ²¯Ïðåçèä³ÿ: ïðîô. Î.ª. Áåðåç³í, ïðîô. Ë.Ã. Âîðîíêîâ, ïðîô.

Â.Ì. Æåáåëü1. Ð³âåíü NT-proBNP, ÿê ïðåäèêòîð ðîçâèòêó ô³áðè-

ëÿö³¿ ïåðåäñåðäü ó õâîðèõ íà ãîñòðèé êîðîíàðíèé ñèíäðîìÂ.É. Öåëóéêî, Ô. Áåí Ñàëåì, Î.Å. Ìàòóçîê (Õàðê³â) — 15 õâ

2. Õðîí³÷íà ñåðöåâà íåäîñòàòí³ñòü ³ ñèíäðîì «íèçüêî-ãî òðèéîäòèðîí³íó»: îñîáëèâîñò³ ë³êóâàííÿ áëîêà-òîðàìè áåòà-àäðåíîðåöåïòîð³âÞ.Ñ. Ðóäèê, Ñ.Ì. Ïèâîâàð, Â.Þ. Ãàëü÷èíñüêà, Ò.Î. ×åí-÷èê (Õàðê³â) — 15 õâ

3. Ä³àãíîñòè÷íå çíà÷åííÿ ST 2 ïðè åñåíö³àëüí³é ã³ïåð-òåíç³¿ ç óðàõóâàííÿì ïîë³ìîðô³çìó ãåíà, ùî éîãî êîäóºÂ.Ì. Æåáåëü, Î.Ë. Ñòàðæèíñüêà, Ä.À. Áàãð³é, Ò.Ì. Êà-ëèíîâñüêà, À.Î. Äîíåöü (Â³ííèöÿ) — 15 õâ

4. Ñó÷àñí³ ìîæëèâîñò³ ³íäèâ³äóàëüíî¿ òåðàï³¿ ³øåì³÷-íî¿ õâîðîáè ñåðöÿ ³ç âèêîðèñòàííÿì á³îìàðêåð³âÂ.Þ. Æàð³íîâà, Ä.À. Áîäðåöüêà, Â.Î. Òàáàêîâè÷-Âàöå-áà, ².Ñ. Øàïîâàëåíêî, Ã.Ã. Âîéíàðîâñüêà (Êè¿â) — 15 õâ

5. Àïîïòîòè÷í³ åíäîòåë³àëüí³ ì³êðîâåçèêóëè ÿê ïðå-äèêòîð ôåíoòèïó ÕÑÍÎ.ª. Áåðåç³í, Î.Î. Êðåìçåð, Ò.À. Ñàìóðà (Çàïîð³æ-æÿ) — 15 õâ

ÕX ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ ÕX UKRAINIAN NATIONAL CONGRESS OF CARDIOLOGYXVII ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ XVII UKRAINIAN NATIONAL CONGRESS OF CARDIOLOGY ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ

36

27 â

åðåñ

íÿ

(ï’ÿ

òíè

öÿ)

36

6. Êë³í³êî-ïðîãíîñòè÷íå çíà÷åííÿ ì³êðîÐÍÊ-155 ó õâîðèõ íà ãîñòðèé ³íôàðêò ì³îêàðäàÎ.Î. Ñîïêî, Â.Å. Äîñåíêî, Î.Ì. Ïàðõîìåíêî (Êè¿â) — 15 õâ

7. Îäíîíóêëåîòèäíèé ïîë³ìîðô³çì Ò786Ñ ãåíà åíäî-òåë³àëüíî¿ NO ñèíòàçè: ðîëü ó ôîðìóâàíí³ ñåðöåâî¿ íåäîñòàòíîñò³ ï³ñëÿ ³íôàðêòó ì³îêàðäàÌ.Ï. Êîïèöÿ, Î.Â. Ïåòþí³íà, Î.ª. Áåðåç³í (Çàïîð³æ-æÿ) — 15 õâ

ÊÎÍÔÅÐÅÍÖ-ÇÀËÀ «ÀËÜÒ²ÓÑ»9:00–9:30 Ìàéñòåð-êëàñ êàðä³îëîãà ç íåâðîëîãîì: âðÿ-òóºìî Óêðà¿íó â³ä ³íñóëüò³â ðàçîìÓ÷àñíèêè: ä.ì.í. Ë.À. Ì³ùåíêî, ê.ì.í. ².Ë. Ðåâåíüêî (Êè¿â)

9:30–13:00 Ïëåíàðíå çàñ³äàííÿÀÊÒÓÀËÜÍ² ÏÈÒÀÍÍß ÏÐÅÂÅÍÒÈÂÍÎ¯ ÊÀÐÄ²ÎËÎÃ²¯ ÒÀ ÐÅÀÁ²Ë²ÒÀÖ²¯Ìîäåðàòîðè: ïðîô. Ë.Ì. Áàá³é, ïðîô. ².Å. Ìàëèíîâñüêà,

ïðîô. Â.Î. Øóìàêîâ 1. EUROASPIRE IV–V â Óêðà¿í³: ÷è çì³íèëèñÿ ïð³îðèòåòè

ëþäñòâà â ïðîô³ëàêòèö³ ñåðöåâî-ñóäèííèõ çàõâî-ðþâàíü?Ì.Ì. Äîëæåíêî (Êè¿â) — 15 õâ

2. Îñíîâí³ ïîñòóëàòè ñó÷àñíî¿ ïàðàäèãìè «Åï³äåì³î-ëîã³ÿ õðîí³÷íèõ íå³íôåêö³éíèõ çàõâîðþâàíü»Î.Î. Êâàøà, Î.Â. Ñð³áíà, ².Ï. Ñìèðíîâà (Êè¿â) — 15 õâ

3. ²íôàðêò ì³îêàðäà òà îö³íêà ðåçóëüòàò³â ïðè ñó÷àñ-íèõ ï³äõîäàõ äî ë³êóâàííÿ: äîñÿãíåííÿ òà íåâèð³-øåí³ ïðîáëåìèË.Ì. Áàá³é, Â.Î. Øóìàêîâ, Î.Ï. Ïîãóðåëüñüêà, Þ.Î. Õîìåíêî (Êè¿â) — 15 õâ

4. Óïîâ³ëüíåííÿ ðåìîäåëþâàííÿ ë³âîãî øëóíî÷-êà ó ïàö³ºíò³â, ùî ïåðåíåñëè ³íôàðêò ì³îêàðäà, íà åòàï³ ðåàá³ë³òàö³¿Â.Î. Øóìàêîâ — 15 õâ

5. Êàðä³îëîã³÷íà ðåàá³ë³òàö³ÿ ïàö³ºíò³â, ÿê³ ïåðåíåñëè Q-³íôàðêò ì³îêàðäà: åôåêòèâí³ñòü ô³çè÷íî¿ òà ìå-äèêàìåíòîçíî¿ ñêëàäîâèõ².Å. Ìàëèíîâñüêà, Â.Î. Øóìàêîâ, Í.Ì. Òåðåùåíêî, Î.Ì. Âîëîøèíà, Ë.Ï. Òåðåøêåâè÷ (Êè¿â) — 15 õâ

6. ²ííîâàö³éíà ïðîãðàìà êàðä³îðåàá³ë³òàö³¿ õâîðèõ íà ³íôàðêò ì³îêàðäà ç êîìîðá³äíîþ ïàòîëîã³ºþÌ.². Øâåä, Ë.Â. Ëåâèöüêà, ².Á. Ëåâèöüêèé (Òåðíî-ï³ëü) — 15 õâ

7. Ìåòàáîë³÷íà òåðàï³ÿ ñåðöåâî-ñóäèííèõ çàõâîðþ-âàíü: ÷è âñ³ ìîæëèâîñò³ ìè âèêîðèñòîâóºìîÎ.Î. Õàíþêîâ (Äí³ïðî) — 15 õâ

8. Â³äíîâëåííÿ ïàö³ºíò³â ï³ñëÿ êîðîíàðíîãî øóíòó-âàííÿ íà ïðàöþþ÷îìó ñåðö³ ç âèêîðèñòàííÿì ïðà-âî¿ øëóíêîâî-ñàëüíèêîâî¿ àðòåð³¿À.Â. Ãàáð³ºëÿí, Ò.Ì. Äîìàíñüêèé, Î.Â. Áåðåãîâèé, Â.Â. Áåëåéîâè÷, ².Â. Êóäëàé (Êè¿â) — 15 õâ

6. Clinical and prognostic value of microRNA-155 in pa-tients with acute myocardial infarction O.Î. Sopko, V.E. Dosenko, O.M. Parkhomenko (Kyiv) – 15 min

7. Oligonuctleotide polymorphism of endothelial NO-syntase T786C gene: the role in development of heart failure after myocardial infarctionM.P. Kopytsya, O.V. Petiunina, O.E. Berezin (Zapori-zhia) – 15 min

CONFERENCE HALL «ALTIVUS»9:00–9:30 Master class of a cardiologist with a neurolo-gist: Together we will save Ukraine from strokesParticipants: L.A. Mishchenko MD, I.L. Revenko PhD (Kyiv)

9:30-13:00 Plenary session CURRENT ISSUES OF PREVENTIVE CARDIOLOGY AND REHABILITATIONModerators: prof. L.M. Babii, prof. I.E. Malynovska, prof.

V.O. Shumakov1. EUROASPIRE IV-V in Ukraine: did priority of huma-

nity change in the prophylaxis of cardiovascular dis-ease?prof. M.M. Dolzhenko (Kyiv) – 15 min

2. The main postulates of the modern paradigm «Epide-miology of noncommunicable diseases»O.O. Kvasha, O.V. Sribna, I.P. Smyrnova (Kyiv) – 15 min

3. Myocardial infarction and estimation of results at modern approaches to treatment : achievement and unsolved problemsL.M. Babii, V.O. Schumakov, O.P. Pogurelskaya, Yu.O. Khomenko (Kyiv) – 15 min

4. Deceleration of left ventricle remodeling in patients after myocardial infarction during rehabilitation

V.O. Shumakov (Kyiv) – 15 min5. Cardiologic rehabilitation in patients after Q-myo-

cardial infarction: efficiency of physical and medicine components I.E. Malynovska, V.O. Shumakov, N.M. Tereshchenko, O.V. Voloshyna, L.P. Tereshkevych (Kyiv) – 15 min

6. Innovative program of cardio rehabilitation of patients with myocardial infarction and comorbid pathologyM.I. Shved, L.V. Levytska, I.B. Levytsky (Ternopil) – 15 min

7. Metabolic therapy for cardiovascular disease: are we using all the possibilitiesO.O. Khanukov (Dnipro) – 15 min

8. Recovery of patients after off pump coronary bypass surgery using right artery gastroepiploica

A.V. Gabriyelyan, T.M. Domanskiy, O.V. Beregovoy, V.V. Beleyovich, I.V. Kudlay (Kyiv) – 15 min


37

27th

of

Sept

embe

r (F

rida

y)

9. Îö³íêà îá³çíàíîñò³ ïàö³ºíò³â ó ïèòàííÿõ âòîðèííî¿ ïðîô³ëàêòèêè àòåðîñêëåðîòè÷íèõ ñåðöåâî-ñóäèí-íèõ çàõâîðþâàíüÑ.À. Òèõîíîâà (Îäåñà) — 15 õâ

10. Äîñâ³ä âïðîâàäæåííÿ ðåã³îíàëüíèõ ðåºñòð³â ïàö³-ºíò³â ï³ñëÿ ïåðåíåñåíîãî ²ÌË.Â. Ðàñïóò³íà (Â³ííèöÿ) — 15 õâ

11. ßê³ñòü æèòòÿ òà êîãí³òèâí³ ôóíêö³¿ ó õâîðèõ íà àðòå-ð³àëüíó ã³ïåðòåíç³þ: ÷è ìîæíà ïîêðàùèòè ðåçóëü-òàòè?Ò.À. Õîìàçþê, Â.Þ. Êðîòîâà (Äí³ïðî) — 15 õâ

12. Äîñâ³ä ë³êóâàííÿ óñêëàäíåíèõ ôîðì ³øåì³÷íî¿ õâîðîáè ñåðöÿ: ôîêóñ íà õðîí³÷íó ïîñò³íôàðêòíó àíåâðèçìó ñåðöÿ Î.Â. Ñîëåéêî (Â³ííèöÿ) — 15 õâ

13. Åôåêòèâíå ë³êóâàííÿ í³êîòèíîâî¿ çàëåæíîñò³ ç ïî-çèö³¿ äîêàçîâî¿ ìåäèöèíè².Ì. Âîëîøèíà (Êè¿â)


9. Assessment of patients’ awareness of secondary pre-vention of atherosclerotic cardiovascular diseases

S.A. Tychonova (Odessa) – 15 min10. The experience of introducing regional registries

of patients after MIL.V. Rasputina (Vinnytsia) – 15 min

11. Quality of life and cognitive function in patients with arterial hypertension: can the results be improved?

T.A. Khomazyuk, V.Yu. Krotova (Dnipro) – 15 min 12. Experience in treating complicated forms of coronary

heart disease: focus on chronic post-infarction heart aneurysmO.V. Soleiko (Vinnytsia) – 15 min

13. Effective treatment of nicotine dependence from the point of view of evidence-based medicineI.M. Voloshyna (Kyiv)



38

25 â

åðåñ

íÿ

(ñåð

åäà)

ÑÒÅÍÄÎÂ² ÄÎÏÎÂ²Ä²ÑÅÐÅÄÀ, 25 ÂÅÐÅÑÍß

(ÎÁÃÎÂÎÐÅÍÍß ÄÎÏÎÂ²ÄÅÉ Ç 13:00 ÄÎ 14:00)ÀÐÈÒÌ²¯ ÑÅÐÖß

Ìîäåðàòîðè: ä.ì.í. À.Î. Áîðîäàé, ä.ì.í. À.². Âèòðèõîâñüêèé, ä.ì.í. Þ.Â. Ç³í÷åíêî1. Ôóíêö³îíàëüíèé ñòàí åíäîòåë³þ ñóäèí òà ð³âåíü Ñ-ðåàêòèâíîãî ïðîòå¿íó ó ïàö³ºíò³â ç ô³áðèëÿ ö³ºþ ïåðåä-

ñåðäü òà ãîñòðèì ïîðóøåííÿì ìîçêîâîãî êðîâîîá³ãóÞ.Ñ. Êóøí³ð, Î.Â. Êóðÿòà, À.Î. Òèõîìèðîâ, Ò.Î. Â³õðîâà, Ì.Ñ. Ä³áðîâà (Äí³ïðî)

2. Îö³íêà ïðèõèëüíîñò³ äî àíòèêîàãóëÿíòíî¿ òåðàï³¿ ó õâîðèõ ç íåêëàïàííîþ ô³áðèëÿö³ºþ ïåðåäñåðäüË.Ì. Ñòð³ëü÷óê, Ë.À. ²ëüíèöüêà, ².Â. Øóìëÿíñüêèé, ².Â. Áîãäàí (Ð³âíå)

3. Ïðåäèêòîðè â³äíîâëåííÿ ñèíóñîâîãî ðèòìó ó ïàö³ºíò³â ç ïåðñèñòåíòíèì òð³ïîò³ííÿì ïåðåäñåðäü ó êë³í³÷í³é ïðàêòèö³À.Â. Àêåð, Ó.Ï. ×åðíÿãà-Ðîéêî, Î.É. Æàð³íîâ (Ëüâ³â)

4. Ïðåäèêòîðè ðàííüîãî ðåöèäèâó àðèòì³¿ ó ïàö³ºíò³â ç íåêëàïàííîþ ïåðñèñòåíòíîþ ô³áðèëÿö³ºþ ³ òð³ïîò³ííÿì ïåðåäñåðäü ï³ñëÿ êàðä³îâåðñ³¿Í.Ñ. Ïàâëèê, Ó.Ï. ×åðíÿãà-Ðîéêî, Î.É. Æàð³íîâ, Ñ.Ñ. Ïàâëèê, Â.Þ. ×åðêàâñüêèé (Ëüâ³â)

5. Ðèçèê ðîçâèòêó òðîìáîåìáîë³÷íèõ óñêëàäíåíü ó ïàö³ºíò³â ç ô³áðèëÿö³ºþ ïåðåäñåðäü, ùî ìàþòü îðãàí³çîâàí³ òðîìáîòè÷í³ ìàñè â ïåðåäñåðäÿõ, ïðè ïðîâåäåíí³ ïëàíîâî¿ åëåêòðî³ìïóëüñíî¿ òåðàï³¿Ñ.Î. Ïðàâîñóäîâè÷, Î.Á. Áîíäàðåíêî, Ë.Ë. Áåëüìàñ, Ä.À. Ìèñþðà, Ë.Ä. Ñóùåíêî, Í.Ï. Àíîñîâà, Ë.Ì. ßêîâëºâà, Ë.Â. Ìå-ëåùèê (Äí³ïðî)

6. Êë³í³÷í³ òà åõîêàðä³îãðàô³÷í³ ïîêàçíèêè ïàö³ºíò³â ³ç òð³ïîò³ííÿì ïåðåäñåðäü ï³ñëÿ ðàä³î÷àñòîòíî¿ àáëÿö³¿Ä.Þ. Ïàâëîâà, Ò.Â. Çîëîòàðüîâà, Ì.Ñ. Áðèíçà (Õàðê³â)

7. Îö³íêà ÷àñó â òåðàïåâòè÷íîìó ä³àïàçîí³ (TTR) ó ïàö³ºíò³â ³ç íåêëàïàííîþ ô³áðèëÿö³ºþ ïåðåäñåðäü, ÿê³ îòðè-ìóþòü âàðôàðèíÌ.². ßëîâåíêî, Î.Î. Õàíþêîâ, Ë.Â. Ñàïîæíè÷åíêî, ª.Ä. ªãóä³íà, Î.Ñ. Êàëàøíèêîâà (Äí³ïðî)

8. Êë³í³÷í³ îçíàêè ïàö³ºíò³â ç ô³áðèëÿö³ºþ òà òð³ïîò³ííÿì ïåðåäñåðäü â ïîºäíàíí³ ç àðòåð³àëüíîþ ã³ïåðòåíç³ºþ, ÿêèì áóëà âèêîíàíà ðàä³î÷àñòîòíà àáëÿö³ÿÂ.Î. Øòåëüìàõ, Ì.Ñ. Áðèíçà, Î.Â. Á³ëü÷åíêî, Ä.ª. Âîëêîâ (Õàðê³â)

9. Àtrial electrical heterogeneity in patients with mitral valve prolapseO.V. Dzekan, G.V. Dehtyaryova (Vinnytsia)

10. Âçàºìîçâ’ÿçîê ì³æ ïîäîâæåííÿì ³íòåðâàëó Q–T òà íàÿâí³ñòþ ìàêðî- òà ì³êðîâàñêóëÿðíèõ óñêëàäíåíü ó õâî-ðèõ íà öóêðîâèé ä³àáåò 2-ãî òèïó².². Îêòÿáðüîâà, Î.Ñ. Ìàõàðèíñüêà, Ì.Ì. Ëåáåäèíñüêà (Õàðê³â)

11. Ïîð³âíÿííÿ âïëèâó á³ñîïðîëîëó òà àì³îäàðîíó íà ïàðàìåòðè öèôðîâî¿ îáðîáêè åëåêòðîêàðä³îãðàìè çà äî-ïîìîãîþ ïðîãðàìíîãî êîìïëåêñó «ÑÌÀÐÒ-ÅÊÃ»Ï.Ð. ²âàí÷óê, Â.Ê. Òàùóê, Ì.Â. Òàùóê (×åðí³âö³)

ÃÎÑÒÐÈÉ ÊÎÐÎÍÀÐÍÈÉ ÑÈÍÄÐÎÌÌîäåðàòîðè: ïðîô. Ë.Ì. Áàá³é, ä.ì.í. Î.². ²ðê³í, ñò.í.ñ. ß.Ì. Ëóòàé 1. Á³îìàðêåð-êåðîâàíà òåðàï³ÿ ïàö³ºíò³â ç ãîñòðèì ³íôàðêòîì ì³îêàðäà

ß.Â. Ã³ëüîâà, Ì.Ï. Êîïèöÿ, Þ.Â. Ðîä³îíîâà, ².Ì. Êóòÿ (Õàðê³â)2. Îïûò ðàáîòû Äîíåöêîé è Ëóãàíñêîé îáëàñòè ïî ýêñòðàòåððèòîðèàëüíîìó ïðèíöèïó ïðè ëå÷åíèè ïàöèåíòîâ

ñ îñòðûì èíôàðêòîì ìèîêàðäà ñ ïîäúåìîì ñåãìåíòà ST (STEMI): ðàçâèòèå ïðîãðàììû óðãåíòíîãî ñòåíòèðî-âàíèÿÑ.Í. Ãåòüìàí, Ä.Þ. Óçóí (Êðàìàòîðñê)

3. Âïëèâ àäåíîçèíâì³ñíîãî ïðåïàðàòó (ÀÒÌÒñ) ³ êîìá³íàö³¿ L-àðã³í³íó òà L-êàðí³òèíó íà ðåçóëüòàòè ÅÊÃ òà åõîÊÃ- äîñë³äæåíü ó íåðåâàñêóëÿðèçîâàíèõ õâîðèõ ç³ STEMI/NSTEMIÍ.Ì. Ñåðåäþê, Ì.Â. Ôåäîð÷åíêî, Ð.Â. Ïåòðîâñüêèé, Î.Ç. Ñêàêóí (²âàíî-Ôðàíê³âñüê)

4. Îñîáëèâîñò³ ãåîìåòð³¿ ë³âîãî øëóíî÷êà ó õâîðèõ ï³ñëÿ ïåðåíåñåíîãî ³íôàðêòó ì³îêàðäà çàëåæíî â³ä òàêòèêè ë³êóâàííÿÐ.Ð. Ãóòà, Í.Ñ. Áåê, Î.Ì. Ðàä÷åíêî (Ëüâ³â)

5. Êëèíè÷åñêèé ñëó÷àé òðîìáîýìáîëèè ëåãî÷íîé àðòåðèè ó áîëüíîãî íà ôîíå îáîñòðåíèÿ íåñïåöèôè÷åñêîãî ÿçâåííîãî êîëèòàÈ.Â. Êóçíåöîâ, Ì.Â. Êóëèêîâà, È.Â. Êàíäûáêî, À.Ã. Ãóêîâ, Ë.Â. Æóðàâëåâà (Õàðüêîâ)


39

25th

of

Sept

embe

r (W

edne

sday

)

6. Çâ’ÿçîê êàëüïðîòåêòèíó ç ïàðàìåòðàìè âóãëåâîäíîãî îáì³íó ó õâîðèõ íà ãîñòðèé ³íôàðêò ì³îêàðäà íà òë³ öóêðîâîãî ä³àáåòó 2-ãî òèïóÍ.Ã. Ðèíä³íà, Ì.². Æóðàâëüîâà, Ï.Ã. Êðàâ÷óí (Õàðê³â)

7. Ðîëü á³îìàðêåðà ÂÅÔÐ-Àâ ïðîãíîçóâàíí³ ðîçâèòêó áàãàòîñóäèííîãî óðàæåííÿ êîðîíàðíèõ àðòåð³é ó õâîðèõ íà ãîñòðèé ³íôàðêò ì³îêàðäà ç åëåâàö³ºþ ñåãìåíòà STÌ.Ï. Êîïèöÿ, ².Ì. Êóòÿ, Þ.Â. Ðîä³îíîâà, Í.Â. Òèòàðåíêî, ß.Â. Ã³ëüîâà, À.Â. Êîáåöü (Õàðê³â)

8. Òhe role of components ofextracellular matrix in the patients with acute myocardial infarction with and withoutdiabetes mellitus type 2M.Yu. Koteliukh (Kharkiv)

9. Ïðåäèêòîðè ñèñòîë³÷íî¿ äèñôóíêö³¿ ë³âîãî øëóíî÷êà ó õâîðèõ íà Q-³íôàðêò ì³îêàðäà, óñêëàäíåíèé ãîñòðîþ ñåðöåâîþ íåäîñòàòí³ñòþÂ.Ä. Ñèâîëàï, Í.². Êàïøèòàð (Çàïîð³ææÿ)

10. Øëÿõè ï³äâèùåííÿ åôåêòèâíîñò³ ë³êóâàííÿ òà ïðîô³ëàêòèêè ðåïåðôóç³éíîãî ñèíäðîìó ó õâîðèõ íà ãîñòðèé êîðîíàðíèé ñèíäðîì (³íôàðêò ì³îêàðäà), ÿêèì ïðîâåäåíî áàëîííó àíã³îïëàñòèêó òà ñòåíòóâàííÿ êîðîíàðíî¿ àðòåð³¿Ì.². Øâåä, ².Î. ßñòðåìñüêà, Ë.Â. Öóãëåâè÷ (Òåðíîï³ëü)

11. Èçó÷åíèå âîçìîæíîñòåé ðàííåãî íàçíà÷åíèÿ ïîëèïèë ó áîëüíûõ, ïåðåíåñøèõ ðàçíûå ôîðìû ÎÊÑÅ.Ñ. Ùóêèíà, Å.À. Êîâàëü (Äí³ïðî)

12. Ïðîãíîñòè÷íå çíà÷åííÿ îäíîíóêëåîòèäíîãî ïîë³ìîðô³çìó Ò786Ñ ãåíà åíäîòåë³àëüíî¿ NO-ñèíòàçè ï³ñëÿ ³í-ôàðêòó ì³îêàðäà ç ï³äéîìîì ñåãìåíòà STÎ.Â. Ïåòþí³íà, Ì.Ï. Êîïèöÿ, Î.ª. Áåðåç³í, Ä.Ï. Áàá³÷åâ (Õàðê³â)

13. Çâ’ÿçîê ì³æ ôàêòîðîì, ùî ³íã³áóº ì³ãðàö³þ ìàêðîôàã³â, òà òðèâîæíî-äåïðåñèâíèìè ñòàíàìè ïðè ³íôàðêò³ ì³îêàðäà ç åëåâàö³ºþ ñåãìåíòà STÎ.Â. Ïåòþí³íà, Ì.Ï. Êîïèöÿ, Î.Â. Ñêðèííèê (Õàðê³â)

²ØÅÌ²×ÍÀ ÕÂÎÐÎÁÀ ÑÅÐÖßÌîäåðàòîðè: ïðîô. Î.À. Õàíþêîâ, ä.ì.í. Â.Â. Áóãàºíêî 1. Îö³íêà ÿêîñò³ æèòòÿ òà êðèòåð³¿ åôåêòèâíîñò³ êîðîíàðíî¿ ðåâàñêóëÿðèçàö³¿ ó ïàö³ºíò³â ç³ ñòàá³ëüíîþ ²ÕÑ ³ çáå-

ðåæåíîþ ôðàêö³ºþ âèêèäó ë³âîãî øëóíî÷êàÞ.À. Áîðõàëåíêî, Î.É. Æàð³íîâ, Î.À. ªïàí÷³íöåâà, Á.Ì. Òîäóðîâ (Êè¿â)

2. Prognostic assessment of the stable coronary heart disease severity in patients with non-alcoholic steatohepatitisI.I. Vakalyuk, N.G. Virstyuk, V.I. Sovtus, O.F. Sovtus (Ivano-Frankivsk)

3. Åôåêòèâí³ñòü âêëþ÷åííÿ äî êîìïëåêñíî¿ òåðàï³¿ ñòàá³ëüíî¿ ñòåíîêàðä³¿ àëîïóðèíîëó ³ êâåðöåòèíóÀëü Ñàëàìà Ìóõàìåä Âàñåê Îáåéä, Î.Ì. Ã³íãóëÿê, Í.À. Òóðóáàðîâà-Ëåóíîâà, ².Ò. Ðóñíàê (×åðí³âö³)

4. Ñòàí âíóòð³øíüîñåðöåâî¿ ãåìîäèíàì³êè òà ì³êðîöèðêóëÿö³¿ ó õâîðèõ íà õðîí³÷íó ³øåì³÷íó õâîðîáó ñåðöÿ ³ç ñóïóòí³ìè äèôóçíèìè çàõâîðþâàííÿìè ïå÷³íêèÑ.ª. Ìîñòîâèé, Î.Á. Äèííèê, Í.À. Ìàðóí÷èí (Êè¿â)

5. Ì³í³³íâàçèâíå áàãàòîñóäèííå êîðîíàðíå øóíòóâàííÿ â ðóòèíí³é ïðàêòèö³Â.Ì. Äåì’ÿíåíêî, Î.Ä. Áàáëÿê, Ä.ª. Áàáëÿê, ª.À. Ìåëüíèê, Ê.À. Ðåâåíêî, Î.Ñ. Ñòîãîâ (Êè¿â)

6. Òîëåðàíòí³ñòü äî ô³çè÷íîãî íàâàíòàæåííÿ ïàö³ºíò³â ç ³øåì³÷íîþ õâîðîáîþ ñåðöÿ â ïîºäíàíí³ ç õðîí³÷íèì îáñòðóêòèâíèì çàõâîðþâàííÿì ëåãåíüÎ.Â. Êíÿçºâà (Äí³ïðî)

7. Àtherosclerotic changes in coronary and cerebral vessels in patients with coronary heart diseaseY.S. Kushnir, K. Perepelytsia (Dnipro)

8. Ðersonalized approach to antiplatelet therapy, depending on the functional activity of platelets and c807t polymorphism of itga2 in patients with hypertension and coronary artery diseaseV.Z. Netiazhenko, A.V. Liakhotska, O.N. Plenova (Kyiv)

9. Îñîáëèâîñò³ ôîðìóâàííÿ ã³ïåðòðîô³¿ ë³âîãî øëóíî÷êà ó õâîðèõ íà ³øåì³÷íó õâîðîáó ñåðöÿ òà öóêðîâèé ä³à-áåò 2-ãî òèïóÌ.Â. Ìàéîðîâà, Î.Â. Øàïàðåíêî, Ê.Ë. Ãàì³ñîí³ÿ (Õàðê³â)

10. Òhe interrelationship between the coronary heart disease’s course and community-acquired pneumonia (the retrospective analysis data)N.S. Mykhailovska, Ò.Î. Kulynych, V.A. Morguntsov (Zaporizhzhia)


40

26 â

åðåñ

íÿ

(÷åò

âåð)

11. Îïòèì³çàö³ÿ ðåàá³ë³òàö³¿ òà â³äíîâíîãî ë³êóâàííÿ õâîðèõ íà ³øåì³÷íó õâîðîáó ñåðöÿ øëÿõîì êîðåêö³¿ êîìïî-íåíò âíóòð³øíüî¿ êàðòèíè çäîðîâ’ÿÐ.Â. Íåñòåðàê (²âàíî-Ôðàíê³âñüê)

12. Ìîæëèâîñò³ îïòèì³çàö³¿ ë³êóâàííÿ õâîðèõ íà ³øåì³÷íó õâîðîáó ñåðöÿÂ.Î. Ðîìàíîâà, Í.Â. Êóçüì³íîâà, Â.Ê. Ñºðêîâà, Ë.Î. Ðîìàíîâà (Â³ííèöÿ)

13. Long-term prognosis and risk factors for major adverse cardiac events in patients with ischemic chronic heart failure with mid-range ejection fractionV.D. Syvolap, D.A. Lashkul (Zaporizhzhia)

×ÅÒÂÅÐ, 26 ÂÅÐÅÑÍß(ÎÁÃÎÂÎÐÅÍÍß ÄÎÏÎÂ²ÄÅÉ Ç 13:00 ÄÎ 14:00)

ÑÅÐÖÅÂÀ ÍÅÄÎÑÒÀÒÍ²ÑÒÜÌîäåðàòîðè: ïðîô. ².Å. Ìàëèíîâñüêà, ïðîô. Î.Ã. Íåñóêàé, ê.ì.í. Í.À. Òêà÷ 1. Ïîêàçíèêè åõîêàðä³îãðàô³¿ ó õâîðèõ ç ïåðåíåñåíèì Q-³íôàðêòîì ì³îêàðäà òà äåêîìïåíñîâàíîþ ñåðöåâîþ

íåäîñòàòí³ñòþ â ïðîöåñ³ ë³êóâàííÿ ÿíòàðíîþ êèñëîòîþ òà ïðåïàðàòàìè àðã³í³íó².Ï. Âàêàëþê, Õ.Â. Ëåâàíäîâñüêà (²âàíî-Ôðàíê³âñüê)

2. Áåçáîëüîâà ³øåì³ÿ ì³îêàðäà â îñ³á ïîõèëîãî â³êó ç ³çîëüîâàíîþ ñèñòîë³÷íîþ àðòåð³àëüíîþ ã³ïåðòåíç³ºþ, óñêëàäíåíîþ õðîí³÷íîþ ñåðöåâîþ íåäîñòàòí³ñòþÑ.Î. Øåéêî, Í.Î. Êîëá, À.Ì. Âàñèëåíêî (Äí³ïðî)

3. Ôàêòîðè ³ìóíîçàïàëüíî¿ àêòèâàö³¿ òà åíäîòåë³àëüíà äèñôóíêö³ÿ ó õâîðèõ ³ç õðîí³÷íîþ ñåðöåâîþ íåäîñòàò-í³ñòþ, êîìîðá³äíîþ ³ç ã³ïîòèðåîçîì (ïîïåðåäíº äîñë³äæåííÿ)².Ã. Êóïíîâèöüêà, Þ.². Ìèêóëà (²âàíî-Ôðàíê³âñüê)

4. Ïðåäèêòîðíå çíà÷åííÿ çàë³çîäåô³öèòó òà àíåì³¿ ó õâîðèõ ³ç õðîí³÷íîþ ñåðöåâîþ íåäîñòàòí³ñòþ ïðè ³øåì³÷-í³é õâîðîá³ ñåðöÿÍ.Ã. Ðèíä³íà, Ï.Ã. Êðàâ÷óí (Õàðê³â)

5. Ê³ëüê³ñíà òà ÿê³ñíà õàðàêòåðèñòèêà õâîðèõ ç íåêîðîíàðîãåííîþ ïàòîëîã³ºþ, ùî ïðîõîäèëè ë³êóâàííÿ ó Â³í-íèöüêîìó ðåã³îíàëüíîìó êàðä³îëîã³÷íîìó öåíòð³Ë.Ï. Ñîëåéêî, Î.Â. Ñîëåéêî, À.ª. Äàíèëü÷óê (Â³ííèöÿ)

ÀÐÒÅÐ²ÀËÜÍÀ Ã²ÏÅÐÒÅÍÇ²ßÌîäåðàòîðè: ïðîô. Ò.Â. Êîëåñíèê, ä.ì.í. Ë.À. Ì³ùåíêî, ïðîô. Ã.Ä. Ðàä÷åíêî 1. Dependence of cardiovascular risk factors on the vascular endothelium damage in patients with comorbidity

of arterial hypertension and subclinical hypothyroidismO.M. Bilovol, V.D. Nemtsova, V.V. Zlatkina, I.A. Ilchenko (Kharkiv)

2. ßê³ñòü æèòòÿ ïàö³ºíò³â ç àðòåð³àëüíîþ ã³ïåðòåíç³ºþ â çàëåæíîñò³ â³ä êë³í³÷íèõ ãðóï õðîí³÷íîãî îáñòðóêòèâíî-ãî çàõâîðþâàííÿ ëåãåíüÒ.Ç. Áóðòíÿê (Äí³ïðî)

3. Âïëèâ ³íäèâ³äóàëüíîãî íàâ÷àííÿ îñíîâàì ìåäè÷íèõ çíàíü íà îñíîâí³ ôàêòîðè ñåðöåâî-ñóäèííîãî ðèçèêóÃ.Ñ. ²ñàºâà, Ë.À. Ðºçí³ê, Ì.Ì. Âîâ÷åíêî, Î.Î. Áóðÿêîâñüêà (Õàðê³â)

4. Âïëèâ ïîðóøåíü ñíó ó ïàö³ºíò³â ç ïîºäíàííÿì ã³ïåðòîí³÷íî¿ õâîðîáè òà öóêðîâîãî ä³àáåòó 2-ãî òèïó íà ïåðå-á³ã çàõâîðþâàííÿÃ.Ñ. ²ñàºâà, Î.Î. Áóðÿêîâñüêà (Õàðê³â)

5. Îñîáëèâîñò³ äîáîâîãî ïðîô³ëþ ÀÒ òà ñòðóêòóðíî-ôóíêö³îíàëüíîãî ñòàíó ñåðöÿ ó õâîðèõ íà àðòåð³àëüíó ã³-ïåðòåíç³þ ó ïîºäíàíí³ ç ïîäàãðîþÎ.Ì. Ëàçàðåíêî, Ã.Ï. Êóçüì³íà (Äí³ïðî)

6. Îñîáëèâîñò³ êîãí³òèâíèõ ôóíêö³é ó õâîðèõ ç ã³ïåðòîí³÷íîþ õâîðîáîþ òà ï³äâèùåíèì ³íäåêñîì ìàñè ò³ëàÂ.À. Ñêèá÷èê, Î.Ñ. Ïåëåøêî (Ëüâ³â)

7. Ïîøèðåí³ñòü àðòåð³àëüíî¿ ã³ïåðòåíç³¿ ó ä³òåé ï³äë³òêîâîãî â³êó ïðîìèñëîâîãî ðåã³îíó Êðèâîð³ææÿ Ñ.Î. Øåéêî, Ñ.Â. Þðêîâà (Äí³ïðî)

8. Îìàíëèâà êîíòðîëüîâàíà àðòåð³àëüíà ã³ïåðòåíç³ÿ: êîãí³òèâí³ ôóíêö³¿ òà ÿê³ñòü æèòòÿÂ.Þ. Êðîòîâà, Ò.À. Õîìàçþê (Äí³ïðî)

9. Ñòàí àíòèêîàãóëÿíòíîãî ãåìîñòàçó ó õâîðèõ íà ã³ïåðòîí³÷íó õâîðîáó â ïîºäíàíí³ ç îæèð³ííÿì òà íåàëêîãîëü-íîþ æèðîâîþ õâîðîáîþ ïå÷³íêèÍ.Ì. Áàæåíîâà (Êè¿â)


41

26th

of

Sept

embe

r (T

hurs

day)

10. Âçàºìîçâ’ÿçîê êë³í³÷íèõ ïîêàçíèê³â êðîâ³ òà ð-ñåëåêòèíó ó õâîðèõ ç àðòåð³àëüíîþ ã³ïåðòåíç³ºþ òà öóêðîâèì ä³àáåòîì 2-ãî òèïóÀ.Î. Á³ëü÷åíêî (Õàðê³â)

11. Ó÷àñòü ãë³ï³êàíó-4 ó ñåðöåâî-ñóäèííîìó ðåìîäåëþâàíí³ ó õâîðèõ íà àðòåð³àëüíó ã³ïåðòåíç³þ òà öóêðîâèé ä³àáåò 2-ãî òèïóÎ.Ì. Á³ëîâîë, Î. Àëü-Òðàâíåõ, ².². Êíÿçüêîâà (Õàðê³â)

12. The influence of dyslipidaemia correction on kidney hemodynamics and calcium metabolism in patients with essential hypertension and osteoarthritisT.A. Rogachova, L.V. Zhuravlyova (Kharkiv)

13. Âçàºìîçâ’ÿçîê ñèðîâàòêîâîãî ð³âíÿ íåñôàòèíó-1 òà áåçáîëüîâî¿ ³øåì³¿ ì³îêàðäà ó õâîðèõ íà ã³ïåðòîí³÷íó õâî-ðîáóÑ.Â. ²âàí÷åíêî, Î.Ì. Êîâàëüîâà (Õàðê³â)

14. Êîðåêö³ÿ ïîðóøåíü ïðîòèçãîðòàëüíîãî ïîòåíö³àëó êðîâ³ ïðè ã³ïåðòîí³÷í³é õâîðîá³ â ïîºäíàíí³ ç õðîí³÷íèì îáñòðóêòèâíèì çàõâîðþâàííÿì ëåãåíüÑ.Î. Ñàìîéëîâà, Â.Ç. Íåòÿæåíêî, Î.Ì. Ïëºíîâà (Êè¿â)

15. Ð³âåíü àëüäîñòåðîíó òà ïðóæíî-åëàñòè÷í³ âëàñòèâîñò³ àðòåð³é â çàëåæíîñò³ â³ä êîíòðîëþ ÀÃ ó ïàö³ºíò³â ³ç õðî-í³÷íîþ õâîðîáîþ íèðîêÂ.Â. Ñåìåíîâ, Î.Â. Êóðÿòà (Äí³ïðî)

16. Âïëèâ ð³âí³â àäèïîöèòàðíèõ ìåä³àòîð³â àïåë³íó-12 òà îáåñòàòèíó ó õâîðèõ ç ã³ïåðòîí³÷íîþ õâîðîáîþ òà öó-êðîâèì ä³àáåòîì 2-ãî òèïó çàëåæíî â³ä ñòóïåíÿ òÿæêîñò³ àðòåð³àëüíî¿ ã³ïåðòåíç³¿Î.Ñ. Òàáà÷åíêî, Î.Þ. Áîðçîâà, Î.Ñ. ªðìàê (Õàðê³â)

17. Îñîáëèâîñò³ ë³êóâàííÿ ïîäàãðè ó õâîðèõ íà àðòåð³àëüíó ã³ïåðòåíç³þÂ.ª. Êîíäðàòþê, Þ.Ï. Ñèíèöÿ, Î.Ì. Òàðàñåíêî (Êè¿â)

ÍÅÊÎÐÎÍÀÐÍ² ÕÂÎÐÎÁÈ ÑÅÐÖßÌîäåðàòîðè: ä.ì.í. Ä.Â. Ðÿáåíêî, ä.ì.í. Ñ.Ì. Êîæóõîâ, ê.ì.í. Ñ.Â. ×åðíþê 1. The contribution of proinflammatory markers into the formation of cardiomyopathy in patients with type 2 diabetes

mellitus and overweightN.V. Sokolnikova, L.V. Zhuravlyova (Kharkiv)

2. Êë³í³÷íèé âèïàäîê ìàëîñèìïòîìíî¿ ã³ãàíòñüêî¿ ì³êñîìè ë³âîãî ïåðåäñåðäÿÌ.². Øâåä, Í.Ì. Êîâáàñà, Ê.Á. Ï³æèöüêà, ².Î. ßñòðåìñüêà (Òåðíîï³ëü)

3. Ä³àãíîñòè÷íå çíà÷åííÿ âèçíà÷åííÿ ôàêòîð³â ðèçèêó çà øêàëîþ SILC ó õâîðèõ íà ì³îêàðäèò ç ïîðóøåííÿì ðèòìó ³ ïðîâ³äíîñò³Ê.Â. Ìèíäç³â, Î.². Êîöþáà, Í.². ßðåìà, Í.Â. Òêà÷óê, Ê.Â. Âåðåùàã³íà (Òåðíîï³ëü)

ÌÅÒÀÁÎË²×Í² ÏÎÐÓØÅÍÍß ÏÐÈ ÑÅÐÖÅÂÎ-ÑÓÄÈÍÍÈÕ ÇÀÕÂÎÐÞÂÀÍÍßÕÌîäåðàòîðè: ïðîô. Î.². Ì³ò÷åíêî, ïðîô. Ò.Â. Òàëàºâà, ê.ì.í. Â.Þ. Ðîìàíîâ1. Ôóíêö³ÿ åíäîòåë³þ, ïîêàçíèêè ë³ï³äíîãî ñïåêòðà òà ³íñóë³íîðåçèñòåíòí³ñòü ó õâîðèõ íà ³øåì³÷íó õâîðîáó

ñåðöÿ â ïîºäíàíí³ ç íåàëêîãîëüíîþ æèðîâîþ õâîðîáîþ ïå÷³íêè òà ¿õ äèíàì³êà ï³ä âïëèâîì óðñîäåçîêñèõî-ë³ºâî¿ êèñëîòèÌ.Ì. Ãðå÷àíèê, ².Ï. Áîãîâ³íà, Í.Ì. Ãðå÷àíèê, Ä.Ë. ×âîðà (Äí³ïðî)

2. Êë³í³êî-ïðîãíîñòè÷íå çíà÷åííÿ ã³ïåðòðèãë³öåðèäåì³¿ ó õâîðèõ íà ³øåì³÷íó õâîðîáó ñåðöÿ ç ìåòàáîë³÷íèì ñèíäðîìîìÎ.ß. Êîðîëþê (Ëüâ³â)

3. Âïëèâ òåðàï³¿ ³ç âêëþ÷åííÿì L-àðã³í³íó òà á³ñôîñôîíàò³â íà êë³í³÷íèé ïåðåá³ã ³øåì³÷íî¿ õâîðîáè ñåðöÿ, êî-ìîðá³äíî¿ ç ïîñòìåíîïàóçàëüíèì îñòåîïîðîçîìÍ.Ñ. Ìèõàéëîâñüêà, ².Î. Ñòåöþê (Çàïîð³ææÿ)

4. Âïëèâ ìåòàáîë³÷íî¿ òåðàï³¿ íà ë³ï³äíèé ñïåêòð êðîâ³ ó õâîðèõ íà îñòåîàðòðèò, ïîºäíàíèé ç ³øåì³÷íîþ õâîðî-áîþ ñåðöÿÑ.². Ñì³ÿí, Ð.ß. Áîäíàð, Ë.Ï. Áîäíàð (Òåðíîï³ëü)

5. Ôóíêö³îíàëüíèé ðåçåðâ íèðîê ó õâîðèõ íà àðòåð³àëüíó ã³ïåðòåíç³þ â çàëåæíîñò³ â³ä ôóíêö³¿ ùèòîïîä³áíî¿ çàëîçè².Ï. Ãàðì³ø (Äí³ïðî)

6. Îñîáëèâîñò³ êîíòðîëþ àðòåð³àëüíîãî òèñêó ó ïàö³ºíò³â ç àðòåð³àëüíîþ ã³ïåðòåíç³ºþ òà ìîðá³äíèì îæèð³ííÿì ï³ä âïëèâîì áàð³àòðè÷íîãî ë³êóâàííÿ é àíòèã³ïåðòåíçèâíî¿ òåðàï³¿À.Â. Íàäþê, Ò.Â. Êîëåñíèê, Ð.Â. Äóêà, À.À. Êîñîâà (Äí³ïðî)


42

ÀÂÒÎÐÑÜÊÈÉ ÏÎÊÀÆ×ÈÊ

Ambrosova T.M. 41Andreieva Y.O. 40Ashcheulova T.V. 41Gilyova Ya.V. 39Honchar O.V. 39, 41Kadykova O. 40Kolesnik E.L. 41Kolesnik T.V. 41Kopytsya M.P. 39Kosova H.A. 41Koteliukh M.Yu. 40Kovalyova O.M. 41Kravchun P.G. 40Matyash N.M. 41Molotiagin D. 40Mykhailovska N.S. 40Nadiuk A.V. 41Nickening G. 8Oliinyk T.V. 40Pasiieshvili T.M. 41Petyunina O.V. 39Rodionova Yu.V. 39Tytarenko N.V. 39Vyshnevska I.R. 39Zelena I.I. 41Zhelezniakova N.M. 41Àáäóðàõìàíîâ Ç.Ì. 37Àáðàìåíêî ².Â. 40Àêêàÿ Å. 33Àëüì³ç Ï.Î. 32Àìåë³íà Ò.Ì. 40Àìîñîâà Ê.Ì. 20, 22, 25, 27Àíäð³ºâñüêà Ñ.Î. 12, 26Àíäð³éö³â Ç.Ñ. 33Àïàíàñåíêî Ã.Ë. 38Àðòåìåíêî Â.Î. 27Àñîíîâ À.Î. 16Áàá³é Ë.Ì. 38Áàáëÿê Î.Ä. 16, 21Áàáî÷ê³íà À.Ð. 33Áàçèêà Î.Ä. 40Áàíàõ Ì. 28Áàðçàê Í.Ñ. 40, 41Áàóåð Ï. 25Áàöàê Á.Â. 36Áåâçþê Ë.Â. 39Áåðåç³í Î.ª. 25, 37Áåðêîâè÷ À. 33Áåø Ä.². 39Áåøëÿãà Â.Ì. 14, 15Á³ëèé Ä.Î. 19, 40Á³ëîâîë Î.Ì. 41Á³ëîóñ Í.². 40Á³ëü÷åíêî Î.Â. 23, 32Áîãîâ³íà Î.Ï. 40Áîéêî Â.Â. 40Áîéêî Î.². 39Áîðîâèê Ê.Ì. 39Áîðîäàé À.Î. 15Áîðõàëåíêî Þ.À. 40

Áðèíçà Ì.Ñ. 32, 39Áóäêî Î.Î. 36Áóæåíêî À.². 17Áóðòíÿê Ò.Ç. 41Áóðÿê Ð.Â. 18Áóðÿêîâñêàÿ À.À. 41Âàâ³ëîâà Ë.Ë. 33Âàðáàíåöü Ñ.Â. 37Âàñèëåíêî À.Ì. 12, 25, 34Âàñèëåíêî Â.À. 25, 34Âàñèëüºâà Ë.². 30Âåðáîâñüêà Î.Ñ. 33Âºðêî Í.Ï. 25Âèøíåâñüêà ².Ð. 40Â³ðíà Ì.Ì. 28Âëàä³ì³ðîâ Î.À. 38Âîâ÷åíêî Ì.Ì. 28Âîâ÷åíêî Ì.Í. 41Âîëêîâ Ä.ª. 32, 33Âîëîøèíà Î.Â. 19Âîðîíêîâ Ë.Ã. 25, 38, 40Âîðîõòà Þ.Ì. 14Ãàâðèëåíêî Ò.². 16, 40Ãàâðèø Î.Ñ. 26Ãàâðîíñüêà Ò.Ì. 16Ãàëàøêî Ê.Þ. 39Ãàëü÷èíñüêà Â.Þ. 28Ãàðêàâåíêî Î.Ã. 39Ãåëåòþê Þ.Ë. 41Ãåðàñèì÷óê Ñ.Ã. 19Ãåòüìàí Ò.Â. 11Ãèë¸âà ß.Â. 39Ãèùàê Ò.Â. 16Ã³ááñ Ñ. 30Ã³íãóëÿê Î.Ì. 17Ã³ðåø É.É. 36Ã³÷óí Â.Ñ. 17Ãîë³êîâà ².Ï. 22, 26Ãîëóáîâñüêà Þ.ª. 16Ãîí÷àð Î.Î. 26Ãîí÷àðü À.Â. 39Ãîðáà÷îâà Â.Â. 17, 38Ãðå÷àíèê Ì.Ì. 40Ãðå÷àíèê Í.Ì. 40Ãðå÷êî Ñ.². 33Ãðèíåíêî Ò.Â. 26Ãð³áåíþê Î.Â. 41Ãðóáÿê Ë.Ì. 14Ãóê Â.Ï. 17Ãóê Î.À. 36Ãóëÿºâà Ì.Â. 13Ãóð’ºâà Î.Ñ. 37Äàâèäîâà Þ.Â. 13Äàâèä÷óê Î. 25Äàí³ëåâè÷ Ò.Ä. 17Äàðîõà Ñ. 30Äåì’ÿíåíêî Â.Ì. 16, 21Äåì’ÿí÷óê Â. 25Äåíèñþê Â.². 33Äåíèñþê Î.Â. 33

Äåÿê Ñ.². 15Ä³äêîâñüêèé Â.Ñ. 17Ä³òê³âñüêèé ².Î. 37Äìèòåðêî Ó.À. 41Äîâãàíè÷ Í.Â. 29Äîëæåíêî Ì.Ì. 12, 13,

14, 25, 38Äîðîí³í Î.Â. 32Äîðîõ³íà Ã.Ì. 17Äîñåíêî Â.ª. 26, 38Äðåâèöüêà Ò.². 26Äóáíîâ³íñüêà Ò.Â. 26Äóáðîâ Ñ.Î. 34Äóäíèê À.ª. 38, 40Äüîëîã Ì.Â. 20Äÿ÷åíêî Â.Ë. 37Äÿ÷åíêî Î.Î. 17ªìåöü Ã.². 37ªìåöü ².Ì. 36, 37ªíà Ë.Ì. 27ªïàí÷³íöåâà Î.À. 25, 40ªðìàê Î.Ñ. 39ªñêå À. 20ªô³ìåíêî Ä.Ñ. 19ªô³ìåíêî Î.Î. 13Æàäàí À.Â. 15, 37Æàð³íîâ Î.É. 9, 15, 25, 27, 40Æàð³íîâà Â.Þ. 38Æåáåëü Â.Ì. 38Æåêîâ ².². 37Æåë³áà Î.Ì. 15Æèâèëî ².Î. 30Æèòèíñüêèé ª. 25Æóðàâëüîâà Ë.Â. 41Çàáîëîòíà Ò.Â. 16Çàé÷åíêî À.Â. 27Çàëåâñüêèé Â.Ï. 9Çàëüöáåðã Ñ. 33Çàðåìáà ª.Õ. 28, 37Çàðåìáà Î.Â. 28, 37Çàðåìáà-Ôåä÷èøèí Î.Â. 28Çåðá³íî Ä.Ä. 36, 39Çäðîºâñüêèé Ò. 38Ç³í÷åíêî Þ.Â. 11Çîëîòàðüîâà Ò.Â. 39Çóáîâñüêèé Ä.Ñ. 17Èñàåâà À.Ñ. 41²âàí³â À.Þ. 14²âàí³â Þ.À. 13, 14, 15, 29²âàíêîâà À.Â. 39²âàíîâ Â.Ï. 27, 39²âàí÷åíêî Ñ.Â. 41²âàí÷óê Ï.Ð. 39, 40²ëü÷åíêî ².À. 41²ëü÷èøèíà Î.ß. 19²ëþøèíà Ã.ß. 12²ðê³í Î.². 9, 12, 19, 27, 34²ñàºâà Ã.Ñ. 28Êàçüì³ðóê Â.Ì. 33Êàïëàí Ï.Î. 22

Êàðïåíêî Þ.². 32Êàðïëÿê Â.Ì. 28, 37Êàõëå Ï. 33Êâàøà Î.Î. 38Êèðè÷åíêî À.Ã. 17Êèðè÷åíêî Ð.Ì. 36Êèñèëåâè÷ Ë.Ô. 19Êèÿê Ã.Þ. 38Ê³íîøåíêî Ê.Þ. 37Êëåêîò Î.Î. 28Êëèìåíêî Î.Î. 26Êîáåëü À.Â. 39Êîáèëÿêà Â.Þ. 19Êîâàëåâñüêà Î.À. 15Êîâàëåíêî Â.Ì. 14, 15, 35Êîâàëü Î.À. 10, 19, 22Êîâàëü Ñ.Ì. 23, 37Êîâàëüîâ Î.Ñ. 40Êîâàëüîâà Ì.Î. 27Êîæèíà Ã.Ì. 23Êîæóõîâ Ñ.Ì. 25, 28Êîçëþê À.Ñ. 29, 36Êîëá Í.Î. 41Êîëåñíèê Å.Ë. 41Êîëåñíèê Ì.Þ. 14, 15, 39Êîëåñíèê Ò.Â. 12, 23, 26, 27, 41Êîëåñí³êîâà Î.Â. 27Êîëîñ Ë.À. 16Êîíäðàòþê Â.ª. 41Êîíîòîï÷èê Ñ.Â. 14Êîïèöà Í.Ï. 39Êîïèöÿ Ì.Ï. 39, 40Êîðíàöüêèé Â.Ì. 17, 23Êîðîñò³é Â.². 23Êîñîâà Ã.À. 41Êîöþáà Î.². 34Êðàâ÷åíêî Â.². 37Êðàâ÷åíêî Ê.Ñ. 41Êðàâ÷óê Á.Á. 32Êðàñíÿêîâ ².Ä. 33Êðåìçåð Î.Î. 25Êðèêóíîâ Î.À. 9, 14, 15, 36Êðè÷êåâè÷ Â.À. 26Êðóøèíñüêà Ç.Ã. 15Êðóøèíñüêà Í.À. 37Êðÿ÷îê ².À. 36Êóçíåöîâ ².Â. 40Êóçíåöîâà Ñ.Ì. 13Êóçíºöîâà Ë.Â. 16Êóçüì³íîâà Í.Â. 39, 40, 41Êóëèê Ë. 30Êóíä³íà Â.Â. 15Êóí³ñ Ì. 33Êóðñ³íà Í.Â. 40Êóðÿòà Î.Â. 22, 23, 39Êóòÿ ².Ì. 39, 40Êóöü Â.Î. 15Êó÷ìåíêî Î.Á. 19, 26Êóøí³ð Þ.Ñ. 39Ëàçàðºâà Ê.Ï. 22


43

Ëàçîðèøèíåöü Â.Â. 9, 15, 21Ëåâèöüêà Ë.Â. 38, 41Ëåâèöüêìé ².Á. 38Ëåîí³äîâà Â.². 39Ëèçîãóá Ñ.Â. 11, 34Ëèìàíñüêèé Î.Â. 38Ëèïîâåöüêà Ñ.É. 34Ëèñåíêî Ã.Ô. 22Ë³ïêàí Í.Ã. 38, 40Ë³ôàíòüºâà Í.Î. 15Ëîçèíñüêà Í.Â. 15Ëóòàé Ì.². 21, 22, 26, 28Ëóòàé ß.Ì. 19, 34, 38Ëó÷èíåöü Î.Ô. 18, 36Ìàçóð Î.À. 37Ìàçóð Ñ.Ã. 13Ìàêàðîâà ².². 15Ìàêîâ³é÷óê ².Î. 39Ìàëèíîâñüêà ².Å. 19Ìàíüêîâñüêà ².Ì. 26Ìàðàðåíêî Î.À. 19Ìàð³ºâñüêèé ².Â. 36Ìàðêîâåö À.Â. 35Ìàðóøêî Ò.Â. 16Ìàðóøêî Þ.Â. 16Ìàòîâà Î.Î. 23, 26Ìàòîõíþê Ì. 38Ìàòþõ Ê.Ì. 39Ìàòþõà Ë.Ô. 12Ìåäâ³äü Â.². 13Ìåëàìóä Ê.Ñ. 23Ìåëåíü Þ.Ï. 40Ìåëüíèê ª.À. 16, 21Ìèòðîõ³íà Î.Ñ. 40Ìèõàéëîâñüêà Í.Ñ. 41Ìèõàéëîâñüêèé ß.Ì. 39Ì³íÿéëåíêî Ë.ª. 41Ì³ò÷åíêî Î.². 12, 27, 28Ì³õàëºâ Ê.Î. 12, 25Ì³õàëºâà Ò.Â. 26Ì³ùåíêî Ë.À. 12, 14, 23, 25Ì³ùåíêî Ò.Ñ. 14Ìîãèëüíèöüêèé ª.Â. 11Ìî³ñåºíêî Î.². 22Ìîêðèê ².Þ. 35Ìîðîç Ì.Ñ. 28Ìðî÷åê À.Ã. 20Ìóäðóê ².Â. 39Ìóçèêà Í.Î. 33Ìóõàììàä Ìóõàììàä 40Ìõ³òàðÿí Ë.Ñ. 26, 38, 40Íàäþê À.Â. 41Íàéäà Ñ.À. 17Íàñò³íà Î.Ì. 40Íàòðóñ Ë.Â. 25Íåâìåðæèöüêà Ë.Î. 9, 18Íåìöîâà Â.Ä. 41Íåñóêàé Î.Ã. 8, 9, 12, 24, 36Íåòÿæåíêî Â.Ç. 14, 19Í³øêóìàé Î.². 22Íîâåðêî ².Â. 15, 37Íîéìàí Ò. 33Íîñàð Â.². 26

Íîñåíêî Í.Ì. 14, 23, 36Îâðàõ Ò.Ã. 18Îí³ùåíêî Î.Â. 40Îðèí÷àê Ì.À. 28Îðèùèí Í.Ä. 15, 29Îñîâñüêà Í.Þ. 12, 14, 15Îñüîäëî Â.². 17Ïàâåëêî Ì.Ì. 38Ïàâëèê Í.Ñ. 16Ïàíòàç³ Î. 25Ïàíüê³â Â.². 13Ïàðàö³é Î.Ç. 34Ïàðõîìåíêî Î.Ì. 19, 34, 38Ïåòêàíè÷ Ì.Ì. 33Ïåòþíåâà Ë.Ë. 28Ïåòþí³íà Î.Â. 40Ïºòêîâ Î.Â. 40Ïèâîâàð Ñ.Ì. 22, 38Ï³âòîðàê Ê.Â. 12Ï³äãàéíà Ë.Â. 16, 21Ï³äãàéíà Î.À. 16Ïîâîðîçíþê Â.Â. 22Ïîãóðåëüñüêà Î.Ï. 38Ïîçíÿê Þ.Â. 18Ïîë³âåíîê ².Â. 40Ïîë³ùóê Ì.ª. 13Ïîëÿíñüêà Î.Ñ. 40Ïîíè÷ Í. 25Ïîíîìàðüîâà Ã.Â. 40Ïîïîâ Â.Â. 33Ïîòàáàøí³é Â.À. 25, 32Ïîòàøîâ Ñ.Â. 14, 15Ïðàâîñóäîâè÷ Ñ.Î. 31Ïðîíîçà-Ñòåáëþê Ê.Â. 17Ïóãà÷ Ò.Â. 22Ïóêàñ Î.Ñ. 37Ðàäåöüêà Ë.Â. 34Ðàä÷åíêî Ã.Ä. 11, 15,

23, 25, 30, 36Ðàê Í.Î. 37Ðàñïóò³íà Ë.Â. 27Ðàñïóòíÿê Î.Â. 16Ðåâåíêî Ê.À. 16, 21Ðåâåíüêî ².Ë. 14, 23Ðåêîâåöü Î.Ë. 37Ðåçíèê Ë.À. 41Ðèáàê À.Þ. 22Ðèá÷èíñüêèé Ñ.Â. 18Ðèæêîâà Í.Î. 16Ðèíãà÷ Í.Î. 38Ðèíä³íà Í.Ã. 39Ð³øêî Ì.Â.Ðîäèîíîâà Þ.Â. 39Ðîä³îíîâà Þ.Â. 39Ðîìàíåíêî Ñ.Â. 22Ðîìàíîâ Â.Þ. 28Ðîìàíîâà Â.Î. 40Ðîìàíîâà Î.Ì. 11, 31, 32Ðóäåíêî À.Â. 27Ðóäåíêî Â.À. 21Ðóäåíêî Ê.Â. 9, 36Ðóäåíêî Í.Ì. 36, 37Ðóäåíêî Ñ.À. 27

Ðóäåíêî Þ.Â. 22, 25Ðóäèê Þ.Ñ. 22, 38Ðóä³ê Ì.Â. 15Ðóñíàê À.Î. 9, 33Ðÿáåíêî Ä.Â. 23, 36Ñàâ³öüêà Þ.Â. 18Ñàâ÷åíêî ².Ï. 34Ñàâ÷óê Î.Â. 40Ñàíåð Õ. 38Ñàòèð Ì.Â. 15Ñâèðèäþê Î.ª. 14Ñåáîâ Ä.Ì. 22Ñåìåíîâ Â.Â. 19, 22, 23Ñåðáåíþê Ê.². 23Ñåðåäþê Í.Ì. 33Ñåð³ê Ñ.À. 22Ñåðüîã³íà Î.Ï. 19Ñºðêîâà Â.Ê. 40Ñèäîðåíêî Ã.Â. 40Ñèíèöÿ Þ.Ï. 41Ñè÷îâ Î.Ñ. 9, 11, 14, 15, 30Ñ³ðåíêî Þ.Ì. 9, 10, 27,

29, 30, 36Ñ³÷êàðóê ².Ì. 22Ñêàêóí Î.Ç. 33Ñêà÷êîâà Í.À. 13Ñêèá÷èê Â.À. 40Ñê³áî Þ.Ì. 40Ñêîðîìíà À.Ñ. 19Ñëîáîä³í Ò.Ì. 14Ñìèðíîâà ².Ï. 38Ñìîëàíêà ².². 29Ñí³ãóðñüêà ².Î. 37Ñîêîëîâ Ì.Þ. 19, 20, 39Ñîêîëîâ Þ.Ì. 19, 20, 21Ñîêîëîâà Ë.Ê. 8, 23, 24Ñîêîëüí³êîâà Í.Â. 41Ñîëåéêî Ë.Ï. 40, 41Ñîëºéêî Î.Â. 40, 41Ñîëîâ’ÿí Ã.Ì. 11Ñîëîíîâè÷ À.Ñ. 18Ñîïêî Î.Î. 38Ñîðîê³âñüêèé Ì.Ñ. 16Ñð³áíà Î.Â. 33, 38Ñòàðæèíñüêà Î.Ì. 38Ñòåáëþê Â.Â. 17Ñòåïàí³øèíà ß.À. 36Ñòåïóðà À.Î. 19Ñòåöþê ².Î. 41Ñòè÷èíñüêèé Î.Ñ. 32Ñòîãîâà Î.Â. 36Ñòóêîâ Þ.Þ. 19Ñóìàíîâà È.À. 39Ñóõîâà Ñ.Ì. 20Òàëàºâà Ò.Â. 22, 26Òàðàïîí ².Â. 19Òàðàñîâà Â.Ê. 26Òàòàð÷óê Ò.Ô. 12Òàùóê Â.Ê. 19, 22, 27,

33, 34, 39Òàùóê Ì.Â. 39, 40Òåðåøêåâè÷ Ë.Ï. 19

Òåðåùåíêî Í.Ì. 19Òèòàðåíêî Í.Â. 39Òèùåíêî ª.Â. 40Ò³ùåíêî Í.Â. 40Òêà÷ Ë.². 21Òêà÷ Í.À. 25Òîâñòóõà Â.Â. 26Òîäóðîâ Á.Ì. 25, 35, 37, 40Òîìàùóê Í.Á. 13Òîðáàñ Î.Î. 37Òðåãóáîâà Ì.Î. 36Òðåìáîâåöüêà Î.Ì. 36Òðåôàíåíêî ².Â. 33Òð³ùèíñüêà Ì.À. 32Òðóíîâà Ë.À. 40Ôåäîðåíêî Î.À. 35Ôåäüê³â Ñ.Â. 14, 15, 22Ôåñåíêî Â.². 25, 32Ô³òöå ². 36Ôëîì³í Þ.Â. 13Ôðîëîâ Î.². 11Ôóðñà Î.Ì. 35Õàâîðò Ø.Ã. 29Õàäæàÿ Í.Â. 17Õàéí À. 33Õàíþêîâ Î.Î. 9Õàòàëà Ð. 31Õîìåíêî Þ.Î. 38Õîõëîâ À.Â. 37Õóäçèê Ì. 32Öâèê À.Ñ. 18Öåë³ê Í.ª. 41Öåëóéêî Â.É. 20, 23, 25,

32, 36, 37Ö³âåíêî Â.Ì. 39×àñíîéò À. 32×åðåäíè÷åíêî Ì.Ç. 11×åðåíüêî Ò.Ì. 41×åðíþê Ñ.Â. 16, 35×åðíÿãà-Ðîéêî Ó.Ï. 16×åðïàê Á.Â. 37Øàá³ëüÿíîâà Ë.Î. 39Øàòàéëî Â.Ï. 22Øâåä Ì.². 34, 38Øâåöü À.Â. 17Øåéêî Ñ.Î. 12, 41Øåðåìåò Ì.Þ. 23Øèìàíêî Ì.Â. 37Øêëÿíêà ².Â. 18Øòåëüìàõ Â.Î. 39Øóìàêîâ Â.Î. 19. 38Ùåãëîâ Ä.Â. 14Þøêî Ê.Î. 23ßáëó÷àíñüêèé Ì.². 39, 41ßâäîøíÿê Õ.Â. 39ßãåíñüêèé À.Â. 10, 22, 33, 38 ßêîâëºâà Ë.Ì. 14ßêóøêî Ë.Â. 16ßëîâåíêî Ì.². 18ßðåìà Í.². 34ßðèíê³íà Î.À. 29ßðîø Â.Î. 27

Õx ÍÀÖ²ÎÍÀËÜÍÈÉ ÊÎÍÃÐÅÑ ÊÀÐÄ²ÎËÎÃ²Â ÓÊÐÀ¯ÍÈ Õx ... · 2019....

Documents